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Integrins are heterodimeric transmembrane glycoproteins present on the surface of
virtually every cell. They play a key role in growth, survival, migration and tumour
metastasis, by maintaining and controlling cell-cell and cell-substratum adhesion.
The precisely controlled changes in cell adhesion, governed by integrins, are a
hallmark of many basic physiological processes. These include leukocyte migration
during infiltration into inflammatory sites, and platelet aggregation. Many cancers
have abnormal integrin function as a result of oncogenic transformation. However,
the precise effect of integrin function on transformation is not well defined.
Central to the role of integrins in regulating adhesion is the ability to modulate
affinity for ligand binding in response to intracellular signal transduction pathways.
The mechanism by which this 'inside-out' signalling governs integrin affinity
requires further definition.
Previous studies have identified H-Ras and its downstream effector Raf-1 as key
suppressors of integrin activation. H-Ras is the most prevalent oncogenic mutation in
human solid tumours and has been implicated in cellular transformation. The related
small GTP-binding protein, R-Ras, was originally identified as a result of its high
homology to H-Ras. The activated variant of R-Ras, R-Ras (G38V), strongly
antagonises the H-Ras/Raf- initiated integrin suppression pathway, leading to
integrin activation and an increase in adhesion in CHO cells. The different effects H-
and R-Ras have on cellular function have provided the first system whereby these
proteins can be distinguished.
In this thesis I have sought to gain further insight into the regulation of integrin
affinity and cellular function by Ras GTPases. A series of H-and R-Ras chimeras
have been used to examine the hypothesis that specific sequences within these
molecules govern their differential effects on integrin function and cellular
transformation. Understanding the structure/function relationship between H-Ras and
R-Ras may help to elucidate their downstream effectors which regulate integrin
function, and define the relevance ofMAP kinase activation with regards to integrin
II
activation and cellular transformation. This may lead to a better understanding of the
development of cancer.
Expression of the H-and R-Ras chimeras within an integrin reporter system (a)3-py
cells) revealed that a C-terminal 25-amino acid stretch ofH-Ras was required for full
suppressive activity, and that the equivalent C-terminal 28-amino acid stretch of R-
Ras was required to fully reverse H-Ras/Raf- initiated integrin suppression. The
effect of these amino acid stretches on integrin function was further confirmed by
investigations into the changes in cytoskeletal organisation and overall cellular
morphology. Furthermore, the data suggest that the effects on integrin function are
independent of the activation of the ERK1/2 MAP kinase pathway. This implicates a
novel mechanism whereby Ras modulates integrin affinity.
In summary, it is shown that H-Ras- and R-Ras-mediated integrin affinity is
regulated by distinct C-terminal domains. Moreover, integrin affinity modulation is
independent of ERK1/2 MAP kinase activation. In addition there is an apparent
correlation between suppression of integrin function and cellular transformation.
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Integrins and integrin signalling
Integrins are a widely expressed family of cell adhesion receptors that enable cells to
bind to extracellular matrix (ECM) proteins and to each other via cell surface Ig
counter-receptors. Integrins provide a physical link between the extracellular
environment and the cytoskeletal elements of the cell interior. The term 'integrin'
relates to the role of the cell adhesion glycoprotein as an integral membrane complex
involved in the transmembrane association between the extracellular matrix and
cytoskeleton (Tamkun et al., 1986). Early studies carried out on the platelet
glycoprotein GPIIb-IIIa, the fibronectin receptor on chick fibroblasts and the
leukocyte antigens (LFA-1, Mac-1 and the VLA antigens), revealed that these
proteins were composed of two non-covalently linked subunits, termed a and ft
which form heterodimeric receptor complexes. Sequence analysis of the subunits
revealed sequence homology between the a and /3 subunits from these proteins
groups (Hynes, 1987; Ruoslahti and Pierschbacher, 1987). The a/3 nomenclature,
adopted to classify the subunits according to their sequence identity, is the most
widely used and most widely applicable (Hynes, 1992).
1.1 Integrin subunits and ligands
Currently, there have been 18a and 8/3 integrin subunits described. Although these
subunits could in theory associate to create more than 100 integrin heterodimers, the
diversity appears to be much more restricted with only 24 different receptors
identified (Plow et al., 2000). Table 1.1 lists the receptors identified to date, along
with their respective ligands and ligand-recognition sequences. Several a subunits
have been shown to associate with only a single /3 subunit, anb associates exclusively
with ft; while others, in particular av, have been shown to be capable of associating
with more than one /3 subunit. Thus, integrins have been classified into subgroups
according to their /3 subunit interactions (Table 1.1). Integrins are expressed on
virtually every mammalian cell, with ft integrins having the most widely expressed
profile whereas expression of the ft integrins is restricted to leukocytes.
1
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Subunit Previous Names Ligands Binding Site
01 al VLA-1, CD41a/CD29 Collagens, laminin
a2 VLA-2, CD41b/CD29 Collagens, laminin DGEA (in collagen
only)
a3 VLA-3, CD41c/CD29 Fibronectin, laminin,
collagens
RGD (all ligands)
a4 VLA-4, CD41d/CD29 Fibronectin, VCAM-1 EILDV (FN only)
a5 VLA-5, CD41e/CD29 Fibronectin RGD








aV CD51/CD29 Vitronectin, fibronectin RGD
£2 aL LFA-1, CD1 la/CD18 ICAM1-5
aM Mac-1, CD 1 lb/CD 18 Fibrinogen, ICAM-1,
FactorX, C3bi
aX P150/95, CD1 lc/CD18 Fibrinogen, C3bl GPRP
aD VCAM-1












/34 a6 Laminin, basement
membrane
05 aV Vitronectin, fibronectin RGD







Table 1.1 Integrin heterodimers and their ligands
Adapted from Hynes et al., (1992) and Plow et al., (2000). Abbreviations used: FN-
fibronectin and Fb-fibrinogen.
Introduction
Although the afi nomenclature is the most widely used, many of the integrins were
described prior to the a(3 nomenclature being adopted and earlier names still exist in
the literature. The platelet integrin 0^,183, is often referred to as GPIIb-IIIa (Philips et
al., 1991) and several /3\ integrins are sometimes referred to as VLA (very late after
activation) antigens (Hemler, 1990). The leukocyte-specific fa integrins are routinely
referred to by their earlier names; aL|32 - lymphocyte function associated antigen-1
(LFA-1) and awifo - macrophage-1 receptor (Mac-1) (Hemler, 1990) (see Table 1.1).
Integrins were initially described by their ability to bind to extracellular matrix
proteins (collagens, laminin, vitronectin and fibronectin) and mediate cell-substratum
adhesion. Other integrin-ligands such as fibrinogen and the integral membrane
proteins of the immunoglobulin superfamily (ICAM-1/2 and VCAM-1) mediate cell-
cell adhesion. Table 1.1 shows that individual integrins can often bind to more than
one ligand and that individual ligands are often recognised by more than one
integrin.
Within the ligand macromolecules, specific integrin recognition sites have been
identified that are essential for ligand binding. Many members of the integrin family
(including a5(3\, a.ub03 and most ov/3 integrins) recognise the Arg-Gly-Asp (RGD)
sequence within their ligands. These ligands include fibronectin, vitronectin, von
Willebrand factor and many other large glycoproteins. The RGD motif is essential,
as peptides containing this motif can effectively block integrin-ligand interaction
(Fernandez et al., 1998). However, it is the residues outside the RGD motif that
provide specificity as well as high affinity for each ligand-integrin pair (Hynes and
Yamada, 1982; Pierschbacher and Ruoslahti, 1984). Different ligand sequences are
also used as integrin recognition sites, one such example is the Lys-Gln-Ala-Gly-
Asp-Val (KQAGDV) sequence in fibrinogen recognised by the cqibft integrin
(Hynes, 1992).
1.2 Integrin structure
All integrins are oj3-subunit heterodimers. The a subunits vary in size between 120
and 180kDa, while the 8 subunits are between 90 and llOkDa (Hynes, 1992). Both
types of integrin subunit contain a relatively large N-terminal extracellular domain, a
single hydrophobic membrane-spanning region and with most integrins, a short
3
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cytoplasmic domain (less than 50 amino acids). The notable exception is (84, as its
cytoplasmic domain comprises over 1000 amino acids (Hynes, 1992).
The overall shape and dimensions of integrins have been determined by electron
microscopy. Early studies by Carrell et al., (1985) revealed that the OmA integrin
comprised of a globular oblong head and two rod-like tails extending into the lipid
bilayer. Electron microscopic analysis of the a5/3\ integrin revealed similar results
(Nermut et al., 1988). Most of the proposed integrin structures have relied on
primary sequence analysis and structure predictions based on homology to proteins
to which tertiary structure have already been determined. Figure 1.1 shows a
schematic representation of the domain structure of an integrin dimer.
On the basis of primary sequence analysis, the N-terminal region of all a subunits
contain a seven-fold repeat of a homologous region, encoding 4 (3-sheets that come
together in a structure known as a /3-propeller (Springer, 1997). The final three or
four of these repeats contain sequences that are similar to the EF-hand-like motif,
that display divalent cation-binding properties. The a. subunits can be divided into
two groups, those that contain an inserted A-domain (found in the cq, a2, ay, Om and
otx subunits), and those with a post-translational proteolytic cleavage site. The A-
domain comprises five parallel and one anti-parallel hydrophobic /3-strands
surrounded by seven hydrophilic a-helices forming a Rossmann fold (Fernandez et
al., 1998). The A-domains contain a metal ion-dependent adhesion site or MIDAS
motif. Cleavage at the proteolytic site of the a3, a5, oy, a7, a%, c^b and oy subunits,
found close to the transmembrane domain, yields an N-terminal heavy and C-
terminal light chain (Fernandez et al., 1998).
An A-domain-like region has also been predicted in the N-terminal half of the /3
subunit. The A-domain of the (3 subunits is preceded by a PSI (plexins, semaphorins
and integrins) domain and is followed by a cysteine-rich region composed of four
epidermal-growth-factor (EGF)-like repeats (Humphries, 2000). As with a subunits,






Figure 1.1 Schematic representation of integrin structure
Schematic shows the proposed domain structure of an integrin heterodimer with (A)
or without (B) an aA-domain.












For a subunits containing A-domains, the ligand-binding pocket has been mapped to
the A-domain (Fernandez et al., 1998). For those integrins which lack an a subunit
A-domain such as am,, the ligand-binding pocket has been mapped to the upper face
in the j8-propeller motif (Bajt and Loftus, 1994; D'Souza et al., 1994). Ligand
binding sites which have been identified in (3 subunits have been mapped to the
presumed A-domain (Flumphries, 2000). The presence of divalent cation binding
sites (MIDAS) in the ligand binding sites of both integrin subunits reflects their
importance in integrin structure. The regulatory role of metal ions on ligand binding
is highlighted by the lack of ligand binding upon removal of cations by chelating
agents (Fernandez et al., 1998).
The short cytoplasmic domains link the integrin with the cytoskeleton either directly
or via adaptor proteins. There are few direct interactions known between the a
subunit tail and the components of the cytoplasm although a.4 has been shown to
have a high affinity for paxillin (Liu et al., 1999). The large cytoplasmic domain of
/?4 connects with the intermediate filament network and has a role in hemidesmosome
formation. The other (3 subunit cytoplasmic domains have three conserved regions
designated Cyto 1, 2 and 3 (Reszka et al., 1992). Cyto 1 is necessary for binding
focal adhesion components such as FAK, filamen and a-actinin (Lewis and
Schwartz, 1995; Otey et al., 1993 and Sharma et al., 1995). Cyto 2 and 3 are NPXY
motifs which are phosphorylation sites for protein kinases (Bodeau et al., 2001;
Mulrooney et al., 2001). All three Cyto domains are required for adhesive function
(Levy et al., 2000). A number of proteins have been shown to bind to the NPXY
motif, including the integrin cytoplasmic domain-associated protein 1 (ICAP-1)
(Chang et al., 1997), and more recently talin has been shown to bind directly with the
183 tail via the NPXY motif (Garcia-Alvarez, 2003).
1.3 Integrin signalling
The interaction of cells with the ECM regulates many cellular processes including
cell survival, proliferation, differentiation and migration. The binding of ligands to
integrins results in the clustering of ligand-occupiea integrins, which increases the
avidity of the cell for its ligand. Integrin clustering also leads to the formation of
specialised sites within the plasma membrane termed focal adhesions, where
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integrins link the outside matrix with intracellular cytoskeletal complexes (Burridge
et al., 1988).
The assembly of many of the signalling components in focal adhesions depends on
focal adhesion kinase (FAK) activity. FAK is recruited to focal adhesions through
interactions with the adaptor proteins talin (Chen et al., 1996), vinculin and paxillin
(Brown et al., 1996). It has been proposed that following recruitment to focal
adhesions, FAK undergoes a conformational change which allows its N-terminal
domain to interact with the (3 subunit tail and subsequent activation of FAK by
autophosphorylation (Richardson and Parsons, 1996).
Despite lacking intrinsic tyrosine kinase activity, integrins have been shown to
influence a number of classical signalling pathways by recruiting adaptor proteins
and kinases through interactions with both the extracellular and cytoplasmic domains
(Kumar, 1998; Giancotti and Ruoslahti, 1999).
1.3.1 Integrin and cytoskeletal organisation
Following the interaction of integrins with ECM proteins, a diverse number of
structural and signalling proteins are targeted to focal adhesions. Structural actin
binding proteins that localise with integrins at focal adhesions include a-actinin,
talin, tensin, paxillin, vinculin and tensin (Dedhar and Hannigan, 1996). Signalling
proteins that colocalise with focal adhesions include the following protein kinases:
focal adhesion kinase (FAK), Src and integrin linked kinase (ILK) (Yamada and
Miyamoto, 1995; Dedhar and Hannigan, 1996). Rho family members have also been
shown to be activated by integrin ligation. Hotchin and Hall (1995) demonstrated
that the interaction of integrins with the ECM is not sufficient to induce integrin
clustering, but requires the activity of the GTP-binding protein Rho.
Cell migration is a key aspect in many normal and abnormal cellular processes,
including wound healing and tumor metastasis. The driving force for cell motility is
provided by dynamic actin reorganisation. Integrins and receptors for soluble
mitogens such as growth factors can regulate cell spreading and migration through
activation of the Rho-family proteins (Nobes and Hall, 1999). Each of the Rho-
family proteins has control over the actin cytoskeleton. Rho regulates the formation
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of contractile actin-myosin filaments to form stress fibres, generating tension within
the cell (Ridley and Hall, 1992), while Rac and Cdc42 regulate lamellipodia and
filopodia formation respectively, which are protrusive structures found at the leading
edge of the cell (Ridley and Hall, 1992; Nobes and Hall, 1995). The activation of the
Ras-ERKl/2 signalling pathway by integrin ligation (see below) has also been shown
to influence cell motility. Signalling by ERK1/2 results in the phosphorylation of
myosin light chain kinase (MLCK), which in turn phosphorylates myosin light
chains (MLC) resulting in a fully functional actin-myosin motor unit which serves to
produce the contractile forces within the cell required for cell motility (Klemke et al.,
1997).
1.3.2 Integrins and cell proliferation
The biological effects attributed to integrin-ligand interaction are a consequence of
recruited signalling molecules. One such molecule, FAK, has been linked to a
number of intracellular signalling pathways described in Figure 1.2. FAK localises to
the plasma membrane at sites of integrin-mediated adhesion. Following integrin
clustering, autophosphorylation of FAK at Tyr397 results in the formation of a Src
homology 2 (SH2) binding domain (Schaller et al., 1994). The recruitment of Src
family kinases to the focal adhesion and subsequent tyrosine phosphorylation of
FAK leads to the phosphorylation of a number of focal adhesion components
including paxillin, tensin and pl30CAS, a docking protein that recruits Crk and Nek
(Vuori et al., 1996). These events lead to the recruitment of adaptor proteins CAS
and Crk and to the subsequent activation of the JNK pathway (Schlaepfer et al.,
1994). Autophosphorylated FAK can also combine with and activate PI 3-kinase
(Chen et al., 1996).
Src can also phosphorylate FAK on Tyr925, creating a binding site for the Grb2-
mSOS complex (Schlaepfer et al., 1994) resulting in the activation of the Ras
signalling pathway (Giancotti and Ruoslathi, 1999). The activation of the Ras-
ERK1/2 signalling pathway by integrin ligation has been shown to require an intact
cytoskeleton suggesting that integrin-dependent cytoskeletal complexes, such as
focal adhesions, are involved in the activation of the MAP kinase pathway (Kumar,
1998). ERK1/2 MAPK activation by integrins can also occur independently of FAK.
8
Introduction
The integrin subunits ov, a5, and ai can associate laterally with caveolin which in
turn binds Fyn (Wary et al., 1996). She can bind to the SH3 domain of Fyn resulting
in its phosphorylation. Once phosphorylated, She can recruit the Grb/SOS complex
leading to Ras activation (Wary et al., 1996).
Normal adherent cells require anchorage to ECM to proliferate. There are several
mechanisms by which integrin engagement may influence the cell cycle. Integrin-
mediated cell attachment is necessary for optimal activation of growth factor
receptors (Giancotti and Ruoslahti, 1999). Several /?i integrins, including i, have
been shown to associate with the EGF receptor (Miyamoto et al., 1996).
Integrin-growth factor complexes appear to be required for optimal mitogenic signal
pathway activation (Kumar et al., 1998).
Signals from She-linked integrins can co-operate in a synergistic manner with growth
factor receptors to promote cell cycle progression. Cell adhesion is specifically
required for the induction of cyclin D1 transcription and for the activation of the
cyclin E-cdk2 complex (Fang et al., 1996; Giancotti and Ruoslahti, 1999). Integrin
signalling may be directly needed for cyclin D1 transcription, as the cyclin D1
promoter is co-ordinately regulated by ERK1/2 and JNK (Albanese et al., 1995). The
effects of cell adhesion on cyclin E-cdk2 complex appears to be indirect and
mediated by downregulation of the cdk inhibitors p21 and p27 (Zhu et al., 1996).
The anchorage-dependent regulation of cyclin-Dl and the cdk inhibitors enables




Figure 1.2 Convergence of integrin and growth factor pathways
The major integrin and growth factor pathways involved in cell proliferation and
survival. Diagram shows signalling pathways which have been well established (bold
arrows) or presumed (dashed arrows) to be co-ordinately regulated by integrins and
growth factor receptors (Giancotti and Ruoslahti, 1999; Kumar, 1998).
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1.3.3 Integrins and cell survival
One of the most important functions of the integrin signalling pathways is to regulate
anchorage dependence. Epithelial and endothelial cells that detach from the
extracellular matrix undergo apoptosis, this has been termed anoikis (Frisch and
Francis, 1994; Meredith et al., 1993). Anoikis is a mechanism to ensure that when
cells are detached from their natural environment, they are eliminated prior to their
colonisation of another inappropriate environment.
FAK is involved in conveying survival signals from the ECM (see Figure 1.2).
Activated FAK can activate the phosphatidyl-inositide-3 kinase (PI-3 kinase)
pathway (Chen et al., 1996). Activation of the PI 3-kinase/Akt pathway results in
Akt promoting survival, by phosphorylation and subsequent inactivation of two pro-
apoptotic proteins Bad and caspase-9 (Khwaja et al., 1997). Since the inhibition of
ERK1/2 or activation of JNK cause apoptosis (Xia et al., 1995), integrins that
combine with She promote cell survival by increasing the activity of ERK1/2 thus
increasing the ratio of ERK1/2 to JNK signalling. The /3i integrins and fibronectin
have been implicated as playing a role in suppression of apoptosis and cell survival.
Fibronectin adhesion through a5iSi prevented CHO cells from undergoing serum-
starved induced apoptosis by increasing Bcl-2 expression (Zhang et al., 1995).
However, CHO cells engineered to express ay/31 as their fibronectin receptor did not
survive in serum-free conditions (Zhang et al., 1995) suggesting that cells may differ
in their integrin specificity to activate survival signals. Therefore, attachment to an
inappropriate surface through the wrong integrin would result in cell apoptosis.
1.3.4 Integrins and cellular transformation
Normal cells require both adherence to matrix proteins and stimulation by serum or
growth factors in order to proliferate. The convergence of the signalling pathways by
integrins and growth factor receptors determines cell cycle progression. Oncogenes
are components of the normal growth regulatory pathways that are constitutively




Constitutive activation of a step succeeding convergence of integrin and growth
factor signalling pathways would elicit both anchorage-and serum-independent
proliferation to the transformed cells (see Figure 1.3) (Kumar et al., 1998; Schwartz,
1997). The Ras oncogene results in both anchorage-and serum-independent
proliferation (Schwartz, 1997). Activation of the integrin signalling pathway, prior to
convergence would give rise to anchorage-independent but serum-dependent growth.
Rho family oncogenes are capable of inducing this phenotype (Schwartz et al.,
1996). Conversely, activation of the growth factor signalling pathway, before
convergence, should induce accelerated proliferation without causing anchorage
independence.
Tumour cell invasion and metastasis relies on constitutive activation of the integrin-

































e.g. Ras, Raf orMEK
Figure 1.3 Oncogenes and cellular transformation
(A) General proposal for the convergence of integrin-and growth factor-mediated
pathways in normal cells. Both pathways are required for normal activation of gene
expression and cell proliferation.
(B) Constitutive activation indicated by boldface arrows. Constitutive activation of
the integrin pathway, prior to convergence, should lead to anchorage-independent
growth. Anchorage-independent growth can be mediated by Rho, Bcr-Abl and ILK.
Constitutive activation of the growth factor pathway, prior to convergence, should
lead to serum-independent growth. Activation of a step subsequent to convergence,
by oncogenes such as Ras, Raf and MEK, induces anchorage-and serum-independent
growth (Schwartz, 1997).
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1.4 Integrin dysfunction and disease.
The in vivo function of integrins has been studied by the generation of monoclonal
blocking-antibodies and by studies of knock-out mice lacking a specific integrin
molecule. The largest subfamily of integrins is the 0i subfamily, which comprises of
twelve heterodimers that share the /3i subunit. Knocking-out the /5i subunit gene
results in very early embryonic lethality (Fassler and Meyer, 1995; Stephens et al.,
1995), due to the critical roles played by specific 0i integrins at early stages in
development. Figure 1.4 shows the critical roles of the subfamily. The interaction
between a5/5i and fibronectin is fundamental for invertebrate development, since lack
of asf3\ binding to fibronectin results in embryonic lethality (Yang et al., 1993).
Knock-out of the 02 subunit gene results in mice exhibiting most of the features of
the leukocyte adhesion deficiency seen in humans (see below) (Schmits et al., 1996).
03 null mice exhibit some embryonic loss due to placental defects and show reduced
survival after birth as a result of haemorrhaging (Hodivala-Dilke et al., 1999).
Studies of patients who have inherited rare and specific genetic defects of integrin
expression have provided an opportunity to observe the in vivo effect of the loss of
proper control of integrin expression or signalling.
Leukocyte adhesion deficiency-1 (LAD-1) disorder results from a lack of normal 02
expression. Mutations within the 02 subunit gene give rise to an altered precursor
protein which fails to bind to the a subunit precursor and prevents Q0 heterodimer
formation (Hogg and Bates, 2000). As a result, there is a lack of LFA-1, Mac-1 p95
and Qfc>02 integrin expression (Anderson and Springer, 1987). The disease
characteristics include re-occurring soft tissue infections, impaired wound healing
and severe gingivitis, primarily as a result of the absence of neutrophil infiltration
(Hogg and Bates, 2000).
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Figure 1.4 Critical roles of the /3i integrin subfamily
Diagram shows the large group of heterodimers that share the (3\ subunit. Also
described are the phenotypes produced by a homozygous null mutation of the j3\
subunit gene, highlighting the critical roles played by these subunits in development
(Sheppard, 2000).
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Glanzmann thrombasthenia (GT) is a bleeding disorder resulting from mutations in
the aiibft platelet integrin. Mutations have been observed in genes encoding both the
a-subunit am,, and the /3-subunit fa (Newman et al., 1991), resulting in deficient
expression or faulty function of the a^fa integrin. The absence of anbft-mediated
fibrinogen crosslinking, essential for platelet aggregation and clot formation, results
in excessive bleeding of the gums, cuts, wounds and other abnormal bleeding (Hogg
and Bates, 2000). The reverse effect is seen when excessive aggregation of platelets
occurs, resulting in embolism and blockage of small blood vessels (Clemetson and
Clemetson, 1998).
A patient has been described with defective function of both the fa and fa integrins
on leukocytes (LAD-1) and an^fa (GT) integrin (Kuijpers et al., 1997). While
expression of the integrins was not affected, they were not able to become activated
and as a result leukocyte adhesion and platelet aggregation were impaired (Etzioni,
1999). This resulted from defective inside-out signalling (see below), leading to
abnormal integrin clustering and deficiency of high avidity ligand binding
(McDowall et al., 2003). This is the first description of a dysfunction affecting three
classes of integrin (fa, fa and fa) (McDowall et al., 2003).
As discussed in section 1.3.4, malignant transformation relies on constitutive
activation of the integrin-dependent signalling pathways. Oncogene expression
associated with integrin signalling has been observed in tumour cells, resulting in
anchorage-independent growth. Studies of integrin expression profiles have
suggested that various integrin subunits may also contribute positively or negatively
to the transformed phenotype (Ruoslahti, 1992). High levels of ctsfa expression seem
to correlate with low levels of transformation (Plantefaber and Hynes, 1989). Over
expression of as fa in CHO cells increased fibronectin matrix assembly, inhibiting
tumour growth when injected into nude mice (Giancotti and Ruoslahti, 1990). In
contrast, increased expression of ctvfa is positively correlated with increased
malignancy in melanomas (Chan et al., 1991). In human melanoma patients, the
increased expression of o^fa together with decreased expression of a^fa correlates
significantly with the occurrence ofmetastases (Juliano and Varner, 1993).
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Analysis of knock-out mice and human disease pathology has provided insight into
the mechanisms by which integrins can affect cell behaviour. The precise control of
cell migration and adhesion is key to many biological processes and central to this
control is the interaction between integrins and their ligands. Levels of integrin
activation and expression must be tightly controlled in order to prevent diseases
arising from integrin dysfunction. The use of mAbs against integrins in vivo has
demonstrated that several integrins are valid therapeutic targets for the treatment of
inflammatory and cardiovascular responses. One such example is ReoPro (Centocor,
Leiden, The Netherlands), a chimeric antibody against the platelet integrin cdIb/33,
which is a potent anti-thrombotic agent used in patients with cardiovascular
complications following coronary angioplasty (Newham and Humphries, 1996).
1.5 Control of integrin affinity state
The ligand-binding activity of integrins is a dynamic and highly regulated process.
Inactivated integrins usually have a low-affinity for their ligand however, upon
activation integrins can participate in high-affinity ligand binding. There are two
non-exclusive mechanisms which can transiently alter the integrin activation state
without changing expression levels; integrin affinity modulation is a conformational
change within the integrin subunits determining integrin binding-state and integrin
avidity modulation is mediated by receptor clustering. Figure 1.5 shows a schematic
representation of integrin affinity and avidity modulation. Both of these mechanisms
are regulated by intracellular signalling proteins acting upon the cytoplasmic
domains of the integrin in a process termed 'inside-out signalling' (Bazzoni and
Hemler, 1998).
1.5.1 Integrin avidity modulation
The activation of /3i and integrins on leukocytes is characteristic of integrin avidity
modulation, as no physiological activators have ever been shown to induce integrin
affinity modulation (Brown and Hogg, 1996). Studies have shown that leukocyte (32
integrins, in particular oyft, (LFA-1) are maintained in a dispersed state due to
constraints imposed by the cytoskeleton (Kucik et al., 1996). Treatment of these cells
with phorbol ester released the cytoplasmic restraints and stimulated LFA-1
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mediated adhesion by rapid integrin clustering (Stewart and Hogg, 1996). In the
physiological environment, leukocyte activation is induced by various inflammatory
mediators including tumour necrosis factor (TNF) and platelet activating factor
which are produced at the endothelium or at sites of inflammation (Hynes et al.,
1992). The actin cytoskeleton is critical for integrin clustering, as treatment of cells
with cytochalasin D (which inhibits actin polymerisation) can inhibit integrin
clustering and cell adhesion (van Kooyk and Figdor, 2000).
Thus, the proposed model for leukocyte adhesion follows a cascade of events. First,
selectin interaction slows the flow-rate ofmigrating leukocytes over the endothelium
at sites of inflammation allowing the cell time to sense inflammatory mediators.
Following cell activation by the inflammatory mediators, rapid integrin clustering
occurs, increasing leukocyte adhesion to ligands such as ICAM-1, ICAM-2, VCAM-
1 and fibrinogen. This integrin-mediated adhesion is essential for transendothelial
migration to sites of infection (Brown and Hogg, 1996), and the requirement of this
step is highlighted by diseases such as LAD-1 arising from genetic defects in fa
expression.
1.5.2 Integrin affinity modulation
Integrins in the /3i, /?2, 1S3 and fa subfamilies have been shown to modulate their
integrin-binding affinity, in response to inside-out signalling (Hughes and Pfaff,
1998). Platelet aggregation is a physiological process dependent on integrin-affinity
modulation. The function of the OmA integrin in platelet aggregation is the best-
described example of integrin-affinity modulation.
The anbfa integrin on resting platelets does not bind to any of its soluble ligands,
therefore preventing thrombosis. Following platelet activation by specific agonists
such as thrombin and ADP, which signal through heterotrimeric G-proteins or by
activation of non-receptor tyrosine kinases such as Src (Payrastre et al., 2000), a
conformational change in otubfa is induced, leading to an increase in affinity for
soluble fibrinogen (Shattil et al., 1985). The subsequent clustering of the atnA
integrin then increases the cell avidity for fibrinogen and this results in irreversible
binding of ligand to am,fa (Hato et al., 1998).
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Figure 1.5 Models of integrin activation and ligand binding
(A) In integrin affinity modulation, a conformational change occurs and the integrin
acquires elevated affinity for ligand. Following ligand binding, the active
conformation is stabilised and further activation epitopes are exposed.
(B) Integrin avidity modulation occurs when integrin diffusion is elevated. Integrins
cluster at adhesive sites to increase avidity for ligand. Conformational changes only
occur following ligand binding.
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1.5.3 Regulation of ligand binding by inside-out signalling
Experimental approaches using recombinant integrins and the generation of ligand-
mimetic antibodies, which mimic ligand binding to the activated integrin and anti-
CLIBS (cation-and-ligand-influenced binding site) antibodies, have enabled further
analyses of the conformational changes which occur within integrins in response to
inside-out signalling. The PAC-1 ligand-mimetic antibody mimics fibrinogen's
ability to bind to the activated amfii integrin (Shattil, et al., 1985). PAC-1 contains
an RGD sequence within its heavy chain which enables affinity-specific recognition
of anbft (Kunicki et al., 1996). The binding of PAC-1 can therefore be used as a
measure for activated Onbft.
The cytoplasmic domains of integrins play a central role in affinity modulation.
Chinese hamster ovary (CHO) cells do not naturally express the oiubPi integrin. CHO
cells expressing aubft were unable to bind to soluble fibrinogen or PAC-1, even in
the presence of platelet agonists (O'Toole et al., 1990). However, anti-CLIBS
antibodies were capable of inducing PAC-1 binding which indicated that this integrin
was capable of undergoing a conformational change (O'Toole et al., 1990). CHO
cells naturally express the 05/31 (fibronectin receptor), which is maintained in a high-
affinity state (Faull and Ginsberg, 1996). CHO cells expressing atibft chimeras
containing the cytoplasmic domains of otsfii were capable of binding soluble
fibrinogen and PAC-1 (O'Toole et al., 1991; O'Toole et al., 1994). This indicates
that the cytoplasmic domains of a$\ are sufficient to induce a conformational
change of the chimeric integrin.
Specific sequences within the integrin cytoplasmic domains control the integrin
affinity state and both integrin subunits are required to regulate integrin affinity state.
Integrin a and (3 subunit cytoplasmic domains share a similar membrane-proximal
organisation (Hughes et al., 1996). The conserved sequences for the a and (3 subunits
are -GFFKR and LLv-iHDR (highly conserved residues are in uppercase, less
conserved residues are in lower case and dashes represent nonconserved residues)
respectively (Fernandez et al., 1998; Hughes et al., 1996). The associations between
the conserved sequences of the a and (3 subunits has been investigated using
mutagenesis of the Ofrbft integrin. Deletion of the either of the conserved sequences
20
Introduction
of the a and (3 subunits activates the integrin, locking it in a high affinity state
(Hughes et al., 1996). This region, termed the 'hinge-domain', results from the
formation of a salt-bridge between the two conserved regions of the a and (3 subunits
and may serve as a physical 'on-off switch in determining integrin affinity state
(Ginsberg et al., 2001; Hughes et al., 1996). Recent nuclear magnetic resonance
(NMR) studies by Vinogradova et al., (2002), who looked at the interaction of the
cytoplasmic domains following mutations that disrupt the salt bridge, support the
suggestion of a spatial separation of the integrin cytoplasmic domains upon integrin
activation.
Another conserved sequence has been identified in many (3 subunits, the NPXY
motif. Point mutations within this motif abolished PAC-1 binding from the aubft/
as/Si chimeric integrin (O'Toole et al., 1995). Mutation of this sequence in the ft
integrin was also shown to be important for integrin activation (Mastrangelo et al.,
1999). Additionally, a similar motif (NXXY) has also been identified on the
cytoplasmic domains of the ft, ft, and ft subunits (Fernandez et al., 1998). These
sequences regulate integrin affinity states by interacting with inside-out signalling
pathways and with cytoskeletal components.
A number of intracellular proteins have been reported to interact with integrin
cytoplasmic domains. These molecules have been implicated in both outside-in and
inside-out signalling. Several molecules including the calcium-and integrin-binding
protein (CIB), ft-endonexin, cytohesin-1 and talin, have been shown to bind to the /3
subunit cytoplasmic tails resulting in integrin activation (Travis et al., 2003).
Talin has been shown to bind to the f3 subunit cytoplasmic tails through its N-
terminal head domain, leading to integrin activation (Calderwood et al., 1999).
Crystal structure analysis of talin-integrin interactions has indicated that the
phosphotyrosine binding (PTB)-like domain of talin interacts directly with the ft tail
through the region containing the NPXY motif (Garicia-Alvarez, 2003). It was
hypothesised that talin binding to the ft tail could perturb the oftinterface, resulting
in integrin activation (Calderwood et al., 1999; Garcia-Alvarez, 2003). This was
confirmed by Vinogradova et al., (2002) who, using NMR studies, demonstrated that
talin binding could activate aubft by separating the a/3 complex. Other proteins that
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are associated with integrin cytoplasmic tails may also act like talin by directly
binding to and perturbing the afi subunit interface.
A number of intracellular signalling pathways have been implicated in modulating
integrin affinity, however they have yet to be fully defined. Studies on platelets
revealed that agonists, such as thrombin, activate the ctubft integrin via heterotrimeric
G-protein coupled receptor signalling and tyrosine phosphorylation (Shattil and
Brass, 1987). Other studies have indicated that the Ras family of small GTP-binding
proteins, and their effectors, play a crucial role in integrin affinity modulation (Keely
et al., 1998; Hughes et al., 1997).
1.5.4 Current model of inside-out integrin signalling
Structural analysis of the oy/33 full-length integrin has indicated that in a low-affinity
state, the extracellular domain of the integrin is in a bent conformation, with the N-
terminal ligand-binding pocket close to the membrane (Xiong et al., 2001). Electron
microscope analyses of the a5[3\ integrin suggest that upon activation, there is a
'flick-knife' opening of the integrin, with the extracellular domain straightening out,
exposing the ligand binding pocket (see Figure 1.6) (Takagi et al., 2003). This is
accompanied by subtle changes in the ligand-binding pocket of the integrin to create
a high-affinity ligand-binding site (Takagi et al., 2002). Currently integrin
cytoplasmic tail separation, following intracellular signalling or intracellular protein
interaction, is at the centre ofmodels of inside-out signalling.
Inside-out signalling is crucial to nonnal integrin function, allowing integrins to bind
to ligand only when appropriate signals and stimuli are present.
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Resting integrin Active integrin
Figure 1.6 'Flick-knife' model of integrin activation
Diagrammatic representation of the 'flick-knife' model of integrin activation.
The a-subunit is shown in red and the p-subunit is shown in blue. Asterisks mark the
position of ligand binding sites either at a P-propeller-A-like domain interface in
integrins lacking aA-domains, or at the top of the A-domain in integrins containing
aA-domains (aA-domains represented by light grey circle). Ligand-binding domains
are kept hidden, close to membrane surface. Following activation, the integrin
subunits bend at the 'knee' (between a-subunit thigh and calf regions). The straighter
conformation exposes the ligand-binding domains. Adapted from Takagi et al.,
(2002).
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Ras and Ras signalling
Research into the Ras proteins began almost forty years ago with the discovery of the
Harvey and Kirsten strains of mouse sarcoma retrovirus (Malumbres and Barbacid,
2002). These were isolated from mouse tumours induced by the murine leukaemia
virus that were passaged through rats (Harvey et al., 1964; Kirsten and Mayer, 1969).
The acronym Ras was derived from the words rat sarcoma, from which these genes
were initially identified. A protein of 21kDa was found to be encoded by the Harvey
and Kirsten strains of mouse sarcoma retrovirus, in cells transformed by these two
viruses (Shih et al., 1979). The p21 viral oncogenes from Ha-MSV and Ki-MSV
were shown to originate from a divergent family of normal rat cellular proteins called
Harvey-Ras (Ha-/H-Ras) and Kirsten-Ras (Ki-/K-Ras) (Ellis et al., 1981;
Langbeheim et al., 1980; Shih et al., 1979).
1.6 Ras genes
The importance of the Ras genes has been highlighted following the identification of
human genetic mutations, found in 30% of all human tumours, which were
homologous to the viral H-ras and K-ras (Der et al., 1982; Santos et al., 1982;
Parada et al., 1982). In 1983, Shimizu et al., (1983) and Hall et al., (1983), both
identified a third member of the Ras family, N-Ras (neuroblastoma). Molecular
cloning of the normal human ras proto-oncogenes and their oncogenic alleles
revealed that functional differences could be mapped to a single point mutation
(Reddy et al., 1982; Tabin et al., 1982). The normal cellular H-ras gene encodes a
glycine residue at position 12 (glyl 2), while the activated form of the H-ras gene
isolated from a bladder sarcoma cell line contains a glyl2 to vail2 mutation (Capon
et al., 1983; Reddy et al., 1982).
The ras genes have been isolated from organisms as diverse as Saccharomyces
cerevisae (DeFeo-Jones et al., 1983), Drosophila melangogaster (Neuman-Silberberg
et al., 1984) and humans. There is up to 65% amino acid sequence homology
between the ras genes from different species compared with the human ras proto-
oncogene (Lowe et al., 1987). The high degree of sequence conservation between
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species suggests that the ras genes serve important roles in fundamental cellular
processes.
The H-, K- and N-ras genes contain five exons, the first of which is noncoding
(Lowy and Willumsen, 1993). The introns differ in their sequence and size, with the
human genomic DNA sequences spanning 3kb {H-ras), 7kb {N-ras) and 35kb for K-
ras. K-ras is alternatively spliced into two isoforms: K-rasAA and K-rasAB
(Barbacid, 1987). The main products of the ras genes are proteins of about 21kDa,
hence the name p21Ras. While the ras genes are ubiquitously expressed, the
expression levels vary in different tissue types: H-ras is highly expressed in the skin
and in the skeletal muscles; K-ras is mostly expressed in the colon and thymus, and
N-ras in male germinal tissue and thymus (Lowy and Willumsen, 1993).
Of the three ras genes only K-ras appears to be essential and sufficient for
development, as mice with a double knock-out of H-ras and N-ras are viable
(Esteban et al., 2001; Koera et al., 1997).
1.6.1 The R (Related)-ras gene
The R-ras gene was first identified in a screen to identify genomic sequences related
to the ras gene family. Using low-stringency hybridisation to a v-H-ras gene probe
(Lowe et al., 1987), R-Ras was isolated due to its 55% sequence homology in the
region of overlap with H-ras. In contrast to the family of ras genes, R-ras had a
completely different exon-intron structure which suggests evolutionary distance
between the genes (Lowe et al., 1987). The R-ras gene contains six coding exons,
and the main product is a protein of about 23kDa (Lowe et al., 1987).
1.6.2 The Ras superfamily
The Ras superfamily now includes over 150 small GTPases. It comprises six
subfamilies, the Ras, Rho, Ran, Rab, Arf and Kir/Rem/Rad/Gem subfamilies
(Ehrhardt et al., 2002). The Rho family members are associated with the cell
cytoskeleton and gene expression (Ridley and Hall, 1992). The Rab family are
associated with secretory and endocytic pathways (Schimmoller et al., 1998) The Arf
family are associated with vesicular trafficking pathways and phospholipase D
activation (Brown et al., 1993). The cellular functions of the Kir/Rem/Rad/Gem
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subfamily remains to be fully established (Finlin et al., 2000) however, Rem and Rad
have been implicated in the regulation of Ca2+ channels (Finlin et al., 2003).
The Ras subfamily contains 13 members: H-Ras, N-Ras, K-Ras4A, K-Ras4B, R-Ras
proteins (R-Ras, R-Ras2/Tc21 and R-Ras3/M-Ras), Ral proteins (A and B), the Raps
(1A, IB, 2A and 2B), Rheb, Rin and Rit.
1.7 Structural comparison between Ras proteins and R-Ras
The amino terminal 84 residues of the three main Ras proteins are identical. The
importance of this sequence homology is highlighted by the fact that this region
includes the effector domain (residues 25 to 45), as well as the switch I (residues 30
to 38) and switch II (residues 59 to 76) domains. The next 80 residues of the Ras
proteins share 90% homology however, the remaining 25 residues of the carboxyl-
terminal region are highly variable. The carboxyl-terminal region has been termed
the 'hypervariable' region (HVR) and it comprises two distinct areas, the HVR linker
domain (H-Ras 166-179) and the carboxyl terminal (CAAX) targeting domain (H-
Ras 180-189) (see Figure 1.7) (Prior et al., 2001)
The main difference between the R-Ras protein and the N-, K- and H-Ras proteins is
the presence of an additional N-terminal 26 amino acids. The R-Ras protein contains
several sequences, which are conserved between the Ras proteins; these include four
blocks of amino acids, from R-Ras residues 32 to 46, 82 to 90, 102 to 110 and 138 to
146 (Lowe et al., 1987). These residues are conserved throughout the GTP-binding
protein superfamily (Halliday et al., 1984; Lebermann and Egner, 1984). In common
with the Ras proteins, R-Ras also contains a hypervariable linker domain (residues
193 to 206) and a C-terminal CAAX box (residues 215 to 219). See Figure 1.8 for H-
Ras and R-Ras amino acid sequence alignment.
1.7.1 Ras proteins function as GTP-binding proteins
The ras and R-ras genes code for proteins that bind guanine nucleotides and have an
intrinsic GTPase activity (McGrath et al., 1984; Gibbs et al., 1984; Lowe et al.,
1987). The Ras and R-Ras proteins function as molecular switches, when bound to
guanosine triphosphate (GTP) they are active and following hydrolysis of GTP to
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GDP they are inactive (Field et al., 1987; Sweet et al., 1984). The mechanisms of
GDP to GTP exchange will be described later.
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Linker domain Membrane-targeting domain
Figure 1.7 The Ras proteins and R-Ras hypervariable regions
Sequence alignment of the four Ras isoforms and R-Ras, focusing on the
hypervariable regions. The hypervariable domain comprises the linker domain (dark
grey) and membrane-targeting domain (light grey). Within the membrane-targeting
domain the C-terminal CAAX box, common to all the proteins, contains a conserved
cysteine residue (red). Second signalling sequences include: cysteine palmitoylation
sites (shown in blue) in H-Ras, N-Ras, K-Ras4A and R-Ras and a polybasic domain
in K-Ras4B (underlined residues). Modified from Prior and Hancock (2001).
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1 15 16 30 31 45 46 60 61 75 76 90
1 Hras MTEY KLVWGAGGVGKSAL TIQLIQNHFVDEYDP TIEDSYRKQWIDGE TCLLDILDTAGQEEY 64
2 Rras MSSGAASGTGRGRPR GGGPGPGDPPPSETH KLVWGGGGVGKSAL TlQFIQSYEVSDYDP TIEDSYTKICSVDGI PARLDILDTAGQEEF 90
Switch I
91 105 106 120 121 135 136 150 151 165 166 180
1 Hras SAMRDQYMRTGEGFL LVFAINNTKSFEDIH QYREQIKRVKDSDDV PMVLVOJKCDLAAR- TVESRQAQDLARSYG IPYIETSAKTRQGVE 153
2 Rras GAMREQYMRAGHGFL LVFAIKDRQSFNEVG KLFTQILRVKDRDDF PWTLVGNKADLESQR QVPRSEASAFGASHH VAYFEASAKLRLNVD 180
181 195 196 210 211 225 226
1 Hras DAFYTLVREIRQHKL RKLNPPDESGPG—C MSCKCVLS 189
2 Rras EAFEQLVRAVRKYQE QELPPSPPSAPRKKG GGCPCVLL 218
HVR linker HVR C-terminal
domain binding domain
Figure 1.8 H-Ras and R-Ras amino acid sequence alignment
Sequence alignment ofH-Ras and R-Ras with homologous amino acids, shown to be
conserved throughout GTP-binding proteins, shown in red. Regions in green denote
areas of high sequence homology within the effector region. Green residues overlap
with Switch I region (underlined). The blue residues highlight the hypervariable-
linker domain, which is the area of most sequence divergence between the Ras
proteins. The orange residues show the conserved CAAX box, found in all Ras
proteins in the C-terminal binding region of the hypervariable domain. HVR domains
labelled.
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1.8 Post-translational modification and membrane-targeting
of Ras and R-Ras proteins
The Ras proteins (H, N and K-Ras) exhibit significant biological differences despite
their high degree of sequence homology. The main sequence divergence is confined
to 23-amino acids of the carboxy-terminal hypervariable region (HVR) (Prior et al.,
2001). The main difference between the R-Ras protein and the N-, K- and H-Ras
proteins is the presence of an additional N-terminal 26 amino acids, as well as the
HVR. The localisation of Ras to the plasma membrane is essential for its correct
biological activity (Williumsen et al., 1984). Figure 1.9 shows the C-terminal
modifications and membrane-trafficking pathways of the Ras proteins.
1.8.1 C-terminal modifications
The two signals responsible for the correct localisation of Ras are contained in the
Ras HVR (Jaumot et al., 2002). The first signal sequence, common to all Ras
proteins, is the C-terminal CAAX box (C, cysteine; A, aliphatic; and X, any amino
acid) (Hancock et al., 1989). Ras proteins undergo a series of post-translational
modifications on their CAAX motif (Okada et al., 1996). The first stage of the
processing involves three successive modifications of the CAAX motif (i)
farnesylation (polyisoprenylation) of the cysteine residue, (ii) proteolytic cleavage of
the amino acids -AAX, and (iii) methyl esterification of the new C-terminal cysteine.
This first stage of modification coverts the primary translation product into an
intermediate form. H-, N-Ras and K-Ras4A are further modified by acylation with
palmitic acid on cysteine residues (Cys181 and Cys184) immediately upstream of the
CAAX motif, yielding the final, fully modified form (Hancock et al., 1990).
Palmitoylation of H-, N-Ras and K-Ras4A and the poly-lysine stretch in K-Ras4B,
contribute to the correct membrane localisation of the proteins.
H-Ras mutants, H-Ras Ser181' 184 (which were farnesylated but lacked the cysteine
residues to be palmitoylated) activated Raf as efficiently as fully modified H-Ras
(Okada et al., 1996). In contrast, H-Ras Ser186 (which lacked the cysteine residue to
be farnesylated) had almost negligible activity, indicating that the post-translational
modifications of H-Ras, especially the farnesylation step, are critical for normal
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activation of Raf (Okada et al., 1996). Moreover, it has recently been observed that
intracellular galectin-1 is essential for, and stabilises the interactions of H-Ras GTP
within the cell membrane and that the H-Ras farnesyl moiety is essential for this
interaction (Paz et al., 2001).
R-Ras is also palmitoylated (Lowe and Goeddel, 1987) but possesses a different C-
terminal prenylation motif to H-Ras for post-translational modification and is
geranyl-geranylated rather than farnesylated (Lowe et al., 1988; Osada et al., 1999).
An important consequence of HVR divergence between the proteins is that the
plasma membrane anchors for each of the proteins is different. Since the H-Ras, N-
Ras and K-Ras proteins all contain identical sequences including the effector,
exchange factor and guanine-nuclcotide-binding domains, perhaps the biological













Figure 1.9 C-terminal modification and membrane-trafficking of Ras
proteins
Ras proteins are synthesised as cytosolic proteins (light grey circles). The common
CAAX box is recognised by the cytosolic farnesyltransferase enzyme, which
catalyses the addition of the farnesyl isoprenoid lipid (F) to the cysteine residue.
Endoplasmic reticulum associated enzymes catalyses the proteolytic removal of the
AAX residues and carboxyl methylation of the farnesylated cysteine residue. H-Ras,
N-Ras and K-Ras4A then migrate through the Golgi. A second set of signalling
sequences are required to traffic Ras proteins to the plasma membrane. The lysine-
rich sequence of K-Ras4B (referred to in diagram as K-Ras) provides the second
signal required for transit to the membrane. H-Ras, N-Ras and K-Ras4A undergo
covalent addition of palmitate fatty acid moieties to cysteine residues located
upstream ofCAAX motif. The palmitate modification of H-Ras targets it to the lipid
rafts and caveolae of the plasma membrane. This is dependent on activation state of
H-Ras. The lysine-rich sequences of K-Ras4B target it to the disordered plasma
membrane. Modified from Prior and Hancock, (2001); Reuther and Der, (2000).
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1.8.2 Trafficking of proteins to the plasma membrane
The post-translational modifications of the Ras and R-Ras proteins increase the
hydrophobic nature of the C-terminal domains of the proteins, increasing their
affinity for membranes. The enzymes required for post-translational farnesylation
and palmitoylation have been identified on the endoplasmic reticulum (ER)
(reviewed by Prior and Hancock, 2001). A mammalian homologue to the recently
cloned Saccromyces cerevisae, ER localised, Ras palmitoyltranferase (RPT) is
thought to exist (Lobo et al., 2002; Hancock, 2003). Following palmitoylation on the
ER, H-Ras and N-Ras proteins access the plasma membrane by vesicular trafficking
through the classical exocytic pathway, on the cytoplasmic surface of the vesicles
(Apolloni et al., 2000; Choy et al., 1999). In contrast, the polybasic K-Ras4B is
largely excluded from the Golgi (see Figure 1.9). The K-Ras trafficking pathway
remains elusive, although it has been suggested that it may involve microtubule
binding (Apolloni et al., 2000; Choy et al., 1999) or simple passive diffusion from
the ER to the plasma membrane (Roy et al., 2000). The trafficking pathway for R-
Ras has yet to be defined.
A consequence of the alternative trafficking pathways adopted by the Ras proteins is
that their eventual membrane microlocalisations are different.
1.8.3 Targeted membrane microdomains
The simple fluid mosaic model of the plasma membrane has been made more
complex by the discovery of microdomains which have distinct protein and lipid
compositions. The lipid raft, comprising sphingolipids and glycosphingolipids
packed together with cholesterol, is the best characterised microdomain (Simons and
Ikonen, 1997). The liquid-ordered structure of lipid rafts promotes phase separation
from the loosely packed, disordered glycosphingolipids of the bulk plasma
membrane (Prior and Hancock, 2001). Lipid rafts have been proposed as important
structures of the plasma membrane which serve as signalling platforms (Simons and
Ikonen, 1997).
Membrane proteins which associate with the lipid rafts, such as
glycophosphatidylinositol (GPI)-anchored proteins, are anchored with long, saturated
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acyl chains (Simons and Ikonen, 1997). While proteins anchored by farnesyl or
geranylgeranyl groups alone are excluded from lipid rafts (Melkonian et al., 1999).
H-Ras has been shown to be efficiently targeted to the lipid rafts following post-
translational modification (Prior et al., 2001). It is thought that H-Ras is initially
trafficked to lipid rafts and caveolae, where lipid rafts have been aggregated into
invaginations of the plasma membrane by caveolin (Simons and Toomre, 2000), but
then exists in a dynamic equilibrium between lipid rafts (in the GDP-bound state)
and the disordered bulk plasma membrane (in the GTP-bound state) (Prior et al.,
2001). In contrast K-Ras, which is anchored by prenylation and electrostatic charge,
resides in the disordered, non-raft plasma membrane regardless of activation state
(Prior et al., 2001). As yet, the targeted membrane microdomain of R-Ras has not
been elucidated.
The importance of correct membrane localisation of the Ras proteins has been
illustrated by Prior et al., (2001), who compared Raf-1 activation by activated H-Ras
with an H-Ras HVR mutant confined to the lipid rafts. Although Raf-1 can be
recruited to the lipid rafts and bulk plasma membrane equally well, activation is
much less efficient in the lipid rafts (Prior et al., 2001).
1.9 Regulating Ras/R-Ras activity
1.9.1 The Ras/R-Ras-GTP/GDP cycle
In addition to post-translational modification, the Ras and R-Ras proteins require
GTP-binding for activation. The proteins cycle between an inactive GDP-bound state
and an active GTP-bound state (see Figure 1.10). Inactive GDP-bound proteins are
activated by interaction with proteins known as Guanine Exchange Factors (GEF),
which catalyse the release of GDP. The lost GDP is then rapidly replaced by the
more abundant GTP (Lenzen et al., 1998). The exchange of GDP for GTP drives an
allosteric change in the Switch I and Switch II regions (Boriack-Sjodin et al., 1998).
The Switch I region, which forms part of the effector binding domain, permits the
binding of effectors when Ras is in the GTP-bound configuration (Ehrhardt el al.,
2002). Several Ras-GEFs have been characterised. Mammalian SOS, a homologue of
the Drosophila son ofsevenless gene product, has been identified as a Ras activator,
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which responds to signals which generate tyrosine phosphorylation at the interior of
the cell (Bowtell et al., 1992; Gotoh et al., 2001; Lai et al., 1993). Other Ras-GEFs
include RasGRFland 2 (Farnsworth et al., 1995; Fam et al., 1997) and Ras-GRP
(Ebinu et al., 1998), which all respond to different signals.
GTPase-activating proteins (GAPs) also bind to the GTP-bound Ras proteins, these
proteins serve to enhance the intrinsic GTPase activity of the proteins, resulting in
the hydrolysis of GTP to GDP and returning the protein configuration to the inactive
state (Wittinghoffer et al., 1997). There have been several distinct Ras-GAPs
identified: pl20GAP, a predominantly cytosolic protein (McCormick, 1998),
neurofibromatosis typel protein (NF-1) (Ballester et al., 1990) and Gaplm (Li et al.,
1996).
The R-Ras GTP-binding protein also cycles between an inactive GDP-bound state
and an active GTP-bound state. The Ras proteins GEFs, Ras-GRP and RasGRFland
2, as well as a Rail GEF called C3G, have been shown to activate R-Ras (Ohba et
al., 2000). As yet, no GEFS specific for R-Ras have been identified. The GAPs for
the Ras family pl20GAP, NF-1 and Gaplm, have all been shown to increase R-Ras
GTPase activity (Ohba et al., 2000). A GAP specific for the activation of R-Ras has
been identified and termed R-RasGAP (Emkey et al., 1991; Yanamoto et al., 1995).
As this regulatory protein seems more specific, it may play a critical role in the
specific regulation of the R-Ras subfamily (Ohba et al., 2000). Figure 1.10(B)
provides a table of all the known H-Ras and R-Ras GAPs and GEFs.
Point mutations within the Switch I and Switch II regions of the Ras and R-Ras
proteins block the GTPase activity, leading to constitutively active proteins. The
amino acids in Ras, Gly12 and Glu61, are essential for Ras GTPase activity by GAP
stimulation (Macaluso et al., 2002) and mutating them inhibits GTP hydrolysis.











GEFs GAPs GEFs GAPs
RasGRFl NF1 RasGRFl NF1
RasGRF2 GAPlm RasGRPl GAPlm
RasGRF3 GAPIII RasGRP3 GAPIII
RasGRPl p 120RasGAP CalDAG-GEFl pl20RasGAP
SOS 1/2 GAPIP4BP GAPIP4BP
Figure 1.10 The Ras GDP/GTP activation cycle
(A) Schematic representation of the regulation of Ras proteins. Extracellular stimuli
mediated by G-protein coupled receptors, RTKs and adhesion molecules activated
various GEFs which exchange bound GDP for GTP producing the active Ras protein.
Ras GAPs enhance the intrinsic Ras GTPase activity, resulting in the hydrolysis of
GTP to GDP and returning protein to inactive state.
(B) Table to show and compare the known H-Ras and R-Ras GAPs and GEFs.
Abbreviations used: GAP, GTPase-activating protein; GEF, guanine-nucleotide
exchange factor; GRF, guanine-nucleotide-releasing factor; GRP, guanine-
nucleotide-releasing protein; SOS, Son of Sevenless; NF1, neurofibromin 1;
CalDAG, calcium and diacylglyceroi. Modified from Kina'bara et al., (2003).
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1.9.2 Ras activation
Ras activation can be mediated by a number of different receptors including receptor
tyrosine kinases (e.g. the epidermal-growth-factor (EGF) receptors, G- protein
coupled receptors and ligand-stimulated integrins (see section 1.3.2). The best
described of these signalling pathways is that of growth factor stimulation of Ras
activity.
Following ligand (EGF) binding, activated receptor tyrosine kinases (RTK) auto-
phosphorylate key tyrosine kinases at their carboxyl terminus (Pazin and Williams,
1992). These phosphotyrosines serve as binding sites for adaptor proteins such as
She and Grb2, which contain SH2-binding domains (Gale et al., 1993; Lowenstein et
al., 1992). Grb2 consists of one SH2 and two SH3 domains. Grb2 is constitutively
associated with the Ras-GEF SOS via its SFI3 domain, whilst the SH2 domains of
Grb2 mediate binding to the EGFR phosphotyrosines either directly or through the
adaptor protein She (Li et al., 1993; Rozakis-Adcock et al., 1993; Okutani et al.,
1994). Recruitment of the Grb2-SOS complex to the EGFR positions SOS adjacent
to the membrane-bound Ras, thus facilitating the release of GDP from Ras and
replacement with GTP.
The heterotrimeric G-protein coupled receptors, in particular the pertussis toxin-
inhibitable (Gj) receptors, can influence Ras activity via their G-protein subunits (a
and /37). Activation of the G-protein receptors increases the phosphorylation of the
adaptor protein She, leading to increased Shc-Grb2-SOS complex formation and
subsequent Ras activation (Denhart, 1996; Lowes et al., 2002). G-proteins are also
capable of activating Ras-GEFs such as RasGRFl and RasGRP, resulting in GDP-
GTP exchange (Reuther and Der, 2000).
While the activation pathways for Ras have been described, the upstream-signalling
pathways involved in the activation ofR-Ras have yet to be elucidated. Activation of
the Ras family proteins family leads to their interactions with a variety of
downstream effector proteins. While methods of activation for the Ras proteins and
R-Ras cannot yet be compared, R-Ras has been shown to bind to similar effector
proteins as the Ras proteins. The interactions and subsequent signalling pathways




Activated Ras stimulates a multitude of downstream signalling cascades and it is
through these pathways that Ras controls cell proliferation, survival and cell
behaviour contributing to a transformed phenotype. Ras effectors preferentially bind
to GTP-bound Ras. The three main Ras effectors Raf kinase, PI3-kinase and Ral-
GEFs, bind to the minimal effector region of Ras (residues 32-40) and increase their
'in-vivo' activity after Ras binding. R-Ras and the other Ras proteins have highly
homologous effector binding domains; consequently GTP-bound R-Ras is capable of
binding to several common effectors. Figure 1.11 shows the main effectors of Ras
and their associated pathways.
1.10.1 Raf kinase
The serine/threonine kinase Rafwas one of the first Ras effectors to be identified and
has been the most intensely studied. The raf gene was first discovered as the
transforming oncogene in the mouse sarcoma virus 3611 (Rapp et al., 1983). The
proto-oncogene, c-raf-1, was identified in non-transformed cells (Kozak et al., 1984).
Upon activation, Raf-1 was demonstrated to activate the p42/44 mitogen activated
protein kinases (MAPKs) or extracellular-signal-regulated kinases (ERK1/2) (Howe
et al., 1992). Three Raf isoforms have been identifed: Raf-1, A-Raf and B-Raf. The
Raf isoforms display differential catalytic activity towards MEK (B-Ras>Raf-l>A-
Raf), and this activity is represented by different levels of ERK1/2 activation
(Pritchard et al., 1995). A key observation that implicated the Raf-1 serine/threonine
kinase as a critical effector of Ras function was that Ras-GTP forms a high affinity
complex with Raf-1 (Zhang et al., 1993; Moodie et al., 1993; Vojtek et al., 1993).
The Raf protein consists of an N-terminal noncatalytic domain and a C-terminal
kinase domain. The N-terminal regulatory domain contains two Ras binding domains
(RBD) and a cysteine rich domain (CRD). Removal of the N-terminal domain results
in a constitutively active Raf (Raf-BxB) (Morrison and Cutler, 1997). The
mechanisms by which Ras mediate Raf activation, and subsequent ERR1/2
activation have been intensely studied. Inactive Raf exists in the cytosol where it is
constitutively associated with several proteins, including the phosphoserine binding
protein, 14-3-3, which may serve as a negative regulator (Wartmann and Davis,
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1994; Campbell et al., 1998). Activated Ras binds to the first RBD and recruits the
Raf complex to the plasma membrane. At the membrane, phosphatidylserine (PS)
facilitates the binding of Ras binds to Raf CRD, by displacing 14-3-3 (Hu et al.,
1995). Other factors including kinase suppressor of Ras (KSR), phospholipids,
HSP90 and both serine/threonine kinases lead to full Raf activation (reviewed by
Morrison and Cutler, 1997; Kolch, 2000).
R-Ras also interacts with the Raf serine/threonine kinases in a GTP-dependent
manner (Spaargaren et al., 1994) however, in contrast to Ras, R-Ras does not
activate Raf (Marte et al., 1997).
1.10.2 PI 3-kinase
Phosphatidylinositol-3-OH kinase (PI 3-kinase) is another effector of the Ras family
that has kinase activity against lipids and proteins. PI 3-kinase can phosphorylate the
3' position of the inositol ring on phosphoinositides (Carpenter and Cantley, 1996).
PI 3-kinase is composed of a pi 10 catalytic and a p85 regulatory subunit. The pi 10
catalytic domain of PI 3-kinase has a high affinity for the GTP-bound form of Ras
G12V through the Ras effector domain (Rodriguez-Viciana et al., 1994; Rodriguez-
Viciana et al., 1996). Ras stimulation of PI 3-kinase activity is required for its
optimal activation in response to growth factors (Rodriguez-Viciana et al., 1994).
The phosphorylated lipid products of PI 3-kinase can regulate a number of proteins
including Rac, p70S6 kinase, PKB/AKT and isoforms of protein kinase C (Carpenter
and Cantley, 1996). PKB/AKT enzyme activity has been implicated in cell survival
by inactivating BAD (pro-apoptotic factor) by phosphorylation (Datta et al., 1999;
Downward et al., 1998). The Ras family are also able to mediate activation of the
Rho subfamily proteins via PI 3-kinase activation ofRac (Ehrhardt et al., 2002).
R-Ras also binds to the pi 10 catalytic subunit of PI 3-kinase in vitro and induces an
elevation in the levels of PI 3-kinase lipid products in vivo, demonstrating that PI 3-
kinase is downstream of R-Ras (Marte et al., 1997). Activated R-Ras may increase
the activity of PI 3-kinase more efficiently than H-Ras, which in turn is more
efficient than K-Ras4B (Yan et al., 1998).
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Figure 1.11 Common Ras effector pathways
Active Ras will interact with several families of effector proteins. The main effectors
are shown here along with their downstream effectors and cellular effects.
Abbreviations: ERK, extracellular regulated kinase; GSK3, glycogen synthase kinase
3; MEK, mitogen-ctivated kinase/ERK kinase; PDK1, phosphatidylinositol
trisphosphate-dependent kinase 1; PLA2, phospholipase A2; PLD, phospholipase D;
RSK, ribosomal protein S6 kinase (Downward, 2003).
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1.10.3 Ral guanine exchange factors
The Ral-GEFs are Ras effectors, which activate the Ras related proteins RalA and
RalB. These RalGEFs include Ral guanine nucleotide dissociation factor (RalGDS),
RalGDS-likel/2 (Rgll/2) and RalGDS-like factor (Rlf) (Hofer et al., 1994; Peterson
et al., 1996; Wolthuis and Bos, 1999). The C-terminal noncatalytic domains of
RalGDS, Rgll/2 and Rlf interact with the effector domain of Ras in a GTP-
dependent manner in vitro and can compete with Raf-1 for binding to the Ras
effector binding region in vitro (Campbell et al., 1998). A role for Ral in the
regulation of the cell cycle has been demonstrated by its ability to upregulate the
expression of cyclin D1 (Henry et al., 2000).
R-Ras also binds RalGDS however, in contrast to Ras it does not enhance the Ral-
GEF activity ofRALGDS (Urano et al., 1996).
1.11 The ERK1/2 signalling pathway
The mitogen-activated protein (MAP) kinases, also termed ERK 1 and 2
(extracellular-regulated kinases), control many cellular responses. In fact, ERK
activity has been implicated as a regulatory component in nearly every fundamental
cellular activity. The Raf/MEK/ERK pathway is perhaps the best described Ras
effector pathway.
The activation of ERK1/2 pathway first requires the activation of the dual specificity
kinases MAPK/ERK Kinasel/2 (MEK1/2), also called MKK1 and MKK2
(Dhanasekaran and Reddy, 1998). The predominant MEK activators are Raf kinases
(Schaeffer and Weber, 1999). MEK1/2 can directly associate with the C-terminal
catalytic domain of Raf-1, resulting in its phosphorylation (Crewes and Erikson,
1993). MEK1 is activated by phosphorylation on two serine residues, Ser218 and
Ser222 and MEK2 is activated by phosphorylation on serine residues Ser219 and
Ser223 (Alessi et al., 1994) leading to full activation of MEK activity. The
interaction between Raf and MEK can be disrupted by Raf kinase inhibitor protein
(RKIP) (Kolch, 2000). RKIP seems to act as a physiological regulator of ERK
signalling by controlling Raf/MEK interactions (Kolch, 2000). Activated MEKs
function as dual specificity kinases and phosphorylate ERK1/2 threonine and
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tyrosine residues (Crews et al., 1992). These residues Thrl83 and Tyrl85 (on
ERK2), reside within a TEY-motif (Thr-X-Tyr, where X is glutamic acid) (Payne et
al., 1991). Phosphorylation of both of these residues is required for full activation
and subsequent increase in ERK activity (Anderson et al., 1990; Robbins et al.,
1993). Map kinase phosphatases (MKP) can specifically dephosphorylate threonine
and tyrosine residues, regulating in vivo ERK activity (Alessi et al., 1993).
Once activated, ERK1/2 translocate to the nucleus where they phosphorylate and
activate a variety of transcription factors that include Elk-1 nuclear transcription
factor (Marais et al., 1993). Elk-1 forms a complex with serum response factor (SRF)
at the serum response DNA element (SRE) present in many promoters (Price et al.,
1996), promoting transcription of genes such as the transcription factor c-fos
(Janknecht et al., 1993).
Ras-ERKl/2 signalling can lead to cell proliferation through the induction of cyclin
D1 expression and degradation of the cell cycle inhibitor p27kip which is induced by
Ras-ERKl/2 signalling. This facilitates passage through G1 and entry into the S-
phase of the cell-cycle (Woods et al., 1997).
Not all activated ERK1/2 translocates to the nucleus, ERK1/2 is also capable of
activating a number of cytoplasmic proteins. Myosin light chain kinase (MLCK) is
activated by ERK1/2 phosphorylation (Morrison et al., 1996). Phosphorylated
myosin light chains (MLC) result in a fully functional actin-myosin motor unit,
which serves to produce the contractile forces within the cell required for cell
motility (Klemke et al., 1997).
1.12 Biological effects of Ras and Ras-related proteins
Despite sharing common activators and effectors the Ras proteins and R-Ras have
distinct biological functions. Ras is the most commonly mutated gene in human
tumours (Bos, 1989). Constitutively active mutants of Ras (G12V) promote
transformation of a variety of fibroblast and epithelial cell lines, whereas R-Ras
(G38V) only causes the transformation of NIH-3T3 cells (Huff et al., 1997; Shields
et al., 2000). Ras activation of the Raf-MEK-ERKl/2 kinase cascade has been shown
to be necessary for cellular transformation (Cowley et al., 1994; Mansour et al.,
1994). H-Ras G12V transformed cells show constitutively elevated Raf-1 kinase
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activity in contrast, no elevated Raf kinase activities were observed in R-Ras G38V
transformed NIH-3T3 cells (Huff et al., 1997). R-Ras, but not H-Ras, has been
observed in complex with the anti-apoptotic protein Bcl-2 suggesting a role for R-
Ras in apoptosis (Fernandez-Sarabia, 1993).
The functions of the Ras and R-Ras GTPases are not restricted to their roles in cell
growth and proliferation, 'inside-out' signalling pathways involving these GTPases
have also been implicated in mediating integrin-affmity modulation. Zhang et al.,
(1996), demonstrated that R-Ras, but not H-Ras, can increase cell adhesion by
modulating integrin function.
Regulation of integrins by Ras proteins
1.13 Modulating integrin expression levels
In order to achieve correct cellular function, the interactions between integrins and
their ligands must be strictly regulated. Cellular adhesive strength to the ECM or
other cells can be regulated in a number of ways including modulation of surface
expression levels of integrins. Leukocytes increase ft expression levels to facilitate
recruitment to sites of tissue injury (Hillis and MacLeod, 1996).
Ras signalling activates several pathways which can result in transcriptional changes,
including levels of integrin expression. The modulation of integrin surface
expression by ras genes is cell-and integrin-specific. Constitutively active Ras
(probably H-Ras) increased ft expression levels in human melanoma and pancreatic
carcinoma cell lines (Woods et al., 2001). Conversely, expression of a constitutively
active Ras mutant in an endothelial cell line resulted in a reduction in a3ft integrin
expression (Shin et al., 1999). While expression of H-Ras G12V in human
osteoblasts reduced the expression levels of ft, c&t, <%, Qfe (Tanaka, 2002), expression
of H-Ras G12V in a pro-B cell line had no significant effect on the expression levels
of the Otft, a5ft, ofeft integrins (Fujimoto et al., 2001; Shibayama et al., 1999;
Tanaka et al., 1999).
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1.14 Regulation of integrin affinity
The rapid activation of integrins is essential for the ability of a cell to respond to
environmental changes. Activation of integrins is often gauged by an increase in cell
adhesion to immobilised substrate. Cell adhesion requires a combination of integrin
affinity and avidity and therefore, pathways which modulate cell adhesion can not be
solely credited to affinity changes (Hughes and Pfaff, 1998). Cell binding to soluble
ligand and ligand-mimetic antibodies provide a better model for measuring integrin
affinity changes.
Soluble fibrinogen and PAC-1 (ligand-mimetic antibody to aubft) binding to
platelets increases upon platelet activation (Bennett and Vilaire, 1979). ttiibft
expressed in CHO cells, however, failed to respond to any anbft-stimulating agonists
such as ADP, thrombin and phorbol esters (O'Toole et al., 1990). Substitution of the
«iibft cytoplasmic domain with that of the laminin (QfcA|8i) integrin produces a
constitutively active chimeric integrin in CHO cells (o^-py cells) (O'Toole et al.,
1991; O'Toole et al., 1994). Binding of the PAC-1 ligand-mimetic antibody (acts
like soluble fibrinogen) to the chimeric integrin can be used to determine integrin
activation state. This o^-py cell model system and adhesion assays have been used to
help investigate the cytoplasmic signalling pathways involved in integrin-affinity
modulation.
1.14.1 H-Ras modulates integrin affinity
Expression of activated H-Ras (G12V) in c^-py cells suppressed the active chimeric
integrin by means of a pathway that was sensitive to MAP kinase phosphatase-1
(Hughes et al., 1997). Suppression of the integrin was not related to protein
synthesis, integrin phosphorylation or mRNA transcription (Hughes et al., 1997).
Suppression of integrin affinity by H-Ras is cell- and integrin-type specific.
Expression of constitutively active H-Ras suppresses integrin activation in fibroblasts
(Hughes et al., 2002). In contrast, constitutively active H-Ras induces the activation
of cq/31, ofs/3i, and Qfe/Ji, (in a pro-B cell line) without altering integrin expression
levels (Fujimoto et al., 2001; Shibayama et al., 1999; Tanaka et al., 1999).
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Investigations into H-Ras downstream effectors and their roles in suppressing
integrin activation highlighted the ability of an activated variant of Raf-1 to
effectively suppress integrins in CHO cells (Hughes et al., 1997). As the suppression
of integrins by activated H-Ras and Raf-1 was alleviated by the MAP kinase
phosphatase-1 (Hughes et al., 1997), it was hypothesised that H-Ras/Raf-mediated
integrin suppression was dependent on ERK1/2 activation. However, more recent
studies have indicated that suppression of integrins by H-Ras/Raf does not require
with ERK1/2 activation (Hughes et al., 2002). Suppression of ct^\ integrin by active
Raf-1 was shown to be independent ofERK1/2 activity, as inhibition ofERK1/2 by a
MEK inhibitor failed to alleviate Raf-1-mediated integrin suppression (Hughes et al.,
2002). Consistent with this, an active variant of MEK1 (which potently activates
ERK1/2) fails to suppress integrins (Hughes et al., 2002; Kinbara et al., 2003).
In cells where H-Ras was shown to enhance integrin activation, the downstream
effector PI 3-kinase has been implicated in mediating the H-Ras effect. In bone-
marrow-derived mast cells H-Ras induced adhesion, through activation of u5fi\
integrin, was susceptible the PI 3-kinase inhibitor wortmannin (Kinashi et al., 2000).
In the study by Kinashi et al., (2000), targeting PI 3-kinase to the cell membrane
using a CAAX tail, resulted in enhanced adhesion and spreading of the mast cells
whereas membrane-targeted Raf-CAAX failed to enhance adhesion and spreading of
the cells. The choice of effector pathway utilised by H-Ras in mediating integrin
affinity may be cell-type dependent (Kinbara et al., 2003).
1.14.2 R-Ras promotes integrin activation
R-Ras was first implicated in integrin regulation when expression of constitutively
active R-Ras (G38V) converted the suspension-cell lines, mouse 32D and human
myeloid cells, into highly adherent cells (Zhang et al., 1996). Stable expression of
activated R-Ras significantly enhanced a2|Si -dependent cell migration in human
breast carcinoma cells, promoting cell invasion across collagen (Keely et al., 1999).
R-Ras causes extensive cell spreading when injected into PC 12 cells, although the
identity of the integrins involved in PC 12 cells is not clear (Self et al., 2001).
Expression of R-Ras G38V also induces the adhesion of bone-marrow-derived mast
cells through activation of a5fi\ (Kinashi et al., 2000). Expression of R-Ras G38V in
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retinal neurons promoted late embryonic stage retinal neurite outgrowth on laminin-1
(LN-1) through activation of CfcjSi integrin (Ivins et al., 2000).
The downstream effectors involved in R-Ras-mediated integrin activation remain to
be elucidated; however a proline-rich, SH3-binding C-terminal motif (Wang et al.,
2000) and C-terminal prenylation (Oertli et al., 2000) within R-Ras have been shown
to be important for integrin activation. The ability of R-Ras to control integrin
activity can be regulated by phosphorylation. Activation of the Eph (ephrin) receptor
EphB2 phosphorylates a tyrosine residue (Tyr66) in the effector domain of R-Ras,
this phosphorylated R-Ras can no longer support integrin activity and cell-ECM
adhesion is lost (Zou et al., 1999; Zou et al., 2002). Zou et al., (2002) found that
oncogenic Src also phosphorylates R-Ras on Tyr66, which may explain the reduced
cell adhesion that is characteristic of Src-transformed cells.
A recent study has implicated PI 3-kinase in R-Ras-induced cell spreading. Keely et
al., (1999) demonstrated that PI 3-kinase inhibitors prevented the restoration of
fibroblastic cell spreading by R-Ras.
1.14.3 R-Ras antagonises H-Ras/Raf-mediated integrin suppression
Despite their sequence homology and overlapping use of effectors and GEFs, H-Ras
and R-Ras have different functional effects on integrins. In CHO cells, expression of
R-Ras promotes the active integrin state while expression of H-Ras suppresses the
integrin activation. Furthermore, co-expression of active R-Ras G38V with active H-
Ras G12V, in CHO cells, reversed H-Ras-mediated integrin suppression (Sethi et al.,
1999). The reversal of H-Ras-mediated integrin suppression by R-Ras is not due to
competition for the common effector Raf-1, as R-Ras can reverse the integrin
suppression caused by an active Raf-1 which lacks the Ras-binding domain (Raf-
BxB CAAX) (Sethi et al., 1999). The mechanism by which R-Ras antagonises H-
Ras/Raf-mediated integrin suppression is currently under investigation however,
several candidate proteins have been proposed which may influence the R-Ras effect.




Resting integrin Active integrin
Plasma membrane
Figure 1.12 R-Ras antagonism of H-Ras/Raf integrin suppression pathway
Boldface arrows highlight the well established pathways. Where a
mechanism/pathway remains to be elucidated, the proposed pathway is shown by
dashed arrows.
H-Ras activates the Raf/MEK/ERK pathway, which can lead to the suppression of
integrin activation. PEA-15 binds directly to ERKs and prevents their translocation
to nucleus, although it has no affect on ERK activity. PEA-15 is capable of reversing
Ras-mediated integrin suppression. Expression of R-Ras reverses H-Ras-mediated
integrin suppression. PEA-15 has been identified as a possible R-Ras effector.
Activated Rap-1 can activate integrins. Rap-1 activation of R-Ras has been proposed
as a mechanism for reversing H-Ras-mediated integrin suppression (Kinbara et al.,
2003).
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In a screen to identify proteins that antagonise Ras-mediated integrin suppression in
fibroblasts, Ramos et al., 1998, identified PEA-15. PEA-15, a small death effector
domain (DED)-containing protein, does not block the capacity of Ras to activate the
ERK1/2 mitogen-activated protein kinase pathway (Ramos et al., 1998). It has been
hypothesised that PEA-15 reverses H-Ras-mediated integrin suppression by means of
R-Ras, as PEA-15's action is blocked by a dominant negative R-Ras (Ramos et al.,
1998).
It is interesting to note that PEA-15 interacts directly with ERK7 MAPKs, to
sequester them to the cytoplasm thus preventing ERK/MAPK-dependent
transcription and cellular proliferation, but does not inhibit ERK/ MAPK activity
(Formstecher et al., 2001). R-Ras G38V reversal of H-Ras-mediated integrin
suppression does not result in diminished levels of ERK1/2 phosphorylation. As
PEA-15 reverses Ras-mediated integrin suppression but does not inhibit ERK/
MAPK activity, this could implicate PEA-15 as a possible R-Ras effector.
Rapl, a member of the Ras subfamily, has been shown to be activated following
stimulation by cytokines and growth factors. Similar to R-Ras, activated Rap-1 has
been shown to activate integrins. Erythropoietin and IL-3 activate Rap-1 to promote
the adhesion of haematopoietic cells through oqjSi or a5(3\ integrins (Arai et al.,
2001). Activated Rap-1 (VI2) increased anbft affinity in megakaryocytes, as
measured by binding of an amA activation-specific monovalent Fab fragment
(antigen-binding fragment) (Bertoni et al., 2002). Both R-Ras and Rap-1 activate the
o.m@2 macrophage integrin to initiate complement-mediated phacocytosis (Caron et
al., 2000). Microinjection of Rap-IGAP in to a macrophage cell line eradicated R-
Ras induced aufii activation (Self et al., 2001), indicating that R-Ras requires Rap-1
activity to activate the integrin, in this cell line.
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General aims of this thesis
As discussed in the first part of the introduction, the strict regulation of integrin
function is essential for normal cellular processes. Despite having 55% homology, H-
Ras and R-Ras have very different effects on integrin affinity. Studies have shown
that expression of the H-Ras oncogene (H-Ras G12V) in CHO ajS-py cells can result
in the suppression of activation of the stably expressed chimeric integrin. However,
expression of activated R-Ras (G38V) reverses H-Ras-mediated integrin suppression.
One of the main aims of this thesis is to further examine the role ofH-Ras and R-Ras
in integrin affinity. For this, a series of H-Ras and R-Ras chimeric molecules will be
utilised. These chimeras have been designed on the basis of transposing the most
variable regions of H-Ras and R-Ras, in the hope of identifying the specific regions
of the proteins involved in conferring their contrasting effects on integrin affinity
state.
A further aim will be to investigate the different functional effects of H-Ras and R-
Ras on CHO cells. Using CHO cells stably expressing the H-and R-Ras chimeric
proteins, it is hoped that the specific areas of the H-Ras and R-Ras proteins relating
to their differing functional effects may be investigated. Results from functional
assays will then be linked back to integrin-affinity status to see if the H-Ras and R-






Unless otherwise stated, all chemicals were purchased from Sigma (Dorset, UK).
The following reagents were obtained from Life Technologies (Paisley, UK):
Dulbecco's Modified Eagles Medium (DMEM); penicillin; streptomycin; dialysed
foetal calf serum (FCS); L-glutamine 30% (w/v) and non-essential amino acids.
Antibodies were obtained from the following sources: anti-HA (Y-ll), anti-myc
(9E10 and A14), anti-ERK2 (C-14), anti-Raf-1 (E-10) were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Phospho-ERKl/2 (ERK-PT115); anti-FLAG
M2 monoclonal antibody; anti-FLAG M2 monoclonal antibody-FITC conjugate;
anti-Cholera toxin and anti-mouse IgG (whole molecule) were from Sigma (Dorset
U.K). All anti-species specific horseradish peroxidase-conjugated antibodies and
RPE-Conjugated monoclonal mouse anti-Human CD25 Interleukin-2 receptor were
from DAKO (Bucks, UK). All anti-species specific Alexa-Fluor-conjugated
antibodies were purchased from Molecular Probes (The Netherlands). Function-
blocking antibody, 4B4, was purchased from Coulter (Hialeah, Florida). Function-
activating jSi antibody, TS2-16, was obtained from an in-house hybridoma.
Transformation competent Escherichia coli strain DH5a cells were purchased from
Life Technologies (Paisley, UK); strain TOPIO cells were purchased from Invitrogen
(Groningen, Netherlands); XL-1 Blue Subcloning-Grade competent cells and XL-1
Blue Competent cells were purchased from Stratagene (La Jolla, CA, USA).
DNA constructs were obtained from the following sources: all pCDNA3.1(+) - H/R-
Ras chimeras (CHI, CH3, CH5, CH6, H197, R197, H201 and R201), Tac-a5
(permission from Dr. S. E. LaFlamme, Centre for Cell Biology and Cancer research,
NY, USA), pDCR-H-Ras (G12V) (permission from Dr. D. H. Wiger, Cold Stream
Harbour Laboratory, NY, USA), pSG5-R-Ras G38V (permission from Prof. J.
Downward, ICRF, London, UK) were provided by Dr. M. H. Ginsberg (Scripps
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Research Institute, La Jolla, USA). pCDNA3-Raf-BxB CAAX was provided by Dr.
C. K. Weber (University of Ulm, Germany), pEGFP-C3 (empty vector, H-Ras WT
and H-Ras G12V) were provided by Dr Yoel Kloog (Department of
Neurobiochemistry, Tel-Aviv University).
2.2 Cell Culture
The QjS-py CHO cell line was a generous gift from Dr. Mark Ginsberg (Scripps
Institute, La Jolla, USA). This cell line stably expresses a chimeric integrin
comprised of OubCvA/Si (Hughes et al, 1997). Stable expression of the chimeric
integrin is maintained through culture in the presence ofG418.
The Q)S-py cell line was cultured in Dulbeccos Modified Eagles Media (DMEM),
supplemented with 10% (or 0.1% for quiescent media) (v/v) FCS (heat inactivated at
57°C for 1 hour, unless pre-inactivated), 1% (v/v) non-essential amino acids and
G418 antibiotic (400pg/ml) (Invitrogen), this will be referred to as complete media.
The CHO-K1 cell line was cultured in the same media as the aj3-py cell line, without
the G418 antibiotic. Stable lines were cultured in the same media as the c$-py cell
line, with G418 antibiotic (800pg/ml) to maintain selection.
All media contained 50 IU/ml streptomycin and 5mg/ml L-glutamine and all cell
lines were maintained in a humidified atmosphere of 5% CO2 / 95% air at 37°C. All
cell lines were used at the lowest possible passage number and regularly screened for
mycoplasma infection.
2.3 Transformation of Escherichia coli
Frozen Escherichia coli (TOP 10, XL-1 Blue or XL-1 Blue) aliquots were thawed on
ice and transferred to chilled eppendorfs. DNA (l-10ng) was gently mixed with the
cells and incubated on ice for 30 minutes. Cells were then heat-shocked at 42°C in a
thermomixer for 60 seconds and returned to ice for a further 2 minutes. Transformed
cells were allowed to grow in antibiotic free SOC media for 60 minutes at 37°C with
agitation (500rpm in thermomixer), prior to spreading onto appropriate antibiotic
selection plate. Plates were incubated at 37°C overnight in an incubator. Individual
colonies were picked into Luria-Bertani (LB) broth containing selection antibiotics
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and grown at 37°C overnight, in an incubator with a shaking platform to agitate
cultures, for DNA purification and restriction enzyme analysis.
2.4 DNA Purification
Mini-prep (1-10ml) DNA purifications were performed using the Wizard SV
Miniprep kit (Promega) as per manufacturers instruction. Large scale (100-500ml)
DNA purifications were performed using the Qiagen Endotoxin Free Maxi-prep kit
(Qiagen, Crawley, UK) as per manufacturers instruction.
Diagnostic restriction digests were performed on purified DNA with the appropriate
restriction enzymes (Promega) and resolved on 1-2% agarose (Seakem, Rockland,
Maine, USA) gels containing 0.3pg/ml ethidium bromide to enable UV visualisation.
The Pharmacia Biotech Ultraspec 2000 UV spectrophotometer was used to quantify
purified DNA.
Where necessary, restriction digest products were gel purified using the Quick Gel
extraction kit (Qiagen), as per manufacturer's instruction.
Ethanol precipitation was used to purify DNA products following restriction digests
where it was necessary to keep the loss of DNA to a minimum. NaAc was added to
the restriction digest at 1/10 total digest volume. EtOH was added at 2X total digest
volume and 1 pi glycogen was added as a carrier. Samples were spun down and the




Transient transfections of afi-py and CHO-K1 cells were performed with
Lipofectamine™ and the Plus reagent (Invitrogen). Cells were seeded at an
appropriate density so as to reach 50-70% confluency overnight in 60/100mm tissue
culture treated dishes (Corning, High Wycombe, UK). Purified DNA was placed in
5ml BD Falcon tubes (Part No: 352034, Oxford, UK) in a volume ranging l-20pl.
The DNA was pre-complexed with 1 lOpl of the Plus reagent and gently mixed. The
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Plus reagent mixture contained Plus reagent 0.25% (v/v) diluted in DMEM
containing 1% non-essential amino acids (+AA). Following a 15 minute room
temperature incubation, the DNA was complexed with llOpl of the Lipofectamine
mixture and gently mixed. The Lipofectamine mixture contained Lipofectamine
reagent 0.25% (v/v) diluted in DMEM(+AA). Following a further 15 minute
incubation, the transfection mixture was made up to a final volume of 4ml in warmed
DMEM(+AA) and placed onto washed cells. Cells were incubated for 5 hours at
37°C and then fed with complete media (4ml). Twenty four hours after transfection,
media containing DNA and Lipofectamine was removed and replaced with fresh
complete media. For experiments where protein kinase activities were to be assessed,
the transfection media was replaced with quiescent media. Forty eight hours post-
transfection cells were either lysed for SDS-PAGE analysis or used for integrin
affinity analysis.
2.5.2 Production of stable cell lines.
For each plasmid DNA to be stably expressed, CHO-K1 cells were transfected in
100mm dishes using 3pg of plasmid DNA. Forty eight hours post transient
transfection, CHO-K1 complete media was supplemented with G418 at 800pg /ml
(stable selection media). Stable selection media was replaced frequently as
untransfected cells began to die and selected cells grew back to confluency. Once the
100mm plates were fully confluent, cells were trypsinised, washed and resuspended
in PBS (w/o ca and mg). The single cell suspension was seeded into 96-well plates at
a density of approximately one cell/well. Cells were incubated at 37°C until clonal
growth was observed in the wells (colour change). Cells were trypsinised from the
wells and plated out in duplicate wells (of 6-well plates) and grown to confluency in
selection media. The expression of some gene products is not well tolerated, such
that cells which have either low or no protein expression may be preferentially
selected. Therefore, it is desirable (and in the case of cells which are not
morphologically transformed, critical) to test the selected populations for expression
of the gene of interest. This was carried out by SDS page and western blot analysis or
by intracellular FACS staining using one set of the duplicate wells, the second well
was maintained to grow up gene positive clones.
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2.6 Assessment of protein concentration
Protein concentrations were quantified using BCA protein reagent (Pierce, IL, USA).
A protein standard curve was generated using bovine serum albumin (Sigma) at a
range of 0.1-0.5mg/ml diluted in 1:5 lysis buffer. Samples were diluted 1 in 5 in
dfUO and lOpl incubated with 200pl BCA reagent (30 minutes, 37°C) in 96 well
plates. Protein concentration was determined using an automated plate reader (MRX
microplate reader, Dynatech, Chantilly VA).
2.7 SDS Page and Western Blotting
2.7.1 Cell Lysis
Transfected cells were washed once with ice-cold PBS and lysed at 4°C in an
appropriate volume of lysis buffer. Lysates were shaken for 20 minutes at 4°C and
then cleared by centrifugation at 13000rpm for 10 minutes at 4°C, assessed for
protein concentration (described in 2.6) and solubilised in 4x sodium dodececyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer at 99°C for
5 minutes. Samples were analysed immediately or stored at -20°C for future analysis.
BUFFERS:
Lysis buffer: 50mM Hepes (Na Salt), 0.3M NaCl, 1.5mM MgCl2, 1.2mM EDTA,
0.5% Triton X-100 (v/v), 20mM /3-glycerphosphate, lOOmM sodium fluoride, lOmM
sodium pyrophosphate, ImM sodium vanadate and 0.5mM dithiothreitol (DTT). One
CompleteIM protease inhibitor tablet (Boehringer Manheim, Lewes, UK) was added
per 50ml of lysis buffer.
2.7.2 SDS PAGE and Western Immunoblotting
Samples were cooled, or thawed from frozen, and equal amounts of protein (10-
lOOpg) were resolved on SDS polyacrylamide gels using a vertical electrophoresis
tank Biorad Protean 3 system (Biorad, Hemel Hempstead, UK). Samples were
electrophoresed at 100-150 volts using SDS-Tris-glycine electrophoresis buffer for
1-2 hours alongside pre-stained molecular weight markers (Invitrogen, Paisley, UK).
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For optimal separation, 8% gels, 10% and 12% gels were used for analysis of 60-120
kDa proteins, 40-70 kDa proteins and 10-40 kDa proteins respectively.
Proteins were transferred onto Hybond C nitrocellulose membranes (Amersham
Pharmacia Biotech, Amersham, UK) in a methanol based transfer buffer at 400
milliamps for 1 hour using a Mini Protean II blotting tank (Biorad, UK). Equal
protein loading was confirmed by incubating blots for 5 minutes in Ponceau S
staining solution (Sigma). Non-specific protein binding sites on the membranes were
blocked by incubation with TBS-Tween 20 containing 5% non-fat dried milk powder
for 1 hour at room temperature. Membranes were probed with appropriate primary
antibodies (Table 2.1) diluted in TBS-Tween 20 containing 5% non-fat dried milk
powder overnight at 4°C. Membranes were washed in TBS-Tween 20 (3 x 10 minute
washes) before species appropriate horseradish peroxidase (HRP) conjugated
secondary antibody (DAKO, Ely, UK) (diluted in TBS-Tween 20 containing 5%
non-fat dried milk powder) was added for 1 hour (Table 2.1). Finally, membranes
were washed as above and immunoreactive bands were identified using enhanced
chemiluminescence (ECL) (Amersham Pharmacia Biotech, Amersham, UK) as per
manufacturer's instructions.
BUFFERS:
4x SDS-PAGE sample buffer: 50mM Tris-HCl, 10% (v/v) glycerol, 2% (v/v) SDS,
0.1% (v/v) bromophenol blue and 10% (v/v) /3-mercapoethanol.
SDS polyacrylamide gels: Resolving Gel - 0.375M Tris base (pH8.8), 0.1% (v/v)
SDS, 8-12% (v/v) acrylamide (Life Technologies, Paisley, U.K.), 0.1% (v/v)
ammonium persulphate and 0.08% (v/v) TEMED.
Stacking Gel - 0.13M Tris Base (pH8.8), 0.15% (v/v) SDS, 4.6% (v/v) acrylamide,
0.13% (v/v) ammonium persulphate and 0.1% (v/v) TEMED.
Gel electrophoresis buffer: 5mM Tris base (pH8.3), 25mM glycine and 0.01% (v/v)
SDS.
Transfer buffer: 210mM glycine, 24.7mM Tris base and 20% (v/v) methanol.
TBS-Tween 20 Wash buffer: TBS containing 0.2% (v/v) Tween 20 (Sigma).
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Primary Antibody Dilution Secondary Antibody Dilution
Ha Antibody (Y-l 1) 1:500 Anti-Rabbit HRP 1:1000
Myc Antibody (9E10) 1:1000 Anti-Mouse HRP 1:1000
Phospho-ERK1/2 1:2000 Anti-Mouse HRP 1:1000
ERK2 (C-10) 1:2000 Anti-Rabbit HRP 1:1000
FLAG (M2) monoclonal 1:3000 Anti-Mouse HRP 1:1000
Raf-1 (E-10) 1:1000 Anti-Mouse HRP 1:1000
Table 2.1 Immunoblotting antibody dilutions
2.8 Integrin affinity determination by flow cytometry
2.8.1 Cell Staining
Integrin affinity in transfected cells was analysed by three-colour flow cytometry,
forty eight hours post transfection. Cells were transfected with test DNA (0-1Opg)
together with 0.75pg Tac-cts transfection reporter construct (extracellular domain of
the IL-2 receptor and the intracellular domain of the a5 integrin). Single cell
suspensions of trypsinised cells were resuspended in a total volume of 50pl
containing 0.4% (v/v) PAC1 ascites (gift from S. Shattil, Scripps Institute, La Jolla,
USA or purchased from Becton Dickinson, Oxford, UK) (Shattil et al., 1985) for 30
minutes at room temperature in Hepes/NaCl buffer. Internal controls for each sample
were performed containing either 5mM EDTA or lOOpM MnCU Cells were washed
with cold PBS (w/o ca and mg) and incubated on ice with 50pl DMEM containing
4% (v/v) anti-mouse IgM-FITC (Biosource, Nivelles, Belgium) for 30 minutes in the
dark. Cells were washed with cold PBS and incubated for a further 30 minutes with
50pl DMEM containing 2% (v/v) anti-Tac-R-phycoerythrin (R-PE) (DAKO, Ely,
UK). Cells were finally washed and resuspended in cold PBS. Immediately prior to
analysis on a FACS-Caliber (Becton Dickinson, Oxford, UK), ToPro3 (Molecular




Hepes/NaCl buffer: 20mM Hepes, 140mM NaCl, 1.8mM CaCb, ImM MgC^ and
2mg/ml Glucose, pH 7.4.
2.8.2 FACS and data analysis
PAC1 binding was determined by gating for live and highly transfected cells
(ToPro3 negative and high Tac binding respectively). To obtain numerical estimates
of integrin activation, an integrin activation index (AI) was calculated.
AI = ((FN - Fi) / (Fa - Fj)) x 100 and Percent Inhibition = ((AI0 -AI) /AIo) x 100
Fn: Geometric mean fluorescence intensity (MFI) of PAC1 binding of the native
integrin
Fp MFI ofPAC1 binding in the presence of 5mM EDTA
Fa: MFI of PAC1 binding in the presence of lOOpM Mn2+
AIo: Activation index with the control vector
AI: Activation index with DNA under test
2.9 Stable expression determination by flow cytometry
2.9.1 Intracellular staining
Stable protein expression was analysed by flow cytometry following antibiotic
selection. Single cell suspensions of trypsinised cells were fixed in lOOpl PBS
containing 70% (v/v) ice cold methanol for 20 minutes on ice. Cells were washed
with cold FACS Flow (Becton Dickinson, Oxford, UK) and resuspended in 150pl
permeabilisation buffer (mixing gently with a pipette) for 10 minutes at room
temperature. Cells were washed with FACS Flow and resuspended in a total volume
of 50pl permeabilisation buffer containing appropriate primary antibodies for 30
minutes at room temperature. Cells were washed with cold permeabilisation buffer
and incubated on ice with 50pl permeabilisation buffer containing appropriate FITC-
conjugated secondary antibodies for 20 minutes on ice in the dark. Cells were finally
washed and resuspended in cold FACS Flow. Cells were analysed on a FACS-
Caliber (Becton Dickinson, Oxford, UK).
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Permeabilisation buffer: 0.5% Saponin (Sigma) (v/v) in FACS Flow, pH 7.4.
Primary Antibody Dilution Secondary Antibody Dilution
Ha Antibody (Y-l 1) 1:50 Anti-Rabbit IgG FITC 1:50
Myc Antibody (9E10) 1:50 Anti-Mouse IgG FITC 1:50
FLAG (M2) monoclonal 1:400 Anti-Mouse IgG FITC 1:50
Table 2.2 Intracellular FACS staining antibody dilutions.
2.9.2 FACS and data analysis
Primary antibody binding was determined by gating for untransfected controls
(primary antibody negative), gated labelled Ml. Numerical estimates for expression
of subsequent samples obtained from the percentage of cells positive for primary
antibody, gated labelled M2.
2.10 Gene subcloning
Fl-Ras G12V and R-Ras G38V genes were obtained from Dr. M. H. Ginsberg
(Scripps Research Institute, La Jolla, USA). H-Ras G12V and R-Ras G38V were
cloned vectors pDCR and pSG5 respectively. To permit stable cell selection, genes
were subcloned into pCDNA3.1(+) (see Appendix I for construct map).
R-Ras G38V was subcloned into pCDNA3.1(+) using a simple EcoRI restriction
digest from pSG5, followed by ligation into a pre-cut pCDNA3.1(+) vector. Cells
were transformed with the ligation products (see section 2.3). Plasmid DNA positive
for a 600bp insert were sent for sequence analysis to check for correct insert
orientation.
Fl-Ras GUV was amplified from pDCR using high-fidelity PCR, with forward and
reverse primers designed against Fl-Ras GUV (see Table 2.3). Following
amplification, PCR products were cloned into pGEMT- vector prior to subcloning
into pCDNA3.1(+).
2.10.1 High fidelity PCR of genes
Primers were designed flanking the gene of interest. All primers were screened
against Genbank databases to check for mismatches or cross-reactivities, none were
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found. High fidelity PCR was performed using Pfu Turbo DNA polymerase
(Stratagene, Amsterdam, Netherlands). Fifty nanograms of template DNA were
amplified in a reaction volume of 50pl containing (IX Pfu reaction buffer (contains
2mM MgS04), 0.2mM of each dNTP, 0.2pM of each primer and 2.5U of Pfu
polymerase). Reactions were performed on a MWG Primus 96 Plus machine
(Ebersberg, Germany), with standard cycle conditions (unless otherwise stated)
which involved a 1 minute incubation at 95°C followed by 25 cycles at 95°C for 1
minute, 62°C for 1 minute and 72°C for 1 minute. After this, a final step at 72°C for
10 minutes was followed by cooling to 4°C. PCR products were resolved on a 1%





Table 2.3 Primers for H-Ras G12V high fidelity PCR
2.10.2 Cloning of genes into pGEMT vector
PCR products were ethanol precipitated and 500ng of the product was used in a poly-
A-tail reaction containing 2mM dATP and 2.5U standard Taq polymerase (Promega,
Southampton, UK), reactions were performed for 30 minutes at 70°C. Poly-A-tailed
PCR products were ligated into the pGEMT vector (Promega) using the Rapid
Ligation kit. Ligations were performed as per manufacturers instructions using 50ng
of pre-cut pGEMT vector and a 3:1 insert ratio. Following a 2 hour ligation at room
temperature, 50% of the ligation mixture was transformed into DH5(X E.Coli and
spread onto LB agar plates containing 50pg/ml ampicillin, 0.5mM isopropylthio-
beta-D-galactoside (IPTG) and 80pg/ml 5-Bromo-4-chloro-3-indoyl beta-D-
galactopyranoside (X-Gal). White colonies were subsequently amplified and
screened for correct insert size by appropriate restriction digests.
Successful ligations were sent for sequencing either at Genetix Genescreen or an in-
house sequencing facility using the ABI automated fluorescence sequencing kit.
Sequences from clones that matched the template DNA were subsequently used for




Site-directed mutagenesis was carried out using the QuikChange® Multi Site-
Directed Mutagenesis Kit (Stratagene) as per manufacturers instructions. In brief:
firstly, mutagenic primers (listed in Table 2.4) were used in a high fidelity PCR (see
2.10.1) of template, 50ng of (R-Ras (G38V) in pCDNA3.1 (+)). Secondly, the PCR
products are treated with the restriction endonuclease Dpn 1. DNA isolated from most
E.Coli strains is dam methylated, the Dpnl endonuclease (target sequence 5'-
Gm6ATC-3') is specific for methylated and hemimethylated DNA and is used to
digest parental DNA template and to select for the newly synthesised DNA,
containing the required mutation. In the third step, the reaction mixture, enriched
with multiply mutated single strand DNA, is transformed into XL-1 Blue Competent











Table 2.4 Site Directed Mutagenesis Primers
2.12 Splice-overlap Extension by PCR
Splice-overlap extension by PCR was carried out according to Warrens et al., (1997).
In brief, high fidelity PCR ( see section 2.10.1) was used to generate PCR products in
all stages of this method. MgCh (BDH) concentrations were optimised for splice-
overlap PCR, and a concentration of 3.5mM MgCl2, was found to the most efficient
concentration. Reactions were performed in a final volume of either 25 or 50pl.
Table 2.5 provides a list of the primers used. See Chapter 5 (figure 5.11) for
schematic representation of SOE by PCR.
In all first stage reactions, 50ng of template DNA (R-Ras G38V) and 125ng of each
oligonucleotide primer were added. The PCR protocol used at this stage (unless
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otherwise stated) involved an initial melting step at 95° for 1 minute, followed by 30
cycles as follows: 92°C for 90s, 55°C for 90s, and 72°C for 1 minute (usually 1
minute per kb of template). After this, a final step at 72°C for 15 minutes was
followed by cooling to 4°C. Appropriate PCR controls were performed for each
reaction. Following the first stage, the PCR products were gel purified (see section
2.4) and used in the second-stage reaction.
Equimolar amounts of the first stage intermediate products were added to the second
stage reaction, along with 125ng of appropriate primers and 3.5mM MgCh. The PCR
protocol used at this stage (unless otherwise stated) involved an initial melting step at
95°for 1 minute followed by 4 cycles at : 95°C for 90s, 58°C for 90s, and 72°C for 2
minutes (usually 1 minute per kb of template), followed by 25 cycles at: 95°C for
90s, 68°C for 90s, and 72°C for 2 minutes. After this, a final step at 72°C for 15
minutes was followed by cooling to 4°C. The final product was gel-purified and

















Table 2.5 Primers for SOE by PCR
2.13 ERK activity assay
Cells were transfected as described in section 2.5.1, and quiesced 24 hours prior to
lysis. Samples were lysed on ice as for SDS-PAGE in 0.5ml kinase lysis buffer.
Lysates were cleared by centrifugation at 13000rpm for 10 minutes and protein
concentration determined (see section 2.6). Protein concentrations were normalised
to approximately lmg/ml and 400pl of each cell lysate was incubated with 2pg of
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anti-ERK2 (C-14) antibody (Santa Cruz) for 1 hour at 4°C. Anti-mouse agarose
beads (20jnl/ sample, Sigma) were added and the samples vortexed for 1 hour at 4°C.
Agarose beads were washed 3x in Wash buffer and once in Kinase buffer. Each
sample was incubated at 30°C for 20 minutes in 20pl of kinase buffer containing
lOpg myelin basic protein, 100pM ATP and lpCi y-33P ATP (500Ci/mmol)
(Amersham Pharmacia Biotech). Samples were spotted onto Whatman p81 paper
(Whatman Inc, new Jersey, USA) and washed extensively in 0.5% phosphoric acid
and allowed to dry, radioactivity was quantified by liquid scintillation counting using
'Flo-Scinf IV (Packard, Biosciences, Groningen, Netherlands) and a Packard 1900
TR liquid scintillation counter.
BUFFERS: (all made up with dH20, at pH7.4, unless otherwise stated)
Kinase lysis buffer: 25mM Hepes (Na Salt), 0.3M NaCl, 1.5mM MgCl2, 0.2mM
EDTA, 0.5% Triton X-100 (v/v), 20mM /3-glycerphosphate, ImM sodium vanadate
(pH7.4) and 0.5mM DTT. One CompleteIM protease inhibitor tablet (Boehringer
Manheim, Lewes, UK) was added per 50ml of lysis buffer).
Wash buffer: 20mM Hepes (Na Salt), 50mM NaCl, 2.5mM MgCl2, O.lmM EDTA
Kinase buffer: 20mM Hepes (Na Salt), 0.5mM sodium fluoride, 7.5mM MgCl2,
0.2mM EGTA, lOmM /3-glycerphosphate, 0.5mM sodium vanadate (pH7.4), 2mM
DTT and Complete1 M protease inhibitor tablet.
2.14 ERK 1/2 ELISA
ERK 1/2 ELISA [pTpY185/187] carried out as per manufacturers instructions
(Biosource International).
In brief: twenty-four hours post transfection cells were quiesced and the following
day cells were lysed (as described in 2.7.1). Protein concentrations were normalised
(see section 2.6) and cell lysates and standards were added to wells coated with
ERK1/2 specific monoclonal antibody and incubated for 2 hours at room
temperature. Wells were washed and lOOpl of antibody specific for ERK1/2
phosphorylated at threonine 185 and tyrosine 187 was added to the wells for 1 hour
at room temperature. Wells were washed and 100pl anti-rabbit IgG-HRP was added
for 30 minutes at room temperature. Wells were washed and lOOpl of Stabilised
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Chromogen was added to each well for 30 minutes at room temperature in the dark.
A Stop solution was added and absorbance was read at 450nm. The intensity of this
coloured product was directly proportional to the concentration of ERK1/2
[pTpY185/187] present in the original sample.
2.15 2-Step Raf kinase assay
Cells were transfected as described in section 2.5.1, and quiesced 24 hours prior to
lysis. Samples were lysed on ice in 0.5ml Barnard lysis buffer. Lysates were cleared
by centrifugation at 13000rpm for 10 minutes and protein concentration determined
(see section 2.6). Protein concentrations were normalised and 400pl of each cell
lysate incubated with lpg of Raf-1 (E-10) antibody for 1 hour at 4°C. Anti-mouse
IgG agarose beads (25 pi / sample, Sigma) were added and the samples vortexed for 1
hour at 4°C. Agarose beads were washed 3x in 500pl RIPA buffer and then 2x in
500pl Dilution buffer. Sample volumes were adjusted to 30pl using Dilution buffer.
First step: Sample (lOpl) was incubated for 15 minutes at 30°C in 15pl of dilution
buffer containing 0.1 pg His-tagged MEK-1 (FL, Santa Cruz), lpg His-tagged ERK
p42 (ERK2) (FL, Santa Cruz) and 5pi Mg2+/ATP buffer. The kinase reaction was
terminated by addition of lOOpl ice cold Assay buffer. Samples were incubated on
ice. The remaining Raf IP was retained for western blot analysis to assure equal Raf
precipitation.
Second step: Activated ERK2 samples (25pl) were incubated for 15 minutes at 30°C
in 25pi reaction mix containing 23pi myelin basic protein (MBP) substrate
(0.61pg/ul, Gibco), 2pl Reaction Start Mix (37.5mM MgCl2 and 1.25 mM ATP) and
0.2pl 32P~7"ATP (3000pCi/mmol). Reactions were terminated by addition of 16.7pl
4x SDS-gel sample buffer. Samples were run on a 12.5% gel, the solvent front was
removed (contains free ATP).
Gels were exposed to a Molecular Dynamics phospho-screen and analysed on a
Molecular Dynamics Storm™ 860 phospho-imager (Amersham Pharmacia Biotech,
Amersham, U.K.). Band density was performed with ImageQuant 5.0 software
(Amersham Pharmacia Biotech). Gels were also exposed to Kodak X-Omat film
(Sigma), overnight at room temperature, with an intensifying screen.
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BUFFERS: (all made up with dH20, unless otherwise stated)
Barnard Lysis buffer: 20mM Tris (pH8), 2mM EDTA, 1% Triton X-100 (v/v), 10%
glycerol (v/v), lOmM /3-glycerphosphate, 2mM sodium fluoride, 2mM sodium
pyrophosphate and 5mM sodium vanadate (pH9). One CompleteIM protease inhibitor
tablet (Boehringer Manheim, Lewes, UK) was added per 50ml of lysis buffer).
RIPA buffer: 20mM TrisHCl (pH7), 150mM NaCl, 1% Triton X-100 (v/v), 0.5%
Deoxycholate (w/v) and 0.1% SDS (w/v).
Dilution buffer: 50mM Tris (pH7.5), 75mM NaCl, 5mM EGTA and 5mM MgCl2.
Mg2+/ATP buffer: 50mM MgCl2 and 0.8mM ATP.
Assay buffer: ImM DTT and ImM sodium vanadate.
2.16 Immunofluorescence
Transfected cells or stable cell lines were grown on sterile glass cover slips (22 x 22
mm, Fisher, Loughborough, UK) placed within 6-well tissue culture plates (Corning,
High Wycombe, UK), and left overnight in complete medium at 37°C.
Cells to be examined live were washed gently with PBS and then non-specific
binding sites were blocked with 0.2% (w/v) fish skin gelatin (FSG)/PBS (Sigma) for
20 minutes at room temperature. Cells were probed with appropriate primary
antibodies (Table 2.5) diluted in 0.2% FSG for a minimum of 1 hour at room
temperature. Cells were washed with PBS (3x 2 minute washes) before species
appropriate Alexa-Fluor -conjugated antibodies (Molecular Probes, The
Netherlands) was added, diluted in 0.2% FSG for 30 minutes on ice and in the dark.
Cover slips were removed from the tissue culture plates, washed in PBS and allowed
to dry before mounting on slides using Mowiol mounting medium (Calbiochem,
Nottingham, UK).
Where cells could be fixed, cells were washed in PBS and a solution of 3% (w/v)
paraformaldehyde (PFA) was added to cells for 20 minutes at room temperature.
PFA was removed and 50mM NH4C1 (made up in uH20) added to quench aldehyde
groups for 10 minutes at room temperature. Cells were washed further with PBS and
non-specific binding sites were blocked with 0.2% (w/v) FSG/PBS (Sigma) for 20
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minutes at room temperature. Cells were probed with appropriate primary antibodies
(Table 2.6) diluted in 0.2% FSG for a minimum of 1 hour at room temperature. Cells
were washed with PBS (3x 2 minute washes) before species appropriate Alexa-Fluor
-conjugated antibodies (Molecular Probes, The Netherlands) was added, diluted in
0.2% FSG for 30 minutes on ice and in the dark. Cover slips were removed from the
tissue culture plates, washed in dH20 and allowed to dry. Cells were mounted on
slides using Mowiol.
All cells were visualised using a Leica TCS NT confocal microscope (Leica
Microsystems, Heidelburg GmbH) and images captured and analysed using Leica
Confocal Software - Lite Version (Leica Microsystems, Heidelburg GmbH).
Primary Antibody Dilution Secondary Antibody Dilution
Ha Antibody (Y-l 1) 1:100
Alexa 488-conjugated goat anti-
rabbit IgG
1:200
Myc Antibody (9E10) 1:100
Alexa 568-conjugated goat anti-
mouse IgG
1:200
Myc Antibody (A-14) 1:100



















1:50 Anti-Cholera toxin 1:100
Table 2.6 Immunofluorescence antibody dilutions
2.17 Incorporation of exogenous GM1 in cell membranes
Incorporation of GM1 was performed as described by Rusnati et ah, (1999). In brief,
CHO-K1 cells were seeded at 5 x 105 cells per 100mm plate and left to adhere
overnight in complete medium. Cell media was then replaced with medium
containing 0.4% (v/v) FCS with lOOpM GM1 (Sigma) for a further 96 hours. At the
end of incubation, cells were washed with PBS, trypsinised, and used for further
experimentations.
Stock solutions of GM1 were prepared in methanol (as per manufacturers'




Lipid raft aggregation or patch staining was adapted from Janes et al., (1999). Cells
were seeded onto coverslips, in 6-well plates and transfected with appropriate
constructs (see section 2.5.1). Cells were quiesced 24 hours prior to treatment. Forty
eight hours post transfection; cells were labelled with lOpg/ml rhodamine-
conjugated cholera toxin B (List Biological Laboratories, Quadratech, Epsom, UK)
made up in PBS with 0.1% BSA, for 1 hour on ice and in the dark. Cells were then
washed 3x with PBS. In cross-linking experiments, cells were further incubated with
rabbit anti-cholera toxin IgG (Sigma; 1:100 in PBS with 0.1% BSA) for 30 minutes
on ice, followed by a 20 minute incubation at 37°C (in the dark). After three washes
in PBS, coverslips were mounted onto slides in Mowiol and visualised (see section
2.16).
2.19 Methyl-/?-Cyclodextrin (M/?CD) membrane disruption
For all cells, transfections were carried out as described in section 2.5.1 and cells
quiesced 24 hours prior to treatment. Samples required for flow cytometry were
trypsinised and neutralised using Soybean Trypsin inhibitor (Sigma) prior to M/3CD-
treatment, cells were resuspended in 2ml of quiescent media. Cells required for
immunofluorescence were left attached to coverslips inside 6-well plates with 2ml of
quiescent media.
Cells were treated with PBS containing M/3CD (Sigma) to a final concentration of
1% and incubated for 1 hour at 37°C. Following incubation, M/3CD-containing
media was removed (by centrifugation for suspended cells) and cells resuspended in
2ml quiescent media. For experiments requiring cholesterol replenishment, 0.5mM
cholesterol/ml was added to quiescent media for 1 hour at 37°C in the form of
cholesterol-M/3CD inclusion complexes. Cholesterol-M^CD inclusion complexes
were produced as described by Klein et al., (1995). In brief, a solution of 30mg
cholesterol (Sigma) in 400pl of 2:1 (v/v) methanol/chloroform was added drop-wise
to a stirred solution of lg M/3CD in 11ml PBS prewarmed in an 80°C waterbath. The
solution was stirred at 80°C until a clear solution resulted. The cholesterol-M/3CD
inclusion complexes were used immediately or aliquoted and lyophilised. For
convenience, 375pl (5 x 69.4pl) aliquots of the cholesterol-M/3CD inclusion complex
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solution were lyophilised. For use, the individual aliquots could be resuspended in
5ml PBS to provide 5 x 1ml treatments (0.5mM cholesterol).
Following treatment, cells were washed in PBS. Cells required for FACS analysis
were then stained as described in section 2.8. Cells for immunofluorescence were left
attached to coverslips and treated as mentioned in section 2.16.
2.20 Anchorage-independent growth assays (Colony assays)
For each cell line, single cell suspensions were prepared in triplicate at 2xl03 cells
per well of a 6 well plate, in a 0.3% top agarose suspension, overlaid onto a 0.5%
agarose bottom layer, and grown at 37°C for colony formation.
A 50:50 mixture of Seakem agarose (Cambrex Bioproducts, Maine): low melting
point agarose (Sigma), was used to prepare 5% and 3% (w/v) (lOx) stock solutions of
agarose in sterile water, in autoclaved bottles. Solutions were boiled to dissolve the
agarose and stored at room temperature. On the day of the assay, stock solutions
were melted and maintained at 45°C in a water bath. The 0.5% agarose layer was
prepared by diluting the 5% stock solution in warmed growth medium (i.e., DMEM
+ required serum concentration); 2ml were added to each well of a 6 well plate.
Once the bottom layer had set, a single cell suspension containing 1x10 cells per ml
of growth medium (i.e., DMEM + required serum concentration + any required
antibiotics) was warmed and the melted 3% agarose stock was added to a final
concentration of 0.3%. The cell and agarose suspension was mixed gently by
pipetting to resuspend the cells uniformly, then 2ml per well was added to the
hardened 0.5% agar base layer and left to set. Plates were covered with tinfoil, to
prevent drying-out, and incubated at 37°C in a humidified 10% CO2 environment.
On days 2, 4 and 6, the number of colonies from five random fields was counted for
each replicate. Percentage cloning efficiency was calculated as follows:
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(((Mean/5*) x 160f)/2000s) x 100.
Mean Total colonies counted for each sample divided by the number of replicates
(in this case, n=3).
Number of fields viewed per well.
' (Well areaI view area). Multiplying by this figure allows an approximation of
the total number of colonies per well to be made.
§ Number of cells seeded
2.21 Adhesion assays
For transiently transfected cells lines, 100mm plates of 40-60% confluent a/3-py cells
were co-transfected with test DNA and a GFP-expressing construct. Twenty-four
hours post transfection, cells were quiesced in preparation for the adhesion assay.
With stable lines, 100mm plates were seeded with cell lines, to reach confluency 24
hours prior to assay. Stable cell lines were also quiesced in preparation for the assay.
Cell adhesion assays were performed using flat bottom tissue culture 96-well plates
(Costar, Cambridge, USA). Wells were coated with appropriate matrix for 1 hour at
37°C (wells left uncoated as a negative control; for transiently transfected cells, wells
were coated with lOpg/ml fibrinogen and for stably transfected CHO-K1 cells, wells
were coated with 20pg/ml fibronectin). All wells were then washed with 200pl PBS
and blocked using lOOpl of 2% (w/v) BSA (made up in PBS) for 1 hour at room
temperature.
Single cell suspensions of each cell line to be tested, were washed thoroughly and
resuspended in DMEM (containing no additives) and diluted to lxl06 cells per ml.
Cell suspension (200pl) was added to triplicate wells. Each sample was plated out
onto plastic (negative control), matrix coated test sample and a matrix coated whole
cell control. Cells were incubated for the required time at 37°C. Plates were gently
shaken on a thermomixer (800rpm, for 3x10 second intervals) and gently washed
with PBS to remove any unadhered cells. Whole cell control wells were incubated
until all cells adhered (checked using a microscope) or alternatively, plates were
centrifuged for 5 minutes at 3000rpm. Transiently transfected cell (co-transfected
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with GFP-construct) adhesion was determined using a fluorescent plate reader
(Wallac Victor2, 1420 Multi-label).
For stable cell lines, following the PBS wash of plastic negative controls and matrix
coated wells, cells were fixed using 200pl of 3% paraformaldehyde (PFA) per well
for 20 minutes. At this stage, whole cell controls were allowed to fully adhere
naturally or they were 'splattered' by centrifuging the plate at lOOOrpm for 5
minutes. Whole cell wells were then also fixed. Following fixation, wells were
allowed to air-dry and cells stained using lOOpl of 1% (w/v) methylene blue (made
up in dH20) per well for 20 minutes. Plates were washed with tap water and then
allowed to air-dry before the colour was eluted by the addition of lOOpl of 0.1M HC1
per well. Adhesion of stably transfected cells was determined using an automated
plate reader (MRX microplate reader, Dynatech, Chantilly VA) at 630nm.
2.22 Migration assays
For transiently transfected cells lines, 100mm plates of 40-60% confluent a)3-py cells
were co-transfected with a test DNA and a GFP-expressing construct (to serve as a
positive control for transfection). Twenty-four hours post transfection, cells were
quiesced in preparation for migration assay. With stable lines, 100mm plates were
seeded with cell lines, to reach confluency 24 hours prior to assay. Stable cell lines
were also quiesced in preparation for assay.
Cell migration assays were performed using Millipore Multiscreen Assay System 96-
well filtration plates (Millipore). Where required, wells were coated on the underside
only, (as per manufacturers instructions) with appropriate matrix for 1 hour at 37°C
(for transiently transfected cells, wells were coated with 10pg/ml fibrinogen and for
stably transfected CHO-K1 cells, wells were coated with 20pg/ml fibronectin). All
wells were then washed with PBS and blocked using 2% (w/v) BSA (made up in
PBS) for 1 hour at room temperature. Teardrop plates were washed and appropriate
media conditions applied (150pl per teardrop well). A single cell suspension of each
cell line to be tested was diluted in DMEM (containing no additives) to 5x10s cells
per ml and 100pl of cell suspension was added to appropriate wells. Each sample
was plated out in triplicate and incubated for the required time at 37°C. Following
incubation, the supernatant was removed from all wells and a cotton swap was used
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to remove cells adhered to the upper surface of all wells excluding the whole cell
controls.
Migration of transiently transfected cells (co-transfected with GFP-construct) was
determined using a fluorescent plate reader (Wallac Victor2, 1420 Multi-label).
Stable cell lines were fixed using ice-cold 70% methanol and stained using the Diff-
Quick system. Plates were washed with tap water and allowed to air-dry before
eluting the colour by addition of lOOpl of 0.1M HC1 per well. Adhesion of stably
transfected cells was determined using an automated plate reader (MRX microplate
reader, Dynatech, Chantilly VA) at 630nm.
2.23 Wound assays
Freshly trypsinised cells (0.5x106) were seeded into 6-well plates in growth medium
containing 10% serum and incubated overnight at 37°C to allow a confluent
monolayer to form. At time point 0 hours, a p200 pipette tip was used to scrape a
small wound through the centre of the cell monolayer. Wells were washed with
sterile PBS to remove any dead or floating cells. Quiescent growth media was added
to the cells. Cells were visualised on a Carl-Zeiss Axiovert 5100 microscope (Jena,
Germany) and an image of an identified stretch of the wound captured using a
Coolsnap cooled CCD camera and Openlab 3.01 software (Improvision, Lexington,
USA). Cells were maintained in quiescent media at 37°C. At time points 24 hours
and 48 hours post-wounding, wells were washed with PBS and following the
addition of fresh quiescent media, images of the identified stretch of wound were re¬
captured.
2.24 Proliferation assays
Freshly trypsinised cells (2xl04) were seeded into 100mm plates in growth medium
containing 10% serum with one plate per day per cell line. The cells were incubated
at 37°C and growth medium was refreshed every 2-3 days. For 8-10 consecutive
days post-seeding, one plate per cell line was counted. Plates were washed with PBS
to remove any dead or floating cells and the remaining adhered cells were trypsinised
and resuspended in growth medium. An aliquot of cell suspension was removed for




Results are reported as pooled data from a series of n separate experiments and
presented as mean ± S.E.M. Statistical significance was analysed by one-way
analysis of variance (ANOVA) with comparisons between groups made using the
Bonferroni Multiple Comparison Test (Prism software).
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Chapter 3
Integrin affinity modulation by H-Ras and R-Ras
3.1 Introduction
A central property of the integrin family of cell adhesion receptors is the capacity to
rapidly modulate their ability to bind ligands. Integrins can use both affinity
('conformation change') and avidity (clustering of integrins) modulation to regulate
ligand-binding strength.
Integrin affinity modulation is proposed to involve the propagation of conformational
changes from the cytoplasmic tails to the extracellular ligand-binding sites, leading
to a direct change in ligand-binding affinity (Hughes and Pfaff, 1998). One of the
best-documented examples of integrin affinity modulation involves the binding of
fibrinogen to platelets via the ttubft fibrinogen receptor. The affinity of am,ft is
tightly regulated and modulated from within platelets by a phenomenon that has been
referred to as 'inside-out' signalling (Ginsberg et al., 1992). Following fibrinogen
binding to ttubft, clustering of integrin can cause tyrosine phosphorylation of specific
platelet proteins resulting in 'outside-in' signalling to the cell (Haimovich et al.,
1993). Platelets have provided a useful model for examining integrin-affinity
modulation. The PAC1 monoclonal (IgM isotype) antibody specifically recognises
the activated ctubft integrin, by mimicking the binding characteristics of fibrinogen
(Shattil et al., 1985). The binding of PAC1 to platelets is stimulated by physiological
agonists, such as ADP and thrombin, which are dependent upon divalent cations. The
binding of fibrinogen to activated platelets can be inhibited by addition of EDTA
(which chelates Ca2+/Mg2+) or stimulated by Mn2+, which has often been used as an
activator of ligand binding to integrins (Abrams et al., 1994).
At present, the cytoplasmic signalling pathways regulating integrin affinity are
poorly understood. A model system in Chinese Hamster Ovary (CHO) cells was
developed to allow genetic and pharmacological study of integrin affinity modulation
(O'Toole et al., 1990). CHO cells were selected for this model due to their simple
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maintenance and ease of transfection (Hughes et al., 1997). CHO cells expressing
Oubft fail to bind PAC1, even in the presence of aubft-activating stimuli including
ADP, thrombin and phorbol esters (O'Toole et al., 1990). Chimeric integrins, in
which the extracellular and transmembrane domains of the a?nb and are joined to
the cytoplasmic domains of as, «6A, OfeB and ft respectively, are constitutively active
in CHO cells and restore PAC1 binding (O'Toole et al., 1994). The combined
properties of the active chimera and the activation-dependent PAC1 antibody, permit
the use of the extracellular domain of anbft as a reporter for cytoplasmic signalling
events involved in integrin activation (Hughes et al., 1997).
Using a CHO cell line stably expressing the chimeric integrin 0^0^183(81 (ojS-py
cells), complementary DNAs were screened for their ability to inhibit PAC1 integrin-
binding. An active variant of the small GTP-binding protein, H-Ras, and its effector
kinase, Raf-1, were capable of inhibiting PAC1 binding in a MAP kinase-dependent
manner (Hughes et al., 1997). Furthermore R-Ras, a small GTP-binding protein
related to H-Ras, antagonises the Ras/Raf-initiated integrin suppression pathway
(Sethi et al., 1999). The changes in integrin affinity modulation by H-Ras and R-Ras
appear to be both integrin- and cell type-specific.
In order to gain further understanding of the mechanisms of H-Ras- and R-Ras-
mediated integrin affinity modulation, the cqS-py model system was employed for this
thesis. The aim of this preliminary results chapter was to investigate whether the
previous observations made by Sethi et al., (1999), that H-Ras G12V mediated
integrin suppression and that R-Ras G38V reverses H-Ras-mediated suppression,
could be reproduced in this laboratory.
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3.2 The cr/?-py transfection system and detection of integrin
affinity modulation
The cqS-py model system makes use of a stably expressed chimeric integrin on the
cell surface which can be used, in conjunction with the PAC1 monoclonal antibody,
as a reporter for integrin affinity modulation (Hughes et al., 1997). The binding of
the PAC1 antibody was detected by flow cytometry using a secondary anti-mouse
IgM-FITC (fluorescein isothiocyanate) antibody.
A cell surface marker encoding the extracellular domain of the IL-2 receptor, known
as Tac, and the intracellular domain of the a5 integrin (Tac-a5) was used as a marker
for transfection efficiency. Transfection efficiency of aft-py cells was detected by
flow cytometry using an antibody against the IL-2 receptor, Tac-R-PE (R-
phycoerythrin). The reporter construct Tac-as has previously been titrated for
maximal expression in a/3-py cells. It was found that transfection of 0.75pg of the
construct, in 60mm plates, was sufficient to obtain a high degree of Tac-PE positive
cells, without interfering with constructs under test.
Previous work in this laboratory has optimised transfection efficiency of a/3-py cells
using Invitrogen's transfection reagent, Lipofectamine, in conjunction with their Plus
reagent. All subsequent transfections have been performed with Lipofectamine in
combination with the Plus reagent.
3.2.1 PAC1 antibody binding to a/3-py cells
Both the primary PAC1 mouse monoclonal antibody and the secondary anti-mouse
IgM-FITC antibody have been previously titrated for maximal binding to the o^S-py
cells. Figure 3.1 shows a representative histogram of FL-1 PAC1 binding in the FL1
channel. Compared to the IgM isotype control, the PAC1 antibody displayed a
rightward shift in the FL1 channel with the mean fluorescence intensity increasing
from 60.1 arbitrary units (AU) to 130.2 AU.
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Figure 3.1 PAC1 antibody binding to ff/3-py cells.
PAC1 antibody binding to a(3-py cells was determined by flow cytometry.
PAC1 antibody binding to afi-py cells (solid grey) and IgM isotype matched control
antibody (grey line). Histogram is representative of three experiments.
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3.2.2 External control factors can modulate integrin affinity
To demonstrate integrin modulation by external factors, PAC1 binding was
determined in the native integrin and in the presence of 5mM EDTA or lOOpM
Mn2+. Figure 3.2A shows a representative histogram of three experiments of PAC1
binding in the presence of EDTA or Mn2+. In the absence of any exogenous
mediators, the mean fluorescence intensity of the native integrin was 97.4 ± 17.7 AU.
Addition of EDTA led to a reduction in PAC1 binding which correlated with a drop
in the mean fluorescence intensity (19.7 ± 3.4 AU). An increase in antibody binding
was observed with addition ofMn2+ , the corresponding mean fluorescence intensity;
118.8 ± 21.4 AU.
Dot plots display PAC1 binding on the x-axis and Tac-PE antibody binding
(transfection efficiency) on the y-axis. The quadrant markers on the dot blots
distinguish between high and low integrin affinity status on the x-axis, as a measure
of PAC1 binding and on the y-axis, highly transfected cells (red) against those of a
lower transfection efficiency (blue). The quadrant marker separating highly
transfected cells was set for each individual experiment to denote the top 20-25% of
Tac-positive cells.
Figure 3.2B shows representative dot plots of cells transfected with control vector
and Tac-a5. In the native state, the majority of the highly transfected cells are in the
upper right quadrant (67%). Addition of 5mM EDTA results in a leftward shift in the
cell population, indicative of a loss of PAC1 binding, with the majority of the highly
transfected cells moving towards the upper left quadrant (99.5%). Addition of
lOOpM Mn2+ leads to a rightward shift in the cell population. In the presence of this
activating stimulus, the percentage of highly transfected cells in the high PAC
binding upper right quadrant is increased to 77%. This demonstrates not only that a(3-
py cells constitutively express the chimeric integrin (XubOkAfoPi in an active state but
that the integrin can be modulated by external factors. The addition of 5mM EDTA
or 1 OOjiM Mn2+ act as internal controls for each transfection representing a
minimum and maximum of PAC 1 binding within these cells. The mean fluorescence
of PAC 1 binding in the native, inactive and active states allow a numerical estimate
of integrin activation to be calculated as an activation index (AI) as described in the
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Materials and Methods (section 2.8.2) whereby 0 units represent an inactive integrin
(+EDTA) and 100 units represents an active integrin (+Mn2+).
3.2.3 The cqibft ligand, fibrinogen, binds to a/3-py cells
To demonstrate that the changes in affinity modulation undergone by the chimeric
integrin are not an artefact of PAC1 antibody binding, affinity modulation was
observed using Alexa-488-conjugated fibrinogen. Cells were treated using the same
external factors i.e. 5mM EDTA and lOOpM Mn2+ as those used in PAC1 binding
experiments. Figure 3.3 shows representative dot blots from cells transfected with
control vector. In the native state, 29% of the highly transfected cells are in the upper
right quadrant. Addition of 5mM EDTA results in a leftward shift in the cell
population, indicative of a loss of PAC1 binding, with the majority of the highly
transfected cells moving towards the upper left quadrant (98%). Addition of lOOpM
9+ ... . . .
Mn leads to a rightward shift in the cell population. In the presence of activating
Mn2+ , the percentage of highly transfected cells in the high PAC1 binding upper
right quadrant is increased to 66%.
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Figure 3.2 Integrin Affinity Modulation by External Control Factors as
Determined by PAC1 binding.
Flow cytometry was performed on control vector (lpg) transfected cells to determine
integrin affinity.
(A) PAC1 binding in the presence of external factors, untreated (solid grey), 5mM
EDTA (grey line) or lOOpM Mn2+ (black line).
(B) Representative dot blots show PAC1 binding versus Tac binding, high Tac
binding cells are shown in red. PAC1 binding was determined in the native integrin
and in the presence of 5mM EDTA or 1 OOpM Mn2+. Quadrant markers distinguish
between high and low Tac and PAC1 binding cells. The percentage of high Tac
binding cells in the upper left- and right- hand quadrants are shown for each dot blot.
Histogram and dot plots are representative of three experiments.




Figure 3.3 Integrin Affinity Modulation by External Control Factors as
Determined by Alexa-488-Conjugated Fibrinogen Binding.
Flow cytometry was performed on control vector (lpg) transfected cells to determine
integrin affinity. Representative dot blots show Alexa-488-conjugated fibrinogen
binding versus Tac binding, high Tac binding cells are shown in red. Fibrinogen
binding was determined in the native integrin and in the presence of 5mM EDTA or
lOOpM Mn2+. Quadrant markers distinguish between high and low Tac and
fibrinogen binding cells. The percentage of high Tac binding cells in the upper left-
and right- hand quadrants are shown for each dot blot.
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3.3 H-Ras- and R-Ras-mediated integrin affinity
3.3.1 H-Ras G12V -Mediated Integrin Suppression is reversed by R-Ras
G38V.
Integrin affinity status in transfected cells was determined as described in Materials
and Methods (2.8.2). Figure 3.4 shows representative dot plots of cells transfected
with control vector ± H-Ras G12V and R-Ras G38V ± H-Ras G12V. Compared with
control vector transfected cells, transfection of H-Ras G12V into a$-py cells (Figure
3.4) results in a decrease in PAC1 binding with 77% of the highly transfected cells
(shown in red) found in the upper left hand quadrant compared with 50% in control
cells. Transfection with R-Ras G38V results in the majority of the highly transfected
cells being found in the upper right hand quadrant (62%). Co-transfection of Qj?-py
cells with R-Ras G38V and H-Ras G12V returns the highly transfected cell
distribution to that resembling the control vector cells with 45% of the highly
transfected cells located in the upper right hand quadrant.
Using the activation index calculated for the cells, percentage inhibition relative to
the control cell activation index was calculated as described in the materials and
methods. Figure 3.5A shows that transfection with H-Ras G12V results in a highly
significant suppression 58.2 ± 4.5 of the integrin (PO.OOl) as compared with control
vector alone. Transfection with R-Ras G38V resulted in a slight activation of the
integrin -34.7 ± 8.6 (P<0.05) compared with the control vector alone. Co-transfection
of Q}3-py cells with both the R-Ras G38V and H-Ras G12V constructs resulted in a
reversal ofH-Ras G12V mediated integrin suppression with the resulting state of the
integrin 4.9 ± 2 showing no significant difference to that of control cells.
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Figure 3.4 H-Ras G12V Mediated Integrin Suppression is reversed by R-Ras
G38V.
Flow cytometry was performed on control vector ± H-Ras G12V (lpg), and R-Ras
G38V ± H-Ras G12V (lpg) transfected cells. In each assay, total DNA content was
standardised to 2pg using control vector. Representative dot blots show PAC1
binding in the native integrin versus Tac binding, high Tac binding cells are shown in
red. Quadrant markers distinguish between high and low Tac and PAC1 binding. The
percentage of high Tac binding cells in the upper left- and right- hand quadrants are
shown for each dot blot. The dot blots are representative of three experiments.
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3.3.2 H-Ras G12V expression leads to ERK1/2 activation
Importantly, Figures 3.5B and C show that levels of H-Ras G12V and R-Ras G38V
expression are unaffected by co-expressing the two constructs together in 0}3-py
cells. In cells transfected with control vector ± H-Ras G12V and cells transfected
with R-Ras G38V± H-Ras G12V, activation of the classical Ras-ERK pathway was
determined with phospho-specific ERK1/2 antibody that recognises the dual
phosphorylated ERK1 and 2. Figure 3.5D shows that in cells quiesced overnight
there was an increase in ERK1/2 phosphorylation in H-Ras G12V cells compared to
control vector transfected cells. Interestingly, co-transfection of cells with H-Ras
G12V and R-Ras G38V show no reduction in ERK1/2 phosphorylation compared to
control vector + H-Ras G12V. Total ERK2 levels in all samples were similar and
remain unaffected by construct expression in these cells (Figure 3.5E).
84














Figure 3.5 R-Ras G38V Reversal of H-Ras G12V Mediated Integrin Suppression
does not affect activation ofERK1/2.
(A) Suppression of integrin activation was determined in control vector ± H-Ras
G12V (lpg), and R-Ras G38V ± H-Ras G12V (lpg) transfected cells. In each assay,
total DNA content was standardised to 2pg using control vector. The results shown
are the mean ± SEM of 3 independent experiments. Statisical analysis was performed
by one-way ANOVA test. * = P<0.05 and *** = PO.OOl, compared with 'Control'.
A duplicate set of transfected cell lysates were probed with (B) the anli-Ha antibody,
(C) the anti-Myc antibody, (D) the phospho-specific ERJC1/2 antibody and (E) the
ERK2 antibody. Western blots are representative of three experiments.
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3.4 Discussion
The o^S-py transfection and flow cytometry system, developed by Dr. M. Ginsberg
and colleagues (Scripps Research Institute, La Jolla, USA), was employed in this
project to enable the examination of the roles of H-Ras and R-Ras, together with
ERK1/2 activation, in modulating integrin affinity.
PAC1 is a pentameric IgM antibody that binds to agonist-stimulated platelets. The
PAC1 monoclonal antibody specifically binds to the activated aiibft integrin,
mimicking the binding characteristics of fibrinogen (Shattil et al., 1985). The ability
of PAC1 to bind to the chimeric aubQfeAftlSi integrin present on afi-py cells is in
accordance with a previous report that this integrin is constitutively active in a)3-py
CHO-K1 cells (Hughes et al., 1997). Expression of full length anbft in CHO-K1
cells does not permit PAC1 binding, as the integrin is in a low affinity state. Inside-
out signalling, directed at the CfcA/3i cytoplasmic domains of the chimeric integrin,
must therefore induce a conformational change in the integrin to a high affinity state.
The affinity status of the aftbGkAftjSi integrin was successfully modulated through
exogenous factors, as shown by Figure 3.2. Addition of EDTA at 20-22°C, which
results in chelation of Ca2+ and Mg2+ ions, induced a low integrin affinity state
9+
(suppressed integrin). Conversely, addition ofMn increased the activation index of
the integrin. This demonstrates that the internal controls used for each transfection,
representing a minimum and maximum of PAC1 binding within these cells, can be
utilised with this chimeric integrin.
PAC1 is a ligand-mimetic antibody. Using the natural ligand for anbft we
hypothesised that Alexa-488 labelled fibrinogen would act in a similar fashion to that
of PAC1 binding in response to exogenous factors. Figure 3.3 shows that, with
addition of the same exogenous factors as used in the PAC1 controls, the integrin
affinity state of cells stained using an Alexa-488-conjugated fibrinogen responded in
a similar fashion. These results helped to confirm that results obtained using PAC1
as a reporter of integrin affinity state could be related back to the binding of the
natural ligand.
Hughes et al., (1997) have shown previously that an activated variant of the small
GTP-binding protein H-Ras can suppress the chimeric integrin in a/3-py CHO-K1
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cells. The results shown in Figure 3.4 are in agreement with Hughes et al. (1997), as
transfection of afi-py cells with the activated mutant H-Ras G12V resulted in a
reduction in PAC1 binding. This effect was cell-autonomous as untransfected cells
(Tac negative) did not show a decrease in PAC1 binding. H-Ras G12V-mediated
suppression is not restricted to (3i and c^a cytoplasmic domains since chimeras
composed of the cytoplasmic domains of c^b or as fused to am,, co-expressed with
either native (33 or a ft/Si chimera could also suppress PAC1 binding (Hughes et al.,
1997).
Affinity modulation of integrins by H-Ras G12V has been described by several
groups. Purified osteoblasts highly express integrins /3i, 04, as, 0and the activation
epitope of (3\ (Tanaka et al., 2002). H-Ras signals inhibit the ligand-binding
activation epitope of (3\ on the surface of osteoblasts and subsequent jSi -mediated
osteoblast adhesion to matrix proteins (Tanaka et al., 2002). In contrast, H-Ras
G12V has also been shown to activate asfi\ in bone-marrow derived mast cells and
also to aid interleukin-3 (IL-3)-induced cell adhesion to fibronectin by the murine
hematopoietic cell line, BaB, through activation of c^/3i and a5&\ (Kinashi et al.,
2000; Shibayama et al., 1999). The conflicting evidence of the effect active H-Ras
has upon integrins demonstrates that modulation of integrin affinity by H-Ras
appears to cell type-specific. H-Ras probably varies its utilisation of protein partners
in a cell-type-specific manner to effect its regulation of integrins (Kinbara et al.,
2003).
Hughes et al., (1997) found that the expression of H-Ras G12V, and its kinase
effector Raf-1, blocks integrin activation and that this suppressive activity correlates
with activation of the ERK MAP kinase pathway. Results shown in Figures 3.5A and
3.5D concur with the findings of Hughes et al., (1997), showing that expression of
H-Ras G12V increased ERK 1/2 phosphorylation in a(3-py cells.
MAP kinase phosphatase 1 (MKP-1) prevents the accumulation of active ERK1/2 in
the cell by dephosphorylation of ERK1/2 (Alessi et al., 1993). Since levels of H-
Ras/Raf mediated suppression can be reduced by treatment with MKP-1, it has been
suggested that suppression appears to be mediated by ERK1/2 (Hughes et al., 1997).
However, other more recent studies have indicated that ERK/MAPKs are not
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required for H-Ras to suppress integrins (Hughes et al., 2002; Hansen et al., 2002).
These reports suggest the possibility of an ERKl/2-independent integrin suppression
pathway. This hypothesis will be addressed in Chapter 4 of this thesis.
In contrast to H-Ras, the closely related small GTP-binding protein R-Ras has been
reported to 'activate' integrins. Zhang et al. (1996) showed, using a CHO cell line
expressing the native anbft integrin in a low affinity state, that expression of a
constitutively active R-Ras (R-Ras G38V) enhanced ligand-binding activity of anbft
present on the cell surface, shown by PAC1 binding. R-Ras G38V was shown to
have strong stimulatory effects on adhesion and ligand binding activity of as(3\ to
fibronectin in bone marrow-derived mast cells (Kinashi et al., 2000).
While R-Ras G38V greatly enhanced the ligand-binding activity of CHO cells
expressing the native am,63 integrin (Zhang et al., 1996), Sethi et al. (1999)
demonstrated that R-Ras G38V does not directly increase PAC1 binding when
transfected into CHO cells stably expressing the chimeric integrin oiubO&AfoPi (a/3-py
cells). The data in Figure 3.5A shows only a slightly significant increase in PAC1
binding of c$-py cells transfected with R-Ras G38V. The reason why R-Ras G38V
has a less obvious activating effect on the a(3-py cells expressing the chimeric
integrin compared with CHO cells expressing the native aubft integrin (Zhang et al.,
1996), may simply be because the chimeric integrin is basally active.
Sethi et al., (1999) hypothesised that the 'activating' effects of R-Ras in CHO cells
might be attributable to it antagonising the suppressive effect of H-Ras. Figures 3.4
and 3.5A show that c$-py cells transfected with H-Ras G12V alone cause a highly
significant decrease in PAC1 binding; however, co-transfection with active R-Ras
G38V completely restored PAC1 binding (Figures 3.4 and 3.5A). Western blot
analysis showed that co-transfection with R-Ras G38V had no effect on H-Ras G12V
expression (Figures 3.5B and 3.5C). Therefore the reversal of suppression observed
with R-Ras is not a consequence of reduced levels ofH-Ras expression.
As previously mentioned, H-Ras/Raf-mediated suppression correlates with the
activation of the ERK1/2 kinase pathway. Reports suggest that levels of H-Ras/Raf-
mediated suppression can be reduced by treatment with MKP-1 (Hughes et al.,
1997). Therefore, it is not unreasonable to assume that activated R-Ras could rescue
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suppression by affecting the capability of H-Ras and Raf-1 to activate ERK1/2.
However, in agreement with Sethi et al., (1999), coexpression of R-Ras G38V with
H-Ras G12V did not influence the ability of H-Ras to activate ERK1/2 (Figure
3.5D). This suggests that the ability of R-Ras G38V to reverse H-Ras G12V-
mediated suppression is not caused by the inactivation of the ERK1/2 kinase
pathway but at a point down stream of ERK1/2 activation (Oertli et al., 2000; Sethi
et al., 1999).
3.4.1 Summary
The 0^3-py integrin affinity detection and transfection system successfully reproduced
the initial findings that, despite high sequence homology, activated H-Ras-mediated
integrin suppression, while activated R-Ras reversed H-RasG12V-mediated integrin
suppression in 0}3-py cells.
H-Ras G12V-mediated integrin suppression correlated with an increase in ERK1/2
phosphorylation. H-Ras/Raf-mediated ERK1/2 phosphorylation was not affected by
co-expression ofR-Ras G38V.
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Chapter 4
Characterisation of H-and R-Ras Chimeras
4.1 Introduction
R-Ras was originally identified by low stringency hybridisation with an H-Ras
probe, as its sequence is 55% identical in the region of overlap with H-Ras (Lowe et
al, 1987).
H-Ras and R-Ras are GTP-binding proteins which cycle between an inactive GDP-
bound slate and an active GTP-bound state. Mutation and deletion studies have
demonstrated that the intrinsic GTPase activity is contained within the conserved N-
terminal 166 amino acids of the Ras proteins (Lowy and Willumsen, 1993). Mutation
of residues Gly12 or Glu61 of H-Ras disrupts the rate of GTP hydrolysis resulting in
constitutively active mutants (Barbacid et al., 1987; Sweet et al., 1984). This project
makes use of the activated mutant of H-Ras which contains a glycine- to- valine
substitution at codon 12 (H-Ras G12V).
The intrinsic GTPase activity ofR-Ras containing a glycine- to- valine substitution at
codon 38 (equivalent to codon 12 in Ras proteins) is insensitive to stimulation by
GAPs and this mutant is therefore constitutively active (Rey et al., 1994). The
constitutively active R-Ras (G38V) has been used in this project.
H-Ras and R-Ras contain conserved sequences in their minimal effector binding
domains and bind to common downstream effectors when in the GTP bound state.
Both H-Ras and R-Ras interact with the pi 10 catalytic subunit of PI 3-kinase in
vitro, and induce elevation of PI 3-kinase lipid products in vivo (Rodriguez-Viciana
et al., 1994; Marte et al., 1997). Like H-Ras, R-Ras interacts with the Raf
serine/threonine kinases in vitro (Rey et al., 1994; Spaargaren et al., 1994).
However, in contrast to H-Ras, R-Ras does not markedly activate Raf, or the ERK1/2
family ofMAP kinases (Marte et al., 1997; Sethi et al., 1999).
Despite the sequence similarity between H-Ras and R-Ras, activated variants of
these proteins confer distinct biological properties when expressed in mammalian
90
Characterisation of H-and R-Ras chimeras
cells. In contrast to activated H-Ras, analogous R-Ras mutants do not contribute to
focus formation or soft-agar growth by rat fibroblasts, indicative of cellular
transformation (Lowe and Goeddel, 1987). When activated, H-Ras or R-Ras were
injected into Swiss 3T3 cells, only H-Ras was capable of inducing DNA synthesis
(Rey et al., 1994). R-Ras was capable of inducing malignant, but not morphologic,
transformation ofNIH3T3 cells (Cox et al., 1994).
In the previous chapter, expression of the active mutant of H-Ras, H-Ras G12V, was
shown to mediate a suppressive effect on integrin activation. Co-expression of the
active mutant form of R-Ras, R-Ras G38V, demonstrated an ability to reverse H-Ras
mediated integrin suppression. The divergent effects of these two proteins on integrin
affinity is surprising as there is a high degree of sequence similarity between H-Ras
and R-Ras with approximately 71% amino acid sequence conservation over the first
120 amino acids of H-Ras. The main areas of sequence divergence between the two
proteins include the 26 additional N-terminal amino acids of R-Ras compared to H-
Ras; the extended effector region, (amino acids 23-46 of H-Ras); and the
hypervariable C-terminal domain which encompasses the hypervariable linker
domain and the C-terminal binding domain.
The aim of this chapter is to further characterise H-Ras and R-Ras to determine what
role, if any, the sequence variations in H-Ras and R-Ras may play in their differing
properties with respect to integrin affinity modulation and activation of ERK1/2
MAP kinases. For the purposes of this chapter, H-Ras G12V and R-Ras G38V were
both cloned out of their original vectors and into pCDNA3.1 (+), along with their N-
terminal HA- and Myc- tags respectively (see Appendix I for sequence verification).
Section 2.10 of the Materials and Methods section describes the subcloning ofH-Ras
and R-Ras into pCDNA3.1(+). The subcloning of the H-Ras G12V and R-Ras G38V
genes into pCDNA3.1(+) was considered necessary for them to act as appropriate
controls for H-and R-Ras chimeras, which are also cloned into pCDNA3.1(+). These
H-and R-Ras chimeras were utilised to help gain insight into the regions responsible
for the contrasting effects H-Ras and R-Ras have on integrin function.
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4.2 Introducing the H-and R-Ras Chimeras
The H-and R-Ras chimeras were provided as a gift by Dr. Mark Ginsberg (Division
of Vascular Biology, The Scripps Research Institute). The chimeras were constructed
using splice overlap PCR mutagenesis with pSG5-R-Ras(G38V) and pcDR-H-
Ras(G12V) as templates. The amplified DNA was ligated into the EcoKl site of
pCDNA 3.1 (+) with an N-terminal FLAG tag sequence. Upon receipt all constructs
were verified by DNA sequencing (see Appendix II for full chimera sequences,
aligned with H-Ras and R-Ras. Areas highlighted in red indicate where exchanges
were made to generate the chimera). Figure 4.1 is a schematic representation of the
chimeras indicating the main areas of sequence divergence between H-Ras and R-
Ras. Chimeras CH3, CH6, H197 and H201 contain the N-terminus of H-Ras G12V
while, reciprocal chimeras CHI, CH5, R197 and R201 contain the N-terminus of R-
Ras G38V. A brief description of these inverted pairs follows:
CHI (R-Ras 1-85; H-Ras 60-198) and CH3 (H-Ras 1-59; R-Ras 86-219) substitute
the N-terminal regions of the H-Ras and R-Ras proteins, to include the N-terminal
minimal and extended effector binding regions and switch I region.
CH5 (R-Ras 1-174; H-Ras 149-198) and CH6 (H-Ras 1-146; R-Ras 175-219),
substitute the N-terminal regions of the H-Ras and R-Ras proteins. This pair extend
the N-terminal to encompass the switch II domain.
H197 (H-Ras 1-171; R-Ras 199-219) and R197 (R-Ras 1-198; H-Ras 172-198)
substitute the N-terminal regions of the H-Ras and R-Ras proteins extending into the
hypervariable linker domain at the C-terminus.
H201 (H-Ras 174; R-Ras 204-219) and R201 (R-Ras 203; H-Ras 175-198) substitute
the C-terminal binding domains ofH-Ras and R-Ras.
At this point, it is worth noting that it may be of advantage to the reader to keep to
hand a copy of the schematic diagram of the chimeras (Figure 4.1), as this may aid
understanding of the following results section.
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Figure 4.1 Schematic representation of H-Ras G12V and R-Ras G38V chimeras.
Schematic represents H-Ras G12V (grey) and R-Ras G38V (black) chimeras.
Amino acid numbers above the box represent the N-terminal segment and those
below denote the C-terminal segment of the chimera.
All chimeras are FLAG-tagged and subcloned into pCDNA3.1(+).
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4.3 The effect of H-/R-Ras chimeras on integrin affinity.
It has previously been described that H-Ras G12V transfection of cq3-py cells
mediates integrin suppression. H-Ras-mediated integrin suppression seems to
correlate with increased ERK1/2 activity. Transfection with R-Ras G38V results in a
slightly higher activation state of the aubCfeA&iSi chimeric integrin compared with
control cells. R-Ras G38V is capable of reversing H-Ras G12V-mediated integrin
suppression, without affecting levels of ERK1/2 activation. The H/R-Ras chimeras
provide us the opportunity to examine whether specific sequences within H-Ras
G12V and R-Ras G38V are required for their contrasting effects on integrin affinity
and ERK1/2 activation.
4.3.1 Modulation of integrin affinity by H-and R-Ras chimeras
PAC1 binding was assessed in a(3-py cells transfected with the H-and R-Ras
chimeras. The percentage inhibition relative to the control cell activation index was
calculated for each of the chimeras (Figure 4.2).
Transfection with full-length H-Ras G12V resulted in suppression 53.3 ± 9.8% of the
active chimeric integrin, while R-Ras G38V demonstrated a slight activation of the
integrin -32.1 ± 18.7%.
Each of the inverted pairs of chimeras had opposite effects on integrin affinity,
except for chimeras HI97 and R197 which appeared to have very little overall effect
on the affinity state of the integrin, compared to control.
Like H-Ras G12V, the chimeras CHI (13.65 ± 5.1%), CH5 (40.8 ± 9.2%) and H201
(21.1 ± 5.9% ) each mediated integrin suppression. The respective inverted pair of
each of the suppressing chimeras was capable of activating the integrin in a manner
similar to R-Ras G38V, CH3 (-12.9 ± 7.8%), CH6 (-17.3 ± 4.9%) and R201 (-27.7 ±
8.9%).
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Figure 4.2 Effects of H-and R-Ras Chimeras on Integrin Affinity.
Integrin affinity was determined in a^-py cells transfected with H- and R-Ras
chimeras (lpg). H-Ras G12V (lpg) and R-Ras G38V (lpg) transfected cells were
used as controls. Percentage inhibition was calculated by comparing the activation
index in the presence of the test DNA to that of the control vector. The results shown
are the mean ± SEM of three independent experiments.
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4.3.2 Suppression of integrin activation does not correlate with ERK1/2
activation
As the integrin suppression mediated by H-Ras G12V correlates with activation of
ERK1/2 (Figure 3.5D), it was decided that it would be of interest to see if any of the
chimeras had a similar effect on ERK1/2 activation. Of particular interest were the
chimeras which caused integrin suppression, CHI, CH5 and H201. The CHI and
CH5 chimeras, despite acting like H-Ras G12V in terms of their ability to suppress
integrin affinity, are lacking in N-terminal H-Ras G12V sequences including the
effector region, and it was hypothesised that this may affect their ability to cause
ERK1/2 activation.
The FLAG-tagged H/R-Ras chimeras were transfected into a)3-py cells and Figure
4.3A shows that they were all expressed at similar levels. Those chimeras containing
the R-Ras G38V N-terminus (CHI, CH5, R197 and R201) were approximately
23kDa and those containing the H-Ras G12V N-terminus (CH3, CH6, HI97 and
H201) were approximately 21kDa.
The ability of the chimeras to mediate the phosphorylation of ERK1/2 was assessed
using a phospho-specific ERK1/2 antibody. Transfection with H-Ras G12V showed
an increase in ERK1/2 phosphorylation (Figure 4.3B), which is consistent with
results from Chapter 3 (Figure 3.5D). The serum stimulated, positive control, cells
also resulted in an increase in ERK1/2 phosphorylation. H201 mediated a slight
increase in ERK1/2 phosphorylation, however none of the other H/R-Ras chimeras
were capable of mediating ERK1/2 phosphorylation above control levels (Figure
4.3B). Total ERK2 levels, used as a control for equal protein loading, remained
unchanged in transfected cells (Figure 4.3C).
As phospho-specific ERK1/2 blots can only provide a qualitative measure of ERK1/2
phosphorylation state, it was decided to further investigate the effects of the chimeras
on ERK1/2 phosphorylation and subsequent activation using more quantitative
approaches.
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Figure 4.3 Effects of H-and R-Ras Chimera Expression on ERK1/2
Phosphorylation.
Cell lysates from chimera (1 |ig) transfected cells were probed for chimera expression
with (A) the anti-FLAG monoclonal antibody. Lysates were also probed with (B) a
phospho-specific ERK1/2 antibody and (C) ERK2 antibody. H-Ras G12V (lpg)
transfected cells and serum stimulated cells used as positive controls for ERK1/2
phosphorylation. Western blots are representative of three experiments.
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The ERK1/2 [pTpY185/187] ELISA is designed to detect and quantify the level of
dual-phosphorylated ERK1 and 2 at Thr202, Tyr204 and Thr185, Tyr187 respectively.
The dual phosphorylation is required for full enzyme activity of ERK1 and ERK2.
The level of phosphorylation of ERK1/2 can be an indirect indication of the level of
ERK1/2 activity and also indicative of the activity of upstream kinases of ERK1/2.
Figure 4.4A shows ERK1/2 activation represented as a fold increase above control
vector. Stimulation of untransfected cells with serum resulted in a significant 3-fold
increase (p<0.05) in ERK1/2 activity compared with control. Transfection with H-
Ras G12V also caused a significant 2.5-fold increase in ERK1/2 activity (P<0.05).
Transfection of a/3-py cells with R-Ras G38V and the El/R-Ras chimeras did not give
rise to any significant activation of ERK1/2, compared to control. Representative
western blots run using the remaining lysates from the ERK1/2 ELISA showed that
the chimeras were all expressed at similar levels (Figure 4.4B). Total ERK2 levels
remained unchanged in the transfected cells (Figure 4.5C).
ERK2 activity was also measured by an in-vitro kinase assay, whereby ERK2
activity was assayed by immunoprecipitating ERK2 from transfected cell lysates
with agarose-conjugated ERK2 phospho-antibody and phosphorylating the substrate
myelin basic protein (MBP) in the presence of 32P-ATP. Figure 4.5A shows a
representative graph illustrating the general trend observed in three independent
experiments. MBP phosphorylation is represented as a fold increase above control
vector. H-Ras G12V and untransfected, serum-stimulated cells both resulted in a 3
fold increase in MBP phosphorylation compared to control. Transfection with
chimera H201 resulted in a 2-fold increase in MBP phosphorylation levels, compared
to control. All other chimeras failed to increase MBP phosphorylation above 1.5-
fold. Cell lysates taken from the assay showed that expression levels were similar for
all the chimeras (Figure 4.5B). Total ERK2 levels remained unchanged in the
transfected cells (Figure 4.5C).
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Figure 4.4 H-and R-Ras Chimeras have no significant effect on the levels of
ERK1/2 phosphorylation.
Lysates from cells transfected with chimeras (lpg) were (A) analysed by ERK1/2
ELISA. Fold increase was calculated where 'Control'=l. Values represent mean ±
SEM of three experiments, each performed in triplicate. H-Ras G12V (lpg)
transfected and serum stimulated cells were used as positive controls for ERK1/2
activation. * = significant difference ,p<0.05, compared with 'Control'.
Lysates were also run on western blots and probed for chimera expression with (B)
the anti-FLAG monoclonal antibody. Total ERK2 (C) was measured as a control for
equal loading.
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A
Figure 4.5 Representative in-vitro ERK2 kinase assay.
Lysates from cells transfected with chimeras (lpg) were (A) subjected to an in-vitro
ERK2 kinase assay using MBP as a substrate. The graph is representative of three
independent experiments carried out in duplicate with results normalised against
control values.
Cell lysates were also probed for chimera expression (B) using the anti-FLAG
monoclonal antibody and total ERK2 (C) was measured using an ERK2 antibody, as
a control for equal protein loading.
Characterisation of H-and R-Ras chimeras
The 2-Step Raf kinase assay is routinely used to measure Raf activity in cells, with
Raf phosphorylating and activating MEK, which in turn activates ERK1/2, leading to
MBP phosphorylation. Endogenous Raf-1 was immunoprecipitated from cell lysates
with an anti-Raf-1 monoclonal antibody in conjunction with anti-mouse IgG agarose
beads. Following the addition of His-tagged MEK-1 and His-tagged ERK2, Raf
activity was assessed as a measure of MBP phosphorylation. Samples were run on a
12.5% SDS-PAGE gel and exposed to a phosphoimager for analysis. Raf-BXB was
used as a positive control for the 2-Step Raf kinase assay. Raf-BXB is a
constitutively active variant of Raf (Stanton et al., 1989), which does not contain a
Ras binding domain.
Figure 4.6A shows a representative graph illustrating the general trend observed in
three independent experiments. MBP phosphorylation is represented as a fold
increase above control vector. Stimulation with serum resulted in a 2-fold increase in
Raf activity, while transfections with H-Ras G12V and Raf-BxB both resulted in a
1.5-fold increase in Raf activity.
None of the El- and R-Ras chimeras showed Raf activity levels much beyond that
observed with control. The Raf activity autoradiograph (Figure 4.6B), used to get a
quantitative reading from the phosphoimager, provided a qualitative representation
of activity levels. The Raf immunoprecipitation blot (Figure 4.6C) confirmed equal
loading of samples.
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Figure 4.6 Representative 2-Step Raf Kinase Assay.
Lysates from cells transfected with constructs under test (1 pg) were (A) analysed by
2-Step Raf Kinase Assay. The kinase activity was assessed by MBP phosphorylation.
H-Ras G12V (lpg) and Raf-BxB (lpg) transfected as well as serum stimulated cells
used as positive controls for MBP phosphorylation. The results are expressed as fold
increase normalised against control cells. The graph represents the trend observed in
three independent experiments carried out in duplicate.
(B) is a representative gel showing the phosphorylation levels ofMBP as detected by
exposure to a phosphoimager. Lysates were also probed with Raf-1 antibody (C) to
detect equal Raf immunoprecipitation
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4.4 C-terminal sequences are sufficient to confer differing
properties of H-Ras and R-Ras
It has been well established that the Ras related protein, R-Ras, has the ability to
reverse H-Ras mediated integrin suppression (Sethi et al., 1999). This reversal does
not affect levels of H-Ras G12V-mediated ERK1/2 activation (Figure 3.5D). The
H/R-Ras chimeras will allow us to determine whether specific sequences of H-Ras
and R-Ras are required for their opposing effects on integrin affinity in CHO cells.
4.4.1 Residues 149-174 of H-Ras are required for suppression of integrin
activation.
Like H-Ras G12V, chimeras CHI, CH5 and H201 all demonstrated an ability to
suppress integrin affinity (see Figure 4.2). As chimera HI97 contains predominantly
H-Ras N-terminal sequences, like H201, it was decided that these four chimeras
should be grouped together for analysis. Integrin affinity was determined in cells
transfected with the CHI, CH5, H197 and H201 chimeras ± H-Ras G12V, see Figure
4.7.
As a positive control, full length R-Ras G38V was used to reverse H-Ras G12V-
mediated suppression. Percentage inhibition fell significantly from 58.2 ± 4.5% to
4.93 ± 2% (P<0.001) in R-Ras G38V co-transfectants. Chimeras CHI, CH5 and
H201 had no significant effect on the level of integrin suppression when co-
transfected with H-Ras G12V (P>0.05). In contrast, H197 failed to suppress integrin
affinity (-0.45 ± 4%) and co-transfection with H-Ras G12V showed significant
reversal of integrin suppression (58.2 ± 4.5% to 19.5 ± 3.2%) (P<0.05).
Figures 4.8A and 4.8B show that co-transfection of chimeras CHI, CH5, H197 and
H201 with H-Ras G12V did not affect the expression levels of the H- and R-Ras
chimeras or H-Ras G12V. Total ERK2 remained similar in all transfected cells
(Figure 4.8C).
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Figure 4.7 Chimeras CHI, CH5 and H201 mediate integrin suppression
Integrin affinity was determined in cells transfected with ljag of chimera CH1,CH5,
HI97 or H201 ± H-Ras G12V (l|ag). In each transfection, total DNA content was
standardised to 2jag using control vector. Percentage inhibition was calculated in
reference to control vector alone. The values represent mean ± SEM of 3-5
experiments. Statistical analysis was performed by one-way ANOVA test compared
with 'Control + H-Ras G12V'; *, ** and *** denoting P<0.05, p<0.01 and PO.OOl
respectively.
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Figure 4.8 Co-transfecting chimeras CHI, CH5, H197 and H201 with H-Ras
G12V does not affect expression levels.
Cell lysates were prepared from cells transfected with lpg of chimera CHI, CH5,
H197 or H201 ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were probed for chimera
expression using the anti-FLAG monoclonal antibody (A). H-Ras G12V expression
was checked for using anti-Ha antibody (B). Total ERK2 was probed for using an
anti-ERK2 antibody (C).
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4.4.2 Residues 175-203 of R-Ras are sufficient to reverse H-Ras-mediated
integrin suppression.
Like R-Ras G38V, chimeras CH3, CH6 and R201 all demonstrated an ability to
activate integrin affinity (see Figure 4.2). As chimera R197 contains predominantly
R-Ras N-terminal sequences, like R201, it was decided that these four chimeras
should be grouped together for analysis. Integrin affinity was determined in cells
transfected with the CH3, CFI6, R197 and R201 chimeras ± H-Ras G12V, see Figure
4.9.
As a positive control, full length R-Ras G38V was used to reverse H-Ras G12V-
mediated suppression. Percentage inhibition fell significantly from 58.2 ± 4.5% to
4.93 ± 2% (P<0.001) in R-Ras G38V co-transfectants. Chimeras CH3, CH6, and
R201 all significantly reversed H-Ras-mediated integrin suppression from 58.2 ±
4.5% to 2.7 ± 2%, -2.8 ± 10%, and -20.43 ± 8.7% respectively (PO.OOl). Chimera,
R197, was capable of reversing H-Ras-mediated integrin suppression from 58.2 ±
4.5% to 20.2 ± 5% (P<0.05) but this reversal was not as highly significant as that
observed with chimeras CH3, CH6 and R201.
Figures 4.10A and 4.10B show that co-transfection of chimeras CH3, CH6, R197
and R201 with H-Ras G12V did not affect the expression levels of the H- and R-Ras
chimeras or H-Ras G12V. Total ERK2 remained similar in all transfected cells
(Figure 4.10C).
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Figure 4.9 Chimeras CH3, CH6 and R201 show reversal of H-Ras G12V-
mediated integrin suppression
Integrin affinity was determined in cells transfected with lpg of chimera CH3, CH6,
R197 or R201 ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Percentage inhibition was calculated in
reference to control vector alone. The values represent mean ± SEM of 3-5
experiments. Statistical analysis was performed by one-way ANOVA test compared
with 'Control + H-Ras G12V'; *, ** and *** denoting P<0.05, p<0.01 and PO.OOl
respectively.
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Figure 4.10 Co-transfecting chimeras CH3, CH6, R197 and R201 with H-Ras
G12V does not affect expression levels.
Cell lysates were prepared from cells transfected with lpg of chimera CH3, CH6,
R197 or R201 ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were probed for chimera
expression using the anti-FLAG monoclonal antibody (A). H-Ras G12V expression
was checked for using anti-Ha antibody (B). Total ERK2 was probed for using an
anti-ERK2 antibody (C).
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4.5 Integrin suppression by Raf-BxB CAAX
One of the main concerns from section 4.4 was that the H-and R-Ras chimeras, in
particular CH3, CH6 and R201, may have been acting as dominant-negative proteins.
This would mean that their reversal of H-Ras G12V-mediated integrin suppression
would only be as a consequence of their sequestering Ras effectors and thus
distorting the normal signalling pathways. Raf-1 is one of the main downstream
effectors of Ras. Cells transfected with the constitutively active Rafmutant, Raf-BxB
CAAX, display a loss in PAC1 binding and suppression of the integrin (Sethi et al.,
1999). The constitutively active Raf-BxB CAAX mutant does not contain a Ras-
binding domain and therefore it would not be capable of binding to the H-and R-Ras
chimeras. An ability to reverse Raf-BxB CAAX-mediated integrin suppression
would discount a dominant-negative effect of the H/R-Ras chimeras on the Ras-Raf
initiated suppression pathway.
4.5.1 R-Ras residues 199-204 may influence the reversal of Raf-BxB CAAX-
mediated integrin suppression
Integrin affinity was determined in cells transfected with the CHI, CH5, HI97 and
H201 chimeras ± Raf-BxB CAAX. Figure 4.11 shows that levels of integrin
suppression mediated by Raf-BxB CAAX were 67.8 ± 5.7%. Chimeras CHI, CH5
and H201 had no significant effect on the level of integrin suppression when co-
transfected with Raf-BxB CAAX (P>0.05) (Figure 4.11). As with previous results,
H197 failed to suppress integrins (-2.8 ± 3.4%). Co-transfection of H197 with Raf-
BxB CAAX showed a significant reversal of Raf-BxB CAAX mediated integrin
suppression from 67.8 ± 5.7% to 18.5 ± 12.7% (P<0.05).
Analysis of the chimera sequences (see Figure 4.1) indicate that the sequence
peculiar to the suppressing chimeras and HI97, which is capable of reversing Raf-
BxB CAAX mediated suppression, is R-Ras 199-204.
Figures 4.12Aand 4.12B show that co-transfection with chimeras CHI, CH5, H197
and H201 with Raf-BxB CAAX did not affect the expression levels of any of the
constructs. Total ERK2 remained similar in all transfected cells (Figure 4.12C).
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Figure 4.11 Chimeras CHI, CH5 and H201 display integrin suppression.
Integrin affinity was determined in cells transfected with lpg of chimera CH1,CH5,
HI97 or H201 ± constitutively active Raf-BxB CAAX (lpg). In each transfection,
total DNA content was standardised to 2pg using control vector. Percentage
inhibition was calculated in reference to control vector alone. The values represent
mean ± SEM of 3-5 experiments. Statistical analysis was performed by one-way
ANOVA test compared with Control + Raf BxB CAAX; *, ** and *** denoting
P<0.05, p<0.01 and P<0.001 respectively.
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Figure 4.12 Co-expressing chimeras CHI, CH5, H197 and H201 with Raf-BxB
CAAX has no effect on expression levels.
Cell lysates were prepared from cells transfected with lpg of chimera CHI, CH5,
H197 or H201 ± Raf-BxB CAAX (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were run on western blots and
probed for chimera expression (A) using the anti-FLAG monoclonal antibody, Raf-
BXB CAAX expression was checked for using (B) anti-Ha antibody. Total ERK2
(C) was measured as a control for equal loading of sample.
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4.5.2 R-Ras like chimeras do not act as dominant negative proteins on the Ras-
Raf initiated integrin suppression pathway
Integrin affinity was determined in cells transfected with the CH3, CH6, R197 and
R201 chimeras ± Raf-BxB CAAX. Figure 4.13 shows that the level of integrin
suppression mediated by Raf-BxB CAAX was 67.8 ± 5.7%. Chimeras CH3, CH6
and R201 all significantly reversed Raf BxB CAAX mediated suppression from 67.8
± 5.7% to -1.2 ± 2.3%, -4.5 ± 4%, and -12.3 ±7.5% respectively (PO.OOl). Co-
transfection with R197 did not have any significant effect on Raf-BxB CAAX
mediated integrin suppression.
That chimeras CH3, CH6 and R201 can reverse constitutively active Raf-BxB
CAAX-mediated integrin suppression, rules out a dominant negative effect. Analysis
of these results with reference to the chimera sequences (see Figure 4.1) indicate that
the sequence residues peculiar to the chimeras capable of reversing Raf-BxB CAAX-
mediated suppression and R197, which is incapable of reversing Raf-BxB CAAX-
mediated suppression, are H-Ras residues 172-175.
Figures 4.14A and 4.14B reveal that co-transfection of Raf-BxB CAAX with the
chimeras CH3, CH6, R197 and R202 did not affect the expression levels of the
constructs. Total ERK2 remained similar in all transfected cells (Figure 4.14C).
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Figure 4.13 Chimeras CH3, CH6 and R201 reverse Raf-BxB CAAX-mediated-
integrin suppression.
Integrin affinity was determined in cells transfected with lpg of chimera CH3, CH6,
R197 or R201 ± constitutively active Raf-BxB CAAX (l|ag). In each transfection,
total DNA content was standardised to 2pg using control vector. Percentage
inhibition was calculated in reference to control vector alone. The values represent
mean ± SEM of 3-5 experiments. Statistical analysis was performed by one-way
ANOVA test. **, *** = significant difference, PO.Ol and PO.OOl respectively,
compared to 'Control+ Raf-BxB CAAX.
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Figure 4.14 Co-expressing chimeras CH3, CH6, R197 and R201 with Raf-BxB
CAAX has no effect on expression levels.
Cell lysates were prepared from cells transfected with lpg of chimera CH3, CH6,
R197 or R201 ± Raf-BxB CAAX (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were run on western blots and
probed for chimera expression (A) using the anti-FLAG monoclonal antibody, Raf-
BXB CAAX expression was checked for using (B) anti-Ha antibody. Total ERK2
(C) was measured as a control for equal loading of sample.
Characterisation of H-and R-Ras chimeras
4.6 Discussion
The suppression of integrin activation by H-Ras and its downstream effector kinase
Raf-1 can control cell morphology, migration and assembly of the extracellular
matrix (Hughes et al., 1997; Brenner et al., 2000). In contrast, the small GTP-binding
protein R-Ras lacks this activity; R-Ras has the ability to promote rather than
suppress integrin activation (Zhang et al., 1996; Sethi et al., 1999; Kinashi et al.,
2000). Consistent with a role for R-Ras in activating integrins, R-Ras stimulates
a2/3i-dependent cell migration of breast epithelial cells (Keely et al., 1999). Activated
R-Ras can also induce the adhesion of bone-marrow-derived mast cells to fibronectin
through activation ofc^i (Kinashi et al., 2000).
Recently there have been studies carried out on H-Ras and R-Ras to try and define
variable and essential regions of each of these proteins. In particular, two separate
studies have been published by Hansen et al., (2002) and Hughes et al., (2002)
during the course of the investigations described in this thesis. While overlap
between this work and the two specified studies is regrettable, this discussion will
focus mainly on the findings obtained during this research, with appropriate
reference made to the aforementioned studies.
With the aim ofmapping the regions of H-Ras and R-Ras responsible for conferring
their differing effects on integrin affinity, a series of chimeric proteins composed of
portions of the N-terminus of H-Ras fused to the C-terminus of R-Ras and the
reciprocal chimeras composed of the N-terminus ofR-Ras fused to the C-terminus of
H-Ras were utilised. The major findings of this chapter are as follows: First, a 25-
amino acid stretch ofH-Ras (149-174) is required for integrin suppression. Second, a
28-amino acid stretch of R-Ras (175-203) is sufficient to reverse H-Ras mediated
integrin suppression. Third, several of the suppressive chimeras had little significant
effect on ERK1 and ERK2 MAP kinase phosphorylation, suggesting that Ras-
induced integrin suppression may be independent of the bulk activation of ERK1/2.
In an attempt to ease the discussion of the relevance of the results obtained in this
chapter, I am going to concentrate first on the affects on integrin affinity modulation
determined by transfection with the H/R-Ras chimeras as compared to H-Ras G12V
and R-Ras G38V. Following this, I will discuss the effects on ERK1 and ERK2 MAP
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kinase phosphorylation. Please refer to the schematic representation of the chimeras
(Figure 4.1) during the following discussion.
4.6.1 Integrin affinity modulation by H/R-Ras chimeras
Using the Q}3-py transfection system, results here indicate that a 25-amino-acid
stretch of H-Ras, comprising residues 149-174, is required for its ability to suppress
integrin activation. This conclusion was drawn from two observations; first, that a
chimera, CH5, comprising FI-Ras sequences C-terminal of Lys149, (R-Ras 174; H-
Ras 149-198), was sufficient to convey suppressive activity to R-Ras. Second, that
chimera H201, that contains H-Ras residues N-terminal of Pro174 (H-Ras 174; R-Ras
204-219) was able to suppress integrin activation (see Figures 4.1 and 4.2). This is in
accordance with the recently published paper by Hughes et al. (2002), where it was
established that a 35-amino acid stretch of H-Ras, encompassing residues 149-174,
was required for its ability to suppress integrin activation.
It would therefore be expected that those chimeras which contain this 25-amino-acid
stretch would confer suppressive effects comparable to H-Ras. Figure 4.6 illustrates
that chimeras CHI, CH5 and H201 have the ability to suppress the integrin to levels
not dissimilar to H-Ras. It was somewhat unexpected to find that despite consisting
of H-Ras residues 1-171, HI97 showed a significant reversal of H-Ras-mediated
integrin suppression. This suggests that the H-Ras C-terminal residues 171-174 (the
area of divergence between chimeras HI97 and H201) may be required for full
suppressive potential of H-Ras. The possible relevance of these C-terminal residues
will be discussed further on.
Results here show that a 28-amino-acid stretch of R-Ras, comprising residues 175-
203, is sufficient for its ability to promote an activated state of integrin. This
conclusion was drawn from the following observations; first, that a chimera, CH6,
comprising R-Ras sequences C-terminal of Leu175, (H-Ras 146; R-Ras 175-219), was
sufficient to convey activation activity to H-Ras. Second, that chimera R201, which
contains R-Ras residues N-terminal of Pro203 (R-Ras 203; H-Ras 175-198) was able
to activate the integrin (see Figure 4.2). These results are in accordance with the
recently published paper by Hansen et al., (2002) who demonstrated that the C-
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terminal 53 amino acids of R-Ras, encompassing residues 175-203, were necessary
and sufficient to confer R-Ras specificity to H-Ras
The 28-amino-acid stretch of R-Ras, comprising residues 175-203, is sufficient for
its ability to promote an activated state of integrin. Full length R-Ras has been shown
to completely reverse Fl-Ras/Raf mediated integrin suppression, see Figure 3.5A
(Sethi et al., 1999). Therefore, it was investigated to see if this 28-amino acid stretch
was sufficient to impart the reversing effect ofR-Ras. Figure 4.9 shows that chimeras
CH3, CH6 and R201 all significantly (PO.OOl) reverse H-Ras mediated integrin
suppression, and that this reversal is not due to a reduction in the level of H-Ras
expression (Figure 4.1OB). Unlike the rest of the 'reversing' chimeras, the effect by
R197 was less significant (P<0.05) (Figure 4.9). This would imply that the area of
divergence between chimeras R197 and R201, R-Ras C-terminal residues 198-203,
affect its ability to fully promote an activated integrin state.
The requirement for Ras in Raf activation can be overcome by targeting Raf to the
plasma membrane (Leevers et al., 1994). Leevers et al., (1994), describe a Raf
protein (Raf CAAX) with a C terminus comprising the C-terminal 20 amino acids of
K-Ras (4B), including the CAAX box required for post-translational modification
and the polybasic domain required for plasma membrane localisation. Raf-CAAX is
constitutively active and this activity is independent of cellular Ras, kinase activity is
not inhibited by dominant-negative N17Ras (Leevers et al., 1994). A variant of the
activated Raf-CAAX, Raf-BxB CAAX, does not contain a Ras-binding domain
(Hughes et al., 1997). Transfection of cq3-py cells with Raf-BxB CAAX results in a
suppression of integrin activity (Figures 4.11 and 4.13), this is in agreement with
several publications (Hughes et al., 1997; Sethi et al., 1999; Hughes et al., 2002). As
Raf-BxB CAAX does not contain a Ras-binding domain, it would not be able to be
bound to and sequestered by the H-and R-Ras chimeras in a dominant negative
manner. Therefore, reversal of Raf-BxB CAAX-mediated suppression would rule out
a dominant negative effect by the H/R-Ras chimeras on the Ras-Raf pathway.
Figure 4.11 shows that chimeras CHI, CHS and H201 have the ability to suppress
the integrin to levels comparable to Raf-BxB CAAX transfected cells. HI97 shows a
significant (P<0.05) reversal ofRaf-BxB CAAX mediated integrin suppression. This
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observation supports the proposal that H-Ras C-terminal residues 171-174 (the area
of divergence between chimeras HI 97 and H201) affect the full suppressive potential
ofH-Ras.
R-Ras has been shown to completely reverse the suppressive effect mediated by Raf-
BxB CAAX (Sethi et al., 1999). This suggests that the R-Ras reversal of H-Ras
induced suppression is not caused by competition for the common effector Raf-1
(since Raf-BxB CAAX does not contain a Ras binding domain) or by a dominant
negative effect (Sethi et al., 1999). Like R-Ras G38V, chimeras CH3, CH6 and R201
are capable of fully reversing Raf-BxB CAAX-mediated suppression (Figure 4.13).
This reversal was not as a consequence of reduced Raf-BxB CAAX expression levels
(Figure 4.14 B). Although R197 was able to reduce Raf-BxB CAAX-mediated
integrin suppression, it was not able to fully reverse integrin suppression. This
observation draws attention, once again, to the area of divergence between chimeras
R197 and R201. It would appear that R-Ras C-terminal residues 198-203 are
necessary for it to be fully capable of reversing Raf-BxB CAAX-mediated
suppression.
The molecular basis for the dependence on H-Ras (149-174) and R-Ras (175-203) on
integrin modulation is not immediately obvious. Prior to the work carried out for this
thesis, and the recent studies by Hansen et al., (2002) and Hughes et al., (2002),
previous analyses of H-Ras and R-Ras have not implicated these regions as critical
for specifying interactions with downstream effectors.
The main sequence variation between H-Ras and R-Ras is the N-terminal 26-amino
acid extension of R-Ras. However, the ability of chimeras CHI and CH5, which
contain this 26-amino acid stretch of R-Ras, to still induce a suppressive effect on
integrins discounts the importance of this 26-amino acid extension with respect to
integrin affinity modulation. A previous study demonstrated the null effect of
substituting the first 30-amino acids ofR-Ras for the first 4-amino acids of H-Ras on
the biological activity of H-Ras G12V, strongly suggesting that the N-terminal of R-
Ras does not interfere with the effector function of H-Ras (Lowe et al., 1988).
Extensive analysis of both H-Ras point mutations and H-Ras/Rapl chimeras has
suggested that the critical sequences involved in determining effector binding and
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activation are amino-acids 20-48 and amino-acids 60-76, which comprise the switch
I (within the effector binding domain) and switch II regions, respectively (Marshall
et al., 1991; Marshall et al., 1996; Campbell et al., 1998). However, in this study, the
substitution of these regions between H-Ras and R-Ras (demonstrated with chimeras
CHI, CH3, CH5 and CH6) had only minimal effects on integrin modulation. This
may be due to the high degree of sequence similarity between H-Ras and R-Ras
effector binding regions, which means that despite swapping the effector regions
they can bind to common effectors such as Raf-1 and PI 3-kinase. Results here
indicate that residues important for integrin affinity modulation, located in the C-
terminal regions of H-Ras and R-Ras, could also be responsible for the regulation of
the activation of bound effectors.
The main sequence divergence between the three Ras isoforms, H, N and K (which
exhibit biologically significant differences despite their high degree of sequence
homology) is confined to 23-amino acids of the carboxy-terminal hypervariable
region (HVR) (Prior et al., 2001). This hypervariable domain can be divided into two
distinct areas, the HVR linker domain (H-Ras 166-179) and the C-terminal targeting
domain (H-Ras 180-189) (Prior et al., 2001). The latter C-terminal targeting domain
contains the -CAAX box, common to all Ras proteins (Hancock et al., 1989). The
targeting of Ras to the plasma membrane is essential for its correct biological activity
(Williumsen et al., 1984).
Results here show that substitution of the C-terminal targeting domains of H-Ras
with R-Ras (chimera H201) was not sufficient to convey the integrin activating
properties of R-Ras (Figures 4.2, 4.7 and 4.11). Consistent with this, substitution of
the C-terminal targeting domains of R-Ras with H-Ras (chimera R201) was not
sufficient to convey suppressive activity (Figures 4.2, 4.9 and 4.13). This
demonstrates that the C-terminal targeting domain alone is not sufficient to mediate
the differing integrin modulating properties of H-Ras and R-Ras, these findings
concur with the recent publication by Hughes et al., (2002).
There have been a number of recent investigations to determine the specific
functions of the HVR linker domain. Prior et al., (2001) showed that palmitolyation
and farnesylation targets H-Ras to lipid rafts and caveolae within the plasma
119
Characterisation of H-and R-Ras chimeras
membrane; subsequent GTP-loading redistributes H-Ras from rafts into the bulk
plasma membrane and the H-Ras HVR linker domain is necessary for GTP-
dependent release of H-Ras from the lipid rafts and for biological activity. The
importance of the HVR linker domain was further supported by Jaumont et al.,
(2002) who used deletion analysis to show that removal of the N-terminal amino
acids of the HVR linker domain, H-Ras residues 166-172, compromised the normal
raft/non-raft equilibrium and effector function of H-Ras. The remaining C-terminal
7-amino acids of the linker domain have been described as an essential spacer
element of the HVR linker domain (Jaumont et al., 2002). While alanine replacement
of residues 166-172 abrogated Raf-1 activity similar to that seen with deletion of the
entire linker domain, alanine replacement of residues 173-179 resulted in activation
ofRaf-1 as efficiently as full-length H-Ras G12V (Jaumont et al., 2002).
The H-Ras (149-174) and R-Ras (175-203) residues identified in this study as having
influence over integrin affinity modulation by H-Ras and R-Ras overlap with the
proteins' HVR linker domains. Therefore, investigations here draw attention to the
importance of the HVR linker domain in the modulation of integrin affinity.
The H/R-Ras chimera, HI97 (H-Ras 171; R-Ras 199-219), despite comprising of
>85% H-Ras N-terminal sequence, has a compromised ability to suppress integrins.
Moreover, H197 demonstrates significant (P<0.05) reversal of both H-Ras G12V-
and Raf-BxB CAAX-mediated integrin suppression. That HI97 does not contain the
specific amino acids of the essential spacer element of H-Ras would not explain its
lack of suppressive ability. As demonstrated by Jaumont et al., (2002), alanine
substitution of these amino acids preserves H-Ras G12V properties.
Likewise, the H/R-Ras chimera R197 (R-Ras 198; H-Ras 172-198), despite being
comprised of -90% R-Ras N-terminal sequence, has a limited ability to reverse H-
Ras G12V and Raf-BxB CAAX mediated integrin suppression.
Since substitution of the C-terminal binding domain of the HVR of H-Ras and R-
Ras, demonstrated by chimeras H201 and R201, does not affect their abilities to
modulate integrin affinity, we can look to see if the areas of sequence divergence
between HI97 and H201 (H-Ras C-terminal residues 171-174) and the equivalent
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area of sequence divergence between R197 and R201 (R-Ras C-terminal residues
198-203) hold any significance.
R-Ras differs from Ras and most other members of the Ras super family of small
GTPases in that it possesses a distinct proline rich site (Wang et al., 2000). This
proline rich site is located within the HVR linker domain (R-Ras residues Pro199 to
Pro206) and overlaps with the area of sequence divergence between R197 and R201;
R-Ras C-terminal residues 198-203.
The proline-rich motif of R-Ras resembles Src Homology 3 (SH3) domain binding
sites (PXXP motifs, where X represents any amino acid) (Wang et al., 2000).
Molecules that contain Src Homology 2 (SH2) and SH3 domains provide one of the
principle ways by which signals are transduced in cells using protein-protein
interactions between proline-rich domains and SH3 domains and induced interactions
between phosphotyrosine residues and SH2 domains (Birge et al., 1996). Wang et
al., (2000) have recently demonstrated that the adaptor protein Nek (SH3-domain
containing protein) interacted strongly with the R-Ras proline-rich sequence,
independent of whether R-Ras was in its GDP or GTP form. Proline to alanine point
mutations to alter the PXXP motifs (P202A, P203A) reduced Nek binding showing
that the proline-rich domain is required for binding to Nek domains (Wang et al.,
2000).
It has been suggested that the adaptor protein, Nek, is required to recruit R-Ras
effectors that are then employed by R-Ras to augment integrin affinity (Kinbara et
al., 2003). Nek could mediate a cross talk between R-Ras and Racl, as it binds to
PAK, which is known to interact with RaclA (Manser et al., 1994; Manser et al.,
1997). Furuhjelm and Peranen, (2003) showed that R-Ras and Racl colocalise to
focal adhesions. The possible cross talk between these two proteins, within focal
adhesions, could help to amplify signals which mediate cell adhesion and spreading.
Nek has also been shown to interact through its SH2 domain with pl30cas (Barbacid,
1987). P130cas is a docking protein that accumulates in focal adhesions (Holland et
al., 1998; Hanks and Polte, 1996). Thus, Nek could, by binding R-Ras, via its SH3
domain, and pl30cas, via its SH2 domain, allow cross talk between these two proteins
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within focal adhesions. In fact a recent study has shown that R-Ras can enhance the
phosphorylation of pl30cas (Kwong et al., 2003).
Expression of constitutively active R-Ras G38V enhanced cell adhesion to
extracellular matrix substrates by enhancing integrin ligand-binding activity in a
CHO cell line (Zhang et al., 1996). Wang et al., (2000) show that 32D mouse
monocytic cells, which grow in suspension, when transfected with R-Ras G38V
adhered to fibronectin however, clones expressing the R-Ras G38V (P202A, P203A)
mutant showed reduced cell attachment to fibronectin. The importance of the
proline-rich domain in contributing to the integrin activating function of R-Ras may
help to explain the effects of chimeras HI 97 and R197 on integrin affinity. It may be
that the significant (P<0.05) reversal of both H-Ras G12V and Raf-BxB CAAX
mediated integrin suppression by HI97 (H-Ras 171; R-Ras 199-219), despite
comprising of >85% H-Ras N-terminal sequence, may be due to the fact that this
chimera contains the proline-rich motifs of R-Ras (R-Ras residues 199-206) which
may help promote integrin activation. The limited ability ofR197 (R-Ras 198; H-Ras
172-198) to reverse H-Ras G12V and Raf-BxB CAAX mediated integrin
suppression, despite being comprised of ~ 90% R-Ras N-terminal sequence, may be
due to it lacking the proline-rich motifs ofR-Ras, which begins with R-Ras Pro'99.
Further investigations into the proline-rich domain of R-Ras would help to resolve
the role, if any, for this sequence in mediating R-Ras's effect on integrin affinity.
4.6.2 Phosphorylation of ERK1/2 by H/R-Ras chimeras.
The Ras proteins function as molecular switches that are controlled by a GDP/GTP
binding cycle, coupling to and activating downstream effectors when in the activated
GTP-bound conformation (Bos et al., 1998). Both H-Ras and R-Ras have similar
core-effector binding domains, and bind to common downstream effectors when in
the GTP-bound state. The major downstream effector of H-Ras is Raf-1 and in its
active (GTP-bound) state, H-Ras recruits Raf-l to the plasma membrane and
stimulates its kinase activity (Leevers et al., 1994). Following on from this, Raf-1
activates the ERK1/2 MAP kinase cascade and eventually leads to changes in
transcription (Leevers et al., 1994). R-Ras interacts with the Raf serine/threonine
kinases (Spaargaren et al., 1994; Rey et al., 1994). However, R-Ras has not been
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reported to activate Raf or the ERK1/2 family ofMAP kinases (Sethi et al., 1999). It
has been described that expression of H-Ras G12V and its kinase effector, Raf-1,
mediates integrin suppression and that this correlates with increased ERK1/2 activity
(Hughes et al., 1997). Constitutively active R-Ras (G38V) has been shown to
antagonise the Ras/Raf initiated integrin suppression pathway furthermore, this
reversal of suppression does not affect ERK2 activation induced by H-Ras or Raf
(Sethi et al., 1999).
Using the H-and R-Ras chimeras the relationship between H-Ras and R-Ras in
modulating integrin affinity, and their ability to influence MAP kinase activation was
further investigated.
The effect of H/R-Ras chimera expression on ERK 1/2 phosphorylation and
activation was observed using a variety ofmethods. A decision was made to employ
several methods to provide both quantitative and qualitative results, as it was obvious
from preliminary experiments that there was little qualitative difference between the
levels of ERK1/2 activation by the individual chimeras. The central aim was to try
and determine the specific sequences of H- and R-Ras which may affect their ability
to activate ERK1/2. As positive controls for each of the methods employed, cells
transfected with H-Ras G12V and serum stimulation of quiesced cells were used.
In contrast to an initial report by Hughes et al., (1997), who suggested that integrin
suppression was a novel function of the Ras/Raf-initiated pathway, results here
demonstrate that the activation of ERK1/2 might not be necessary for suppression of
integrins. This is in agreement with several recent studies by Hughes et al., (2002)
and Hansen et al., (2002). The chimeras, CHI; CH5 and H201, which have
demonstrated suppressive effects on integrins similar to H-Ras G12V (Figures 4.2,
4.7 and 4.11), did not activate ERK1/2 to any significant level (see Figure 4.4).
Hughes et al., (2002) also showed that H-and R-Ras chimeras very similar to those
employed in this study, which had a suppressive effect on integrin-affinity, were
poor activators of ERK 1/2. Hughes et al., (2002) further investigated this finding by
inhibiting bulk ERK1/2 activation by: co-expressing MAP kinase phosphatase 3
(MKP3), a phosphatase which specifically binds and dephosphorylates ERK1 and
ERK2 (Muda et al., 1996; Keyse et al., 2000); and using MEK kinase inhibitor,
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U0126 (Favata et al., 1998), neither of which affected the ability of H-Ras or Raf-1
to suppress integrin activation. Additionally, it was found that activation of ERK1/2
alone, using a constitutively active mutant of MEK1, was not sufficient for integrin
suppression (Hughes et al., 2002). Using H/R-Ras chimeras similar to those used in
the investigations for this project and those used by Hughes et al., (2002), Hansen et
al., (2002) further verify the conclusion that integrin suppression does not necessarily
correlate with the activation of the ERK1/2 pathway.
Hansen et al., (2002) reported that ERK1/2 activity, as determined using a phospho-
specific ERK1/2 antibody, correlated with the presence of H-Ras N-terminal
sequences. Their study revealed that H-and R-Ras chimeras which contained H-Ras
sequences N-terminal of Ala121 were capable of activating ERK1/2 to levels
comparable to H-Ras G12V (Hansen et al., 2002). Results here conflict with this
account. Figures 4.3B and 4.4A show the phosphorylation state of ERK1/2 using a
western blot probed with a phospho-specific ERK1/2 antibody and an ERK1/2
ELISA respectively. Results suggest that none of the H/R-Ras chimeras, whether
they contain H-Ras N-terminal sequences or not, exhibited the ability to activate
ERK1/2, to levels similar to H-Ras G12V. The H201 chimera, which contains the H-
Ras sequences 1 to 174, did increased the phosphorylation state of ERK1/2, but not
to the levels observed with H-Ras G12V.
One hypothesis that may be drawn from the overall null effect of the H-and R-Ras
chimeras on levels of ERK1/2 phosphorylation may be that, in order for H-Ras to
interrelate with and stimulate the kinase activity of its down stream effector kinase
Raf-1 it must first of all be targeted to the correct membrane microdomain by the C-
terminal farnesyl group. H-Ras Ser186 (which lacked the cysteine residue to be
farnesylated) had almost negligible activity, indicating that the post-translational
modifications of H-Ras, especially the farnesylation step, are critical for normal
activation ofRaf (Okada et al., 1996).
The above hypothesis may explain why H201 is incapable of phosphorylating
ERK1/2 to similar levels ofH-Ras GUV, despite possessing >85% H-Ras sequence.
As H201 comprises the C-terminal targeting domain of R-Ras, it is likely be to be
targeted to an alternative plasma membrane domain where it may not be as proficient
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at interacting with Raf sufficiently to induce its kinase activity. Alternatively, it may
be that the chimeric 3-D structure (determined by post-translational modifications) of
H201 may disrupt the ability of the chimera to target the correct microdomain or
affect its ability to interact with Raf. Cell passage number (age) may also affect the
cell's ability to activate ERK1/2.
The use of the phospho-specific ERK1/2 antibody and an ERK1/2 ELISA allowed us
to determine the phosphorylation of ERK1/2, as an indicator of the activation state.
The kinase assays, Figures 4.5 and 4.6, were performed to allow us to quantify the
effect the chimeras had on levels of kinase activity, for ERK1/2 and Raf respectively.
However, a number of problems encountered while perfomiing the kinase assays,
concerning kinase assay sensitivity, limited the value of performing statistical
analyses on the data. The above-mentioned problems included: inaccurate pipetting,
resulting from the use of agarose beads; radioactive decay; deterioration of substrate
activity and washing techniques. Despite taking appropriate steps to rule out some of
the problems encountered with the kinase assays, the discrepancy of scintillation
counts and phospho-imager readings caused by biological variations between
experiments meant that collating data from several experiments would lead to
increased error and a lack of statistical significance. Therefore, it was decided to use
representative graphs to display the general trend observed within each individual
kinase assay.
As expected, H-Ras G12V and serum stimulation induced the greatest increase in
MAPK and Raf kinase activity. The H201 chimera also increased the kinase activity
of Rafl and ERK1/2, but not to the same extent as observed with H-Ras G12V
transfection and serum stimulation (Figure 4.5). The other H/R-Ras chimeras were
incapable of inducing kinase activities to levels beyond those observed with control
vector alone.
Although the H201 chimera was capable of inducing phosphorylation of ERK1/2
(Figures 4.3B and 4.4A), perhaps the lack of the H-Ras C-terminal domain
diminished the ability of the chimera to increase the phosphorylation state of ERK1/2
to the levels required for full ERK1/2 kinase activity (4.5A). This would suggest that
for maximal stimulation of ERK1/2 kinase activity (i.e. dual phosphorylation of the
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relevant ERK1/2 Thr and Tyr residues) the full-length sequence of H-Ras is
necessary.
4.6.3 Summary
The H/R-Ras chimeras imply that the C-terminal sequences of H-Ras and R-Ras are
critical to determining their different effects on integrin affinity. More specifically, a
25-amino acid stretch ofH-Ras (Arg149 to Pro174) is required for integrin suppression,














The areas of H-Ras and R-Ras identified as being important for determining their
different effects on integrin affinity are shown as a hatched effect on the above
schematic. The sequences are shown to be in the same place for each of the proteins,
in a C-terminal position which overlaps with the HVR.
The proline-rich domain of R-Ras (residues Pro199 to Pro206) may be important in
conferring R-Ras's ability to fully reverse H-Ras G12V-mediated integrin
suppression.
Like H-Ras G12V, chimeras CHI, CH5 and H201, all suppressed integrin affinity.
However, only H201 induced integrin suppression correlated with ERK1/2
activation, which suggests that Ras-induced integrin suppression may be independent
of the bulk activation of ERK1/2. Results indicate the presence of a possible integrin
suppression pathway that is independent ofERK1/2.
Further analysis of the effect of the H-and R-Ras chimeras on ERK1/2 kinase activity
suggests that the full-length H-Ras sequence is required for maximal activation of
ERK1/2.
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See below for a summary table showing all the observations made for each chimera
in this chapter; refer to Figure 4.1 for schematic representation of chimeric
sequences.
Integrin Reversal of Reversal ofRaf-BxB ERK1/2
Chimera affinity H-Ras suppression CAAX suppression activation
R-RAS Activated *** *** +
H-RAS Suppressed N/A N/A +++
CH3 Activated *** *** +
CH6 Activated *** *** +
HI 97 Little effect * * +
H201 Suppressed N/A N/A ++
CHI Suppressed N/A N/A +
CH5 Suppressed N/A N/A +
R197 Little effect * * +
R201 Activated *** *** +
Key: Influence on the reversal of suppression of H-Ras G12V and Raf-BxB CAAX
shown with asterisks, where * = small reversal and *** = highly significant reversal.
Effect on ERK1/2 activation shown using crosses, where + = control level activation,
++ = slight increase in activation and +++ = significant increase in activation.
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H-Ras G12V sequence in pCDNA3.1(+)
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 HRAS ATGACGGAATATAAG CTGGTGGTGGTGGGC GCCGGCGGTGTGGGC AAGAGTGCGCTGACC ATCCAGCTGATCCAG AACCATTTT-GTGGA 89
2 HRASSP6 ATAACGGAATATAAG NTGGTGGTGGTGGGC GCCGTCGGTGTGGGC AAGAGTGCGCTGACC ATCCAGCTGATCCAG AACCATTTTTGTGNN 90
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 HRAS CGAATACGACCCCAC TATAGAGGATTCCTA CCGGAAGCAGGTGGT CATTGATGGGGAGAC GTGCCTGTTGGACAT CCTGGATACCGCCGG 179
2 HRASSP6 CGAATACGACCCCAC TATAGAGGATTCCTA CCGGAAGCAGGTGGT CATTGATGGGGAGAC GTGCCTGTTGGACAT CCTGGATACCGCCGG 180
Page 3.1
181 195 196 210 211 225 226 240 241 255 256 270
1 HRAS CCAGGAGGAGTACAG CGCCATGCGGGACCA GTACATGCGCACCGG GGAGGGCTTCCTGTG TGTGTTTGCCATCAA CAACACCAAGTCTTT 269
2 HRASSP6 CCAGGAGGAGTACAG CGCCATGCGGGACCA GTACATGCGCACCGG GGAGGGCTTCCTGTG TGTGTTTGCCATCAA CAACACCAAGTCTTT 270
Page 4.1
271 285 286 300 301 315 316 330 331 345 346 360
1 HRAS TGAGGACATCCACCA GTACAGGGAGCAGAT CAAACGGGTGAAG-G ACTCGGATGACGTGC CCATGGTGCTGGTGG GGAACAAGTGTGACC 358
2 HRASSP6 TGAGGACATCCACCA GTACAGGGAGCAGAT CAAACGGGTGAAGAG ACTCGGATGACGTGC CCATGGTGCTGGTGG GGAACAAGTGTGACC 360
Page 5.1
361 375 376 390 391 405 406 420 421 435 436 450
1 HRAS TGGCTGCACGCACTG TGGAATCTCGGCAGG CTCAGGACCTCGCCC GAAGCTACGGCATCC CCTACATCGAGACCT CGGCCAAGACCCGGC 448
2 HRASSP6 TGGCTGCACGCACTG TGGAATCTCGGCAGG CTCAGGACCTCGCCC GAAGCTACGGCATCC CCTACATCGAGACCT CGGCCAAGACCCGGC 450
page b.l
451 465 466 480 481 495 496 510 511 525 526 540
1 HRAS AGGGAGTGGAGGATG CCTTCTACACGTTGG TGCGTGAGATCCGGC AGCACAAGCTGCGGA AGCTGAACCCTCCTG ATGAGAGTGGCCCCG 538
2 HRASSP6 AGGGAGTGGAGGATG CCTTCTACACGTTGG TGCGTGAGATCCGGC AGCACAAGCTGCGGA AGCTGAACCCTCCTG ATGAGAGTGGCCCCG 540
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 HRAS GCTGCATGAGCTGCA AGTGTGTGCTCTCCT GA 570
2 HRASSP6 GCTGCATGAGCTGCA AGTGTGTGCTCTCCT GA 572
R-Ras G38V sequence in pCDNA3.1 (+)
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
2 RRASb ATGAGCTCTGGTGCT GCTTCTGGTACAGGT CGTGGTCGTCCACGT GGTGGAGGTCCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC 90
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 RRAS AAGCTGGTGGTCGTG GGCGGC . GGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
2 RRASb AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
Page 3.1
181 195 196 210 211 225 226 240 241 255 256 270
1 RRAS ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGC GGGCCAGGAAG 265
2 RRASb ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACATCTCT NGTCGGGCCAGGAAG 270
Page 4.1
271 285 286 300 301 315 316 330 331 345 346 360
1 RRAS AGTTCGGGGCCATGA GAGAGCAGTACATGC GTGCTGGCCACGGCT TCCTGCTGGTGTTCG CCATTAATGACCGGC AGAGTTTCAACGAGG 355
2 RRASb AGTTCGGGGCCATGA GAGAGCAGTACATGC GTGCTGGCCACGGCT TCCTGCTGGTGTTCG CCATTAATGACCGGC AGAGTTTCAACGAGG 360
Page 5.1
361 375 376 390 391 405 406 420 421 435 436 450
1 RRAS TGGGCAAGCTCTTCA CGCAGATTCTGCGGG TCAAGGACCGCGACG ACTTCCCCGTTGTGT TGGTCGGGAACAAGG CAGATCTGGAGTCAC 445
2 RRASb TGGGCAAGCTCTTCA CGCAGATTCTGCGGG TCAAGGACCGCGACG ACTTCCCCGTTGTGT TGGTCGGGAACAAGG CAGATCTGGAGTCAC 450
Page 6.1
451 465 466 480 481 495 496 510 511 525 526 540
1 RRAS AGCGCCAGGTCCCCC GATCAGAAGCCTCTG CC-TTCGGCGCCTCC CACCACGTGGCCTAC TTTGAGGCCTCGGCC AAACTGCGTCTCAAC 534
2 RRASb AGCGCCAGGTCCCCC GATCAGAANCCTCTG CCCTTCGGCGCCTCC CACCACGTGGCCTAC TTTGAGGCCTCGGCC AAACTGCGTCTCAAC 540
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 RRAS GTGGACGAGGCTTTT GAGCAGCTGGTGCGG GCTGTCCGGAAATAC CAGGAACAAGAGCTC CCACCGAGCCCTCCC AGTGCCCCCAGGAAG 624
2 RRASb GTGGACCANGCTTTT GAGCAGCTGGTGCGG GCTGTCCGGAAATAC CAGGAACAAGAGCTC CCACCGAGCCCTCCC AGTGCCCCCAGGAAG 554
Page 8.1
631 645 646 660 661 675 676 690 691 705 706 720
1 RRAS AAGGGCGGGGGCTGC CCCTGCGTCCTCCTG TAG 657
2 RRASb AAGGGCGGGGGCTGC CCCTGCGTCCTCCTG TAG 554
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Chimera CHI alignment sequence
1 15 16 30 31 45 46 60 61 75 76 90
1 CHI AAGAGCTCTGGTGCT GCTTCTGGTACAGGT CGTGGTCGTCCACGT GGTGGAGGTCCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC 90
2 HRAS ATGACG-GA-ATAT 12
3 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
Page 2.1
91 105 106 120 121 135
1 CHIcon AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG
2 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG
3 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG
136 150 151 165 166 180
ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
Page 3.1
181 195 196 210 211 225
1 CHlcon ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
2 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
3 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
226 240 241 255 256 270
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCATGAGGAGT 268
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
Page 4.1
271 285 286 300 301 315
1 CHlcon ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
2 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
3 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
316 330 331 345 346 360
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 358
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
Page 5.1
361 375 376 390 391 405
1 CHlcon ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
2 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
3 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
406 420 421 435 436 450
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGGCTGCAC-G 447
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGG-CTGCAC-G 368
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGT-CACAG 447
Page 6.1
451 465 466 480 481 495
1 CHlcon CACTGTGGAATC TCGGCAGGCTCAGGA CCTCGCCCGAAGCTA
2 HRAS CACTGTGGAATC TCGGCAGGCTCAGGA CCTCGCCCGAAGCTA
3 RRAS CGCCAGGTCCCCCGA TCAGAAGCCTCTGC- CTTCGGCGCCTCCCA
496 510 511 525 526 540
CGGCATCCCCTACAT CGAGACCTCGGCCAA GACCCGGCAGGGAGT 534
CGGCATCCCCTACAT CGAGACCTCGGCCAA GACCCGGCAGGGAGT 455
CCACGTGGCCTACTT TGAGGCCTCGGCCAA ACTGCGTCTCAACGT 536
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 CHlcon GGAGGATGCCCTTCT ACNCNTNGGGTGCTT GAAATCCNGCAGCAC AANCTGCGGAACCNN ACCCCTCCCTGA—T TANATTGNCCCCGGC 622
3 RRAS GGACGAGGCT-TTTG AGCAGCTGG-TGCGG GCTGTCCGGAAATAC CAGGAACAAGAGCT- —CCCACCGAGCCCT CCCAGTGCCCCCAGG 621
Page 8.1
631 645 646 660 661 675 676
1 CHlcon T GCTTTANC TGCAATTNTNTGCTC TCCTGA— 652
2 HRAS T GCATGAGC TGCAAGTGTGTGCTC TCCTGA— 570
3 RRAS AAGAAGGGCGGGGGC TGCCCCTGCGTCCTC —CTGTAG 6
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Chimera CH3 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 CH3 ATGACGGAATAT 12
2 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
3 HKAS ATGACGGAATAT 12
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 CH3 AAGCTGGTGGTGGTG GGCGCCGTCGGTGTG GGCAAGAGTGCGCTG ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
2 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
3 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
Page 3.1
181 195 196 210 211 225
1 CH3 ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
2 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
3 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG --GTCATTGATGGGG
226 240 241 255 256 270
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAAGAGT 190
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
Page 4.1
271 285 286 300 301 315
1 CH3 TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
2 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
3 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
316 330 331 345 346 360
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 280
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
Page 5.1
361 375 376 390
1 CH3 GCAAGCTCTTCACGC AGATTCTGCGGGTCA
2 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA
3 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA









451 465 466 480 481 495
1 CH3 GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
2 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
3 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC
496 510 511 525 526 540
CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG 459
CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG 537
GGCATCCCCTACATC GAGACCTCGGCCAAG ACCCGGCAGGGAGTG 456
Page 7.1
541 555 556 570 571 585
1 CH3 GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
2 RRAS GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
3 HRAS GAGGATGCCTTCTAC ACGTTGGTGCGTGAG ATCCGGCAGCACAAG
586 600 601 615 616 630
GAACAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCCCAGGAAGAAG 549
GAACAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCCCAGGAAGAAG 627







TGCGTC TCCTGT AG 578
TGCGTCC—TCCTGT AG 657
TGTGTGCTCTCCTGA — 570
675 676 690 691 705 706 720
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Chimera CH5 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 CH5 ATGAGCTCTGGTGCT GCTTCTGGTACAGGT CGTGGTCGTCCACGT GGTGGAGGTCCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC 90
2 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
3 HRAS ATGACGGAATAT 12
Page 2.1
91 105 106 120 121 135
1 CH5 AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG
2 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG
3 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG
136 150 151 165 166 180
ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
Page 3.1
181 195 196 210
1 CH5 ACTATTGAGGACTCC TACACGAAG-ATCTG
2 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG
3 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG









271 285 286 300 301 315
1 CH5 TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
2 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
3 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
316 330 331 345 346 360
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
Page 5.1
361 375 376 390 391 405
1 CH5 GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
2 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
3 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
406 420 421 435 436 450
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC 448
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC 448
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGCTGCAC-GC 369
Page 6.1
451 465 466 480 481 495
1 CH5 GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
2 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
3 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC
496 510 511 525 526 540
CACGTGGCCTACTTT GAGGCCTCGGCCAAG ACCCGGCAGGGAGTG 537
CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG 537
GGCATCCCCTACATC GAGACCTCGGCCAAG ACCCGGCAGGGAGTG 456
Page 7.1
541 555 556 570 571 585
1 CH5 GAGGATGCCTTCTAC ACGTGGGTGCGTGAG ATCCGGCAGCACAAG
2 RRAS GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
3 HRAS GAGGATGCCTTCTAC ACGTTGGTGCGTGAG ATCCGGCAGCACAAG
586 600 601 615 616 630
CTGCGGAAGCTGACC CCTCCTGATGAGAGT GGCCCGG-CTGCATG 626
GAACAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCC CAGGAAG 624











Chimera CH6 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 HRAS ATGACGGAATAT 12
2 CH6 ATGACGGAATAT 12
3 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
2 CH6 AAGCTGGTGGTGGTG GGCGCCGTCGGTGTG GGCAAGAGTGCGCTG ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
3 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
Page 3.1
181 195 196 210 211 225
1 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
2 CH6 ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
3 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
226 240 241 255 256 270
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
Page 4.1
271 285 286 300 301 315
1 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
2 CH6 ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
3 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
316 330 331 345 346 360
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
Page 5.1
361 3/5 376 390
1 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA
2 CH6 ACCAGTACAGGGAGC AGATCAAACGGGTGA
3 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA









451 465 466 480
1 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC
2 CH6 ACTGTGGAATC T CGGCAGGCTCAGGAC
3 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C




511 525 526 540




541 555 556 570 571 585
1 HRAS GAGGATGCCTTCTAC ACGTTGGTGCGTGAG ATCCGGCAGCACAAG
2 CH6 GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
3 RRAS GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
586 600 601 615 616 630
CTGCGGAAGCTGAAC CCTCCTGATGAGAGT GGCCCCGGCTGCATG 546
GANCAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCCCAGGAAGAAG 546










675 676 690 691 705 706 720
132
Chimera HI97 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 HRAS ATGACGGAATAT 12
2 HI97 ATGACGGAATAT 12
3 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
Page 2.1
91 105 106 120 121 135
1 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG
2 HI97 AAGCTGGTGGTGGTG GGCGCCGTCGGTGTG GGCAAGAGTGCGCTG
3 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG
136 150 151 165 166 180
ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC 102
ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
Page 3.1
181 195 196 210 211 225
1 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
2 HI97 ACTATAGAGGATTCC TACCGGAAGCAGGTG --GTCATTGATGGGG
3 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
226 240 241 255 256 270
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
Page 4.1
271 285 286 300 301 315
1 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
2 HI 97 ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
3 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
316 330 331 345 346 360
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
Page 5.1
361 375 376 390 391 405
1 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
2 HI 97 ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
3 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
406 420 421 435 436 450
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGCTGCAC-GC 369
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGCTGCAC-GC 369
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC 448
Page 6.1
451 465 466 480 481 495
1 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC
2 HI97 ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC
3 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
496 510 511 525 526 540
GGCATCCCC-TACAT CGAGACCTCGGCCAA GACCCGGCAGGGAGT 455
GGCATCCCCCTACAT CGAGACCTCGGCCAA GACCCGGCAGGGAGT 456
CACGTGGCC-TACTT TGAGGCCTCGGCCAA ACTGCGTCTCAACGT 536
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 HRAS GGAGGATGCCTTCTA CACGTTGGTGCGTGA GATCCGGCAGCACAA GCTGCGGAAGCTGAA CCTCCTGATGAGAG TGGCCCCGGCTGCAT 545
2 HI97 GGAGGATGCCTTCTA CACGTTGGTGCGTGA GATCCGGCAGCACAA GCTGCGGAAGCTGCC ACCGAGCCCTCCCAG TGCCCCCANNAAGAA 546










675 676 690 691 705 706 720
133
Chimera R197 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 R197 CTGAGCTCTGGTGCT GCTTCTGGTACAGGT CGTGGTCGTCCACGT GGTGGAGGTCCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC
2 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC
3 HRAS — ATGACGGAATAT
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 R197 AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC
2 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC
3 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG GGCAAGAGTGCGCTG ACCATCCAGCTGATC CAGAACCATTTTGTG GACGAATACGACCCC
Page 3.1
181 195 196 210 211 225 226 240 241 255 256 270
1 R197 ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT
2 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT
3 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT
Page 4.1
271 285 286 300 301 315 316 330 331 345 346 360
1 R197 TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG
2 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG
3 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC
Page 5.1
361 375 376 390 391 405 406 420 421 435 436 450
1 R197 GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC
2 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC
3 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGCTGCAC-GC
Page 6.1
451 465 466 480 481 495 496 510 511 525 526 540
1 R197 GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG
2 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG
3 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC GGCATCCCCTACATC GAGACCTCGGCCAAG ACCCGGCAGGGAGTG
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 R197 GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG GAACAAGAGCTCAAC CCTCCTGATGAGAGT GGCCCN-GCTGCATG
2 RRAS GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG GAACAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCCCAGGAAGAAG
3 HRAS GAGGATGCCTTCTAC ACGTTGGTGCGTGAG ATCCGGCAGCACAAG CTGCGGAAGCTGAAC CCTCCTGATGAGAGT GGCCCCGGCTGCATG
Page 8.1
631 645 646 660 661 675 676 690 691 705 706 720
1 R197 AGCTGCAAGTG TGTGCTCTCCTGA— 650
2 RRAS GGCGGGGGCTGCCCC TGCGTCCTCCTGTAG 657























Chimera H201 alignment sequence
Page 1.1
1 15 16 30 31 45 46 60 61 75 76 90
1 HRAS
2 H201
3 RRAS GAATTCATGGAACAA AAACTAATATCGGAA GAAGATCTAATGAGC AGCGGGGCGGCGTCC GGGACAGGGCGGGGG CGGCCCCGGGGCGGG
Page 2.1
91 105 106 120 121 135 136 150 151 165 166 180
1 HRAS ATGA CGGA-ATATAAGCTG GTGGTGGTGGGCGCC GGCGGTGTGGGCAAG AGTGCGCTGACCATC
2 H201 AAGA CGGA-ATATAAGCTG GTGGTGGTGGGCGCC GTCGGTGTGGGCAAG AGTGCGCTGACCATC
3 RRAS GGACCTGGGCCCGGG GACCCCCCGCCCAGC GAGACACACAAGCTG GTGGTCGTGGGCGGC GGCGGCGTGGGCAAG AGCGCGCTGACCATC
Page 3.1
181 195 196 210 211 225 226 240 241 255 256 270
1 HRAS CAGCTGATCCAGAAC CATTTTGTGGACGAA TACGACCCCACTATA GAGGATTCCTACCGG AAGCAGGTG—GTCA TTGATGGGGAGACGT
2 H201 CAGCTGATCCAGAAC CATTTTGTGGACGAA TACGACCCCACTATA GAGGATTCCTACCGG AAGCAGGTG—GTCA TTGATGGGGAGACGT
3 RRAS CAGTTCATCCAGTCC TACTTCGTGTCTGAC TACGACCCCACTATT GAGGACTCCTACACG AAG-ATCTGCAGTG- TGGATGGCATCCCAG
Page 4.1
271 285 286 300 301 315 316 330 331 345 346 360
1 HRAS GCCTGTTGGACATCC TGGATACCGCCGGCC AGGAGGAGTACAGCG CCATGCGGGACCAGT ACATGCGCACCGGGG AGGGCTTCCTGTGTG
2 H201 GCCTGTTGGACATCC TGGATACCGCCGGCC AGGAGGAGTACAGCG CCATGCGGGACCAGT ACATGCGCACCGGGG AGGGCTTCCTGTGTG
3 RRAS CCCGGCTGGACATCC TGGACACCGCGGGCC AGGAAGAGTTCGGGG CCATGAGAGAGCAGT ACATGCGTGCTGGCC ACGGCTTCCTGCTGG
Page 5.1
361 375 376 390 391 405 406 420 421 435 436 450
1 HRAS TGTTTGCCATCAACA ACACCAAGTCTTTTG AGGACATCCACCAGT ACAGGGAGCAGATCA AACGGGTGAAGGACT CGGATGACGTGCCCA
2 H201 TGTTTGCCATCAACA ACACCAAGTCTTTTG AGGACATCCACCAGT ACAGGGAGCAGATCA AACGGGTGAAGGACT CGGATGACGTGCCCA
3 RRAS TGTTCGCCATTAATG ACCGGCAGAGTTTCA ACGAGGTGGGCAAGC TCTTCACGCAGATTC TGCGGGTCAAGGACC GCGACGACTTCCCCG
Page 6.1
451 465 466 480 481 495 496 510 511 525 526 540
1 HRAS TGGTGCTGGTGGGGA ACAAGTGTGACCTGG CTGCAC-GCACTGTG GAATC TCGGCAG GCTCAGGACCTCGCC CGAAGCTACGGCATC
2 H201 TGGTGCTGGTGGGGA ACAAGTGTGACCTGG CTGCAC-GCACTGTG GAATC TCGGCAG GCTCAGGACCTCGCC CGAAGCTACGGCATC
3 RRAS TTGTGTTGGTCGGGA ACAAGGCAGATCTGG AGTCACAGCGCCAGG TCCCCCGATCAGAAG CCTCTGC-CTTCGGC GCCTCCCACCACGTG
Page 7.1
541 555 556 570 571 585 586 600 601 615 616 630
1 HRAS CCCTACATCGAGACC TCGGCCAAGACCCGG CAGGGAGTGGAGGAT GCCTTCTACACGTTG GTGCGTGAGATCCGG CAGCACAAGCTGCGG
2 H201 CCCTACATCGAGACC TCGGCCAAGACCCGG CAGGGAGTGGAGGAT GCCTTCTACACGTTG GTGCGTGAGATCCGG CAGCACAAGCTGCGG
3 RRAS GCCTACTTTGAGGCC TCGGCCAAACTGCGT CTCAACGTGGACGAG GCTTTTGAGCAGCTG GTGCGGGCTGTCCGG AAATACCAGGAACAA
Page 8.1
631 645 646 660 661 675 676 690 691 705 706 720
1 HRAS AAGCT GAAC CCTCCTGATGAGAGT GGCCCCGGCTGCATG AGCTGCAAGTG TGTGCTCTCCTGA— 570
2 H201 AAGCT GAAC CCTCCCGAT-AG—T GCCCCCAGGAAAAAG GGCGGGGGCTGCCCC TGCGTCCTCCTGTAG 570























Chimera R201 alignment sequence
Page 1.1
1 15 16 30 31 45
1 R210 ATGAGCTCTGGTGCT GCTTCTGGTACAGGT CGTGGTCGTCCACGT
2 RRAS ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG
3 HRAS
46 60 61 75 76 90
GGTGGAGGTCCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC 90
GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
ATGACGGAATAT 12
Page 2.1
91 105 106 120
1 R210 AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG
2 RRAS AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG
3 HRAS AAGCTGGTGGTGGTG GGCGCCGGCGGTGTG









181 195 196 210 211 225
1 R210 ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
2 RRAS ACTATTGAGGACTCC TACACGAAG-ATCTG CAGTG-TGGATGGCA
3 HRAS ACTATAGAGGATTCC TACCGGAAGCAGGTG —GTCATTGATGGGG
226 240 241 255 256 270
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT 268
AGACGTGCCTGTTGG ACATCCTGGATACCG CCGGCCAGGAGGAGT 190
Page 4.1
271 285 286 300 301 315
1 R210 TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
2 RRAS TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC
3 HRAS ACAGCGCCATGCGGG ACCAGTACATGCGCA CCGGGGAGGGCTTCC
316 330 331 345 346 360
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG 358
TGTGTGTGTTTGCCA TCAACAACACCAAGT CTTTTGAGGACATCC 280
Page 5.1
361 375 376 390 391 405
1 R210 GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
2 RRAS GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT
3 HRAS ACCAGTACAGGGAGC AGATCAAACGGGTGA AGGACTCGGATGACG
406 420 421 435 436 450
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC 448
TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC 448
TGCCCATGGTGCTGG TGGGGAACAAGTGTG ACCTGGCTGCAC-GC 369
Page 6.1
451 465 466 480 481 495
1 R210 GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
2 RRAS GCCAGGTCCCCCGAT CAGAAGCCTCTGC-C TTCGGCGCCTCCCAC
3 HRAS ACTGTGGAATC T CGGCAGGCTCAGGAC CTCGCCCGAAGCTAC
496 510 511 525 526 540
CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG 537
CACGTGGCCTACTTT GAGGCCTCGGCCAAA CTGCGTCTCAACGTG 537
GGCATCCCCTACATC GAGACCTCGGCCAAG ACCCGGCAGGGAGTG 456
Page 7.1
541 555 556 570 571 585
1 R210 GACGAGGCTNTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
2 RRAS GACGAGGCTTTTGAG CAGCTGGTGCGGGCT GTCCGGAAATACCAG
3 HRAS GAGGATGCCTTCTAC ACGTTGGTGCGTGAG ATCCGGCAGCACAAG
586 600 601 615 616 630
GAACAAGAGCTTC-A CCGAGCCCTGAGAGT GGCCCCGGCTGCATG 624
GAACAAGAGCTCCCA CCGAGCCCTCCCAGT GCCCCCAGGAAGAAG 627
CTGCGGAAGCTGAAC CCTCCTGATGAGAGT GGCCCCGGCTGCATG 546
Page 8.1
631 645 646 660 661 675 676
1 R210 ANCTGCAAG TGTGTGCTCTCCTGA 652
2 RRAS GGCG-G GGGCTGC-C-CCTGC GTCCTCCTGTAG 657
3 HRAS AGCTGCAAG TGTGTGCTCTCCTGA 570
136
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Chapter 5
Analysis of H-Ras and R-Ras C-terminal domains
5.1 Introduction
Results from Chapter 4 indicated that the C-terminal sequences of H-Ras and R-Ras
are critical in determining their effects on integrin affinity modulation. It was shown
that H-Ras amino acids Arg149 to Pro174 are required for integrin suppression, and
that R-Ras amino acids Leu175 to Pro203 are sufficient to reverse H-Ras-mediated
integrin suppression.
Recently, the main area of study of the H-Ras and R-Ras structures has been the
hypervariable region (HVR), which comprises H-Ras His166 to Pro179 and R-Ras
Tyr to Pro . Most of the areas of importance indicated by these new studies
correlate to the specific C-terminal regions highlighted in Chapter 4. A study by
Hansen et al., (2002) showed, using H-and R-Ras chimeras, that the C-terminal 26
amino acids of R-Ras G38V (which include the full-length HVR) were specific for
directing an R-Ras specific antagonism of H-Ras-mediated integrin suppression.
Another study by Jaumot et al., (2002) demonstrated that the HVR linker domain (H-
Ras amino acids His166 to Asn172), in association with C-terminal spacer sequences
17^ 17Q
(H-Ras amino acids Pro to Pro ) were necessary for H-Ras function.
With an aim to further investigate the relevance of these specific C-terminal regions
of H-Ras and R-Ras, amino acids within the C-terminal regions were manipulated
using several techniques. Early work presented in this chapter relies on site-directed
mutagenesis to mutate smaller sections of amino acids. The resulting mutants were
analysed using the cq3-py transfection system to determine their effects on integrin
affinity modulation. Later work concentrates on the generation of a new H-and R-
Ras chimera. This chimera was designed to exchange R-Ras G38V amino acids
Ser172 to Tyr193 for the equivalent H-Ras amino acids Ser145 to His166. It was
hypothesised that substitution of the C-terminal R-Ras G38V sequences for H-Ras
G12V sequences may confer the ability to suppress integrin affinity modulation.
137
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5.2 Site-directed mutagenesis of R-Ras G38V C-terminal
amino acids
5.2.1 High fidelity PCR generation of site-directed mutagenesis products
Site-directed mutagenesis was performed on R-Ras G38V using the QuikChange®
Multi Site-Directed Mutagenesis Kit. Primers were designed to introduce a single
base pair mutation into the R-Ras G38V sequence converting the selected R-Ras
G38V amino acid into the equivalent H-Ras G12V amino acid. PCR cycle conditions
were optimised (see Materials and Methods Table 2.4 for primer sequence details
and section 2.10.1 for PCR cycle protocol). Figure 5.1 shows the amino acid
alignment of H-Ras and R-Ras, the area highlighted in red identifies the specific R-
Ras sequences targeted by the site-directed mutagenesis and the equivalent H-Ras
sequences.
Primers JLsdmlF and JLsdmlR were used to mutate R-Ras G38V Tyr193 into the
equivalent H-Ras amino acid histidine (base pair mutation from TAC to CAC). The
resulting product, R-Ras (G38V/Y193H), was termed R-RasSDMl.
Primers JLsdm2F and JLsdm2R were used to mutate R-Ras G38V Gin194 into the
equivalent H-Ras amino acid lysine (base pair mutation from CAG to AAG). The
resulting product, R-Ras (G38V/Q194K), was termed R-RasSDM2.
Primers JLsdm5F and JLsdm5R were used to mutate R-Ras G38V Glu197 into the
equivalent H-Ras amino acid lysine (base pair mutation from GAG to AAG). The
resulting product, R-Ras (G38V/E197K), was termed R-RasSDM5.
Site-directed products were amplified as shown in Figure 5.2. Since the R-Ras G38V
template used for site-directed mutagenesis was still in the pCDNA3.1(+) vector, R-
RasSDMl, R-RasSDM2 and R-RasSDM5 were amplified as 6kb products. No PCR
products were observed in reactions performed in the absence of template DNA for
all reactions. All PCR products were digested with Dpnl endonuclease, to digest any
parental DNA template and select for the synthesised DNA containing the required
mutation. E.Coli (XL-1 Blue strain) cells were transformed wifn the digested PCR
products and the plasmid DNA bulked-up and purified. PCR products were verified
by sequence analysis (see Appendix I) prior to further investigation.
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1 15 16 30 31 45
1 H-Ras MTEY KLVWGAGGVGKSAL
2 R-Ras MSSGAASGTGRGRPR GGGPGPGDPPPSETH KLVWGGGGVGKSAL
46 60 61 75 76 90
TIQLIQNHFVDEYDP TIEDSYRKQWIDGE TCLLDILDTAGQEEY 64
TIQFIQSYFVSDYDP TIEDSYTKICSVDGI PARLDILDTAGQEEF 90
91 105 106 120 121 135
1 H-Ras SAMRDQYMRTGEGFL CVFAINNTKSFEDIH QYREQIKRVKDSDDV
2 R-Ras GAMREQYMRAGHGFL LVFAINDRQSFNEVG KLFTQILRVKDRDDF
136 150 151 165 166 180
PMVLVGNKCDLAAR- TVESRQAQDLARSYG IPYIETSAKTRQGVE 153
PWLVGNKADLESQR QVPRSEASAFGASHH VAYFEASAKLRLNVD 180
181 195 196 210 211 225
1 H-Ras DAFYTLVREIRQHKL RKLHPPDESGPG—C MSCKCVLS 189
2 R-Ras EAFEQLVRAVRKYQE QELPPSPPSAPRKKG GGCPCVLL 218
Figure 5.1 H-Ras and R-Ras Amino Acid Alignment
H-Ras and R-Ras amino acid sequence alignment with areas targeted by site-directed
mutagenesis highlighted in red. Hypervariable regions of H-Ras and R-Ras are
underlined.




SDM 2 SDM 5
Figure 5.2 Site-directed mutagenesis PCR products.
Using high fidelity PCR, site directed mutagenesis was performed on 50ng of
template DNA, R-Ras G38V. The negative controls contained no template DNA.
PCR products (IOjliI) were resolved on 1% agarose gels.
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5.2.2 Effect of R-Ras SDM 1, 2 and 5 on H-Ras G12V-mediated integrin
suppression
Integrin affinity was determined in Q}S-py cells transfected with control vector, R-Ras
G38V, R-RasSDMl, R-RasSDM2 and R-RasSDM5 ± H-Ras G12V, see Figure 5.3.
As a positive control, full length R-Ras G38V was used to reverse H-Ras-mediated
integrin suppression from 40.62 ± 17.18% to -21.52 ± 9.12% (P<0.01). SDMI,
SDM2 and SDM5 all reversed H-Ras-mediated integrin suppression from 40.62 ±
17.18% to -19.17 ± 6.71%, -24.19 ± 1.21% and -13.23 ± 2.04% respectively
(P<0.05).
Figures 5.4A and 5.4B show that levels of R-RasSDMl, 2 and 5 expression are all
similar and that co-expression with H-Ras G12V did not affect construct expression
levels. Figure 5.4C shows that levels of ERK1/2 activation are increased by H-Ras
G12V expression but that expression of R-Ras SDMI, SDM2 and SDM5 alone fail
to increase ERK1/2 activation levels beyond that observed with control. Total ERK2
remained similar in all transfected cells (Figure 5.4D).
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Figure 5.3 Site-directed mutagenesis products show reversal of H-Ras G12V-
mediated integrin suppression.
Integrin affinity was determined in o;S-py cells transfected with lpg of SDMI,
SDM2 or SDM5 ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Percentage inhibition was calculated in
reference to control vector alone. The values represent mean ± SEM of 3
experiments. Statistical analysis was performed by one-way ANOVA test compared
to 'Control + H-Ras G12V', * and ** denoting P<0.05 and PO.Ol respectively.



















Figure 5.4 SDM product expression levels and effects on ERK1/2 activation.
Cell lysates were prepared from cells transfected with lpg of R-Ras SDMI, SDM2
or SDM5 ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were probed for SDM product
expression using anti-Myc antibody (A) and for H-Ras G12V expression levels using
anti-Ha antibody (B). ERK1/2 phosphorylation levels were detected with phospho-
specific ERK1/2 antibody. Total ERK2 (D) was measured as a control for equal
loading of sample.
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5.3 Site-directed mutagenesis of R-Ras G38V amino acids
Tyr193 to Glu197.
5.3.1 High fidelity PCR generation of 5 amino acid site-directed mutagenesis
product
Using the QuikChange® Multi Site-Directed Mutagenesis Kit, primers were
designed to introduce a 5 amino acid mutation into the R-Ras G38V sequence
converting the selected R-Ras G38V amino acids into the equivalent H-Ras G12V
amino acid. Figure 5.1 shows the amino acid alignment of H-Ras and R-Ras, the area
highlighted in red identifies the specific R-Ras sequences targeted by the site-
directed mutagenesis and the equivalent H-Ras sequences. See Table 2.4 for primer
sequences. Primers JLsdm5aaF and JLsdm5aaR were used to mutate R-Ras G38V
amino acids Tyr193, Gin194, Glu195, Gin196 and Glu197 into the equivalent H-Ras amino
acids His, Lys, Leu, Arg, and Lys respectively. The resulting product R-Ras (G38V/
Y193H/ Q194K/ E195L/ Q196R /E197K) was termed R-Ras5aaSDM.
Figure 5.5 shows that the R-Ras5aaSDM PCR product was amplified as a 6kb
product. No PCR products were observed in reactions performed in the absence of
template DNA. PCR products were verified by sequence analysis (see Appendix II)
prior to further investigation.
5.2.1 Reversal of H-Ras-mediated integrin suppression by R-Ras5aaSDM
Integrin affinity was determined in O/3-py cells transfected with control vector, R-Ras
G38Vand R-Ras5aaSDM ± H-Ras G12V, see Figure 5.6. As a positive control, full
length R-Ras G38V was used to reverse H-Ras-mediated integrin suppression from
43.13 ± 8.93% to -27.50 ± 5.3% (P<0.001). Cells transfected with R-Ras5aaSDM
alone did not suppress the integrin (-0.64 ± 14.95%). Cells co-transfected with R-
ras5aaSDM + H-Ras G12V, demonstrated a slight reversal of H-Ras-mediated
integrin suppression (43.13 ± 8.93% to 15 ± 6.10%), however results were not
significant.
Figures 5.7A and 5.7B show that co-expression ofR-Ras 5aaSDM with H-Ras G12V
does not affect construct expression levels
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Figure 5.5 Five amino-acid site directed mutagenesis PCR product.
Using high fidelity PCR, site directed mutagenesis was performed on 50ng of
template DNA, R-Ras G38V. The negative control (Lane 2) contained no template
DNA. PCR products (lOpl) were resolved on 1% agarose gel.













Figure 5.6 R-Ras 5aaSDM does not significantly reverse H-Ras-mediated
integrin suppression.
Integrin affinity was determined in a)3-py cells transfected with lpg of 5aa SDM ±
H-Ras G12V (lpg). In each transfection, total DNA content was standardised to 2pg
using control vector. Percentage inhibition was calculated in reference to control
vector alone. The values represent mean ± SEM of 3 experiments. Statistical analysis
was performed by one-way ANOVA test compared to H-Ras G12V, ** and ***
denoting P<0.01 and P<0.001 respectively.
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+ - + - + H-Ras G12V
Control R-Ras R-Ras
5aaSDM
Figure 5.7 R-Ras 5aaSDM expression levels unaffected by co-transfection
with H-Ras G12V.
Cell lysates were prepared from cells transfected with lpg of R-Ras G38V or R-Ras
5aaSDM ± H-Ras G12V (lpg). In each transfection, total DNA content was
standardised to 2pg using control vector. Cell lysates were probed for SDM product
expression using anti-Myc antibody (A) and for H-Ras G12V expression levels using
anti-Ha antibody (B).
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5.4 Generation of a new H-and R-Ras chimera using PCR
and blunt-ended ligation
To further investigate the importance of the H-Ras and R-Ras C-terminal sequences,
a new H-and R-Ras chimera was generated. Thus allowing the investigation of a
larger stretch of sequence. Using R-Ras G38V (in pCDNA3.1 (+)) as the template
DNA, a series of primers and PCR cycles were utilised in order to exchange R-Ras
G38V amino acids Ser172 to Tyr194 for the equivalent H-Ras G12V amino acid
sequences Ser145 to His166. Figure 5.8 shows the amino acid alignment of H-Ras and
R-Ras, the areas highlighted in red identify the specific R-Ras sequences which will
be exchanged for the equivalent H-Ras sequences.
5.4.1 Production of H-and R-Ras chimera blunt-ended PCR products 1 and 2.
Using high fidelity PCR, two separate reactions were used to generate products
which would be used to construct a new H-and R-Ras chimera. See Materials and
methods (Table 2.5) for primer sequences.
The flanking primers for each reaction, PCRlfwdFLAG and splicePCR2Rev, were
designed to include appropriate restriction sites for ligation into the pCDNA3.1(+)
vector. The N-terminal flanking primer PCRlfwdFLAG also included a FLAG-tag
sequence to allow expression analysis of the resulting protein. The hybrid primers
SplicePCRlrev and SPLPCR2fwd each contained sequences homologous to the R-
Ras G38V template as well as the relevant H-Ras G12V sequences. SplicePCRlrev
contained R-Ras Glu171 to Ala174/ H-Ras Lys147 to Tyr157 and SPLPCR2fwd
contained H-Ras Thr158 to His166/ R-Ras Glu194 to Leu198. The PCR cycle
programmes used to generate the two products were repeated on several occasions
until the optimal conditions were established.
PCRlfwdFLAG (which includes an EcoRI restriction site) and SplicePCRlrev, with
the original PCR cycle conditions (as described in Materials and Methods section
2.12, the first stage reaction cycle) were used to produce product 1, containing the N-
terminal sequences of the new H- and R-Ras chimera. Figure 5.9A shows that the
amplified product was 500bp. No PCR products were observed in reactions
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performed in the absence of template DNA. The PCR product was excised from gel
and purified.
Primers SPLPCR2fwd and splicePCR2Rev (which includes a Hind III restriction
site), with the original PCR cycle conditions were used to produce product 2,
containing the C-terminal sequences of the new H-and R-Ras chimera. Figure 5.9B
shows that the amplified product was 125bp. No PCR products were observed in
reactions performed in the absence of template DNA. The PCR product was excised
from gel and purified.
5.4.2 Ligation of new H-and R-Ras chimera into pCDNA3.1
In preparation for ligation of the new H-and R-Ras chimera into pCDNA3.1,
appropriate restriction digests were carried out on the PCR products and pCDNA3.1
vector. The gel purified PCR product 1, containing the N-terminal sequences of the
new H-and R-Ras chimera, was digested using the EcoRI restriction enzyme. The gel
purified PCR product 2, containing the C-terminal sequences of the new H-and R-
Ras chimera, was digested using the Hindlll restriction enzyme. The pCDNA3.1
vector was digested using both the EcoRI and Hindlll restriction enzymes. Following
digestion, all DNA products were ethanol precipitated (Section 2.4). The
pCDNA3.1(+) product was treated with shrimp alkaline phosphatase (SAP) for 30
minutes at 37°C then 62°C for 10 minutes, to inhibit self-ligation.
An 18°C ligation reaction was setup overnight using equal (and excess) amounts of
products 1 and 2 (at 1:3 total ligation volume, to encourage blunt-ended ligation of
the two products) and pCDNA3.1 (at 1:25 total ligation volume). Competent library
efficient DH5a cells were transformed using lOpl ligation mix and resulting colonies
were selectively grown and mini-prepped. Figure 5.10 shows that ligations were not
successful as mini-prep cultures did not contain any plasmid DNA. The ligation
reaction was repeated on several occasions with alternative conditions however,
subsequent analyses of mini-prep cultures showed a lack of plasmid DNA.
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1 15 16 30 31 45 46 60 61 75 76 90
1 H-Ras MTEY KLWVGAGGVGKSAL TIQLIQNHFVDEYDP TIEDSYRKQWIDGE TCLLDILDTAGQEEY 64
2 R-Ras MSSGAASGTGRGRPR GGGPGPGDPPPSETH KLVWGGGGVGKSAL TIQFIQSYFVSDYDP TIEDSYTKICSVDGI PARLDILDTAGQEEF 90
91 105 106 120 121 135
1 H-Ras SAMRDQYMRTGEGFL CVFAINNTKSFEDIH QYREQIKRVKDSDDV
2 R-Ras GAMREQYMRAGHGFL LVFAINDRQSFNEVG KLFTQILRVKDRDDF
136 150 151 165 166 180
PMVLVGNKCDLAAR- TVESRQAQDLARSYG IPYIETSAKTRQGVE 153
PWLVGNKADLESQR QVPRSEASAFGASHH VAYFEASAKLRLNVD 180
181 195 196 210 211 225
1 H-Ras DAFYTLVREIRQHKL RKLNPPDESGPG—C MSCKCVLS 189
2 R-Ras EAFEQLVRAVRKYQE QELPPSPPSAPRKKG GGCPCVLL 218
Figure 5.8 H-Ras and R-Ras Amino Acid Alignment
H-Ras and R-Ras amino acid sequence alignment with the area of R-Ras to be
exchanged for H-Ras, in the generation of a new chimera, highlighted in red.





PCR1 product PCR2 product
Figure 5.9 High fidelity PCR products for new H-and R-Ras chimera.
Using high fidelity PCR, on R-Ras G38V in pCDNA3.1 (+) (50ng), the two products
for a new H-and R-Ras chimera were amplified. Gel A (lanes 1 and 2) shows product
1, resolved on a 1% agarose gel, using a lkb and lOObp ladder. The negative control
PCR (lane 3) contained no template. Gel B (lanes 1-5) shows product 2, resolved on
a 2% agarose gel, using a 25bp ladder. The negative control PCR (lane 6) contained
no template. The image contrast for Gel A has been reversed to allow clear
visualisation of bands.





Figure 5.10 Results of blunt-ended ligation of new H-and R-Ras chimera
products into pCDNA3.1 (+).
Mini-prepped DNA from blunt-ended ligation of new H-and R-Ras chimera products
into pCDNA3.1 (+) were resolved on a 1% agarose gel (Lanes 5-10). Lane 1 contains
uncut pCDNA3.1 (+) and Lanes 2-4, contain pCDNA3.1 (+), digested with EcoRI.
Samples were resolved against a lkb ladder.
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5.5 Generation of H-and R-Ras chimera using splice-
overlap extension by PCR (SOE by PCR).
Subsequent to the unsuccessful blunt-ended ligation of the H-and R-Ras chimera into
pCDNA3.1(+), it was decided to redesign the original primers so that the internal
hybrid primers contained a site of overlap, thus SOE by PCR could be utilised.
Following the first stage generation of PCR products 1 and 2, a second stage PCR
would generate the full-length H-and R-Ras chimera with appropriate restriction sites
for ligation into pCDNA3.1(+). Figure 5.11 is a schematic representation of the steps
involved in the generation of the H-and R-Ras chimera using splice-overlap
extension by PCR.
5.5.1 Generation of products 1 and 2 using high fidelity PCR.
Using high fidelity PCR, first stage reactions were used to generate products 1 and 2
which would be used to construct a new H-and R-Ras chimera. New internal hybrid
primers were designed to include a sequence overlap between products 1 and 2 (see
Table 2.5). The hybrid primer PCRlRevOvlp contained R-Ras Glul71 to Alal74/ H-
Ras Lysl47 to Vall60 and PCR2FwdOvlp contained H-Ras Glul53 to Hisl66/ R-
Ras Glul94 to Pro203. The seven amino acid sequence (21 base pair) overlap
between PCRlRevOvlp and PCR2FwdOvlp, H-Ras Glul53 to Vail60, provided a
sequence of homology between the two first stage PCR products. The area of overlap





It was discovered that the restriction sites originally used for ligation into pCDNA3.1
(5.4.2) were selected for orientation into pCDNA3.1(-) and not pCDNA3.1(+).
Therefore, new flanking primers were designed to include the appropriate restriction
sites for correct orientation into pCDNA3.1(+).
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Figure 5.11 Schematic Representation of SOE by PCR
R-Ras G38V cDNA is represented with solid black shading. Flanking
oligonucleotide primers (PCRIfwdFLAGHind and splPCR2RevEco) are represented
by arrows. Hybrid primers (PCRlOvlp and PCR20vl) are represented by an arrow,
with the extended H-Ras sequences represented by a diagonal and hatched fill-effect.
Areas ofH-Ras sequence overlap on the two hybrid primers are shown with a spotted
effect.
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Primers PCRlfwdFLAGhind (which includes a Hindlll restriction site) and
PCRlOvlp were used to produce product 1, containing the N-terminal sequences of
the H-and R-Ras chimera. The final product contains a Hindlll restriction site and
FLAG-tag at the N-terminus as well as a C-terminal overlap sequence. Figure 5.12A
shows that the amplified product was 500bp. No PCR products were observed in
reactions performed in the absence of primers or template DNA. The PCR product
was excised from the gel and purified.
Primers PCR20vlp and splPCR2RevEco (which includes an EcoRI restriction site)
were used to produce product 2, containing the C-terminal sequences of the H-and R-
Ras chimera. The final product contains an EcoRI restriction site at the C-terminus as
well as an N-terminal overlap sequence. Figure 5.12B shows that the amplified
product was 125bp. No PCR products were observed in reactions performed in the
absence of primers or template DNA. The PCR product was excised from the gel and
purified.
5.5.2 High fidelity PCR of H-and R-Ras chimera (CHX).
From Figure 5.11, it can be seen that following the first stage PCRs (5.5.1), it is
possible to perform a third high fidelity PCR to generate the full-length H-and R-Ras
chimera, termed CHX.
The second stage PCR used the flanking primers PCRlfwdFLAGhind and
splPCR2RevEco. The gel purified products 1 and 2 were used as the template DNA.
It was necessary to use equal molecular amounts of the two template DNAs. Since
product 1 was 500bp and product 2 was 125bp, the concentration of each template
used was calculated based on a 4:1 ratio on weight (product 1: product 2,
respectively). The PCR cycle programme was adjusted for the second stage PCR (see
Materials and Methods, 2.12). The melting temperatures of the flanking primers as
well as that of the area of sequence overlap between the two template DNAs were an
important consideration in their designs. For the second stage PCR, it was important
that the melting temperature of the overlap sequence, H-Ras Glul53 to Vail60
(68°C), was lower than the melting temperatures of the two flanking primers
PCRlfwdFLAGhind (>75°C) and splPCR2RevEco (>75°C). This encourages the
annealing of the two template DNAs during the first PCR cycle (which uses lower
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temperatures) prior to increasing the PCR cycle temperatures to allow the flanking
primers to anneal and amplify the final product.
Figure 5.13A shows that the amplified CHX was about 600bp. No PCR products
were observed in reactions performed in the absence of template DNA. The PCR
product was excised from the gel and purified.
Following gel purification, CFIX was digested with Hindlll and EcoRI, ethanol
precipitated and ligated into pCDNA3.1 (+) (pre-digested with both Hindlll and
EcoRI). The ligation product was subsequently transformed into DH5a competent
cells and resulting colonies mini-prepped and digested with Hindlll and EcoRI to
confirm plasmid DNA content and insert size. Figure 5.13B shows positive plasmid
content for all samples, each with an insert measuring between 500 and 750bp. CHX
clones 1-6 were all sent for sequence verification. Sequencing not shown.
5.5.3 New H-and R-Ras chimera, CHX, was not expressed in CHO cells.
Following sequencing, one of the CHX clones was selected to test for expression in
CHO cells. The N-terminal FLAG-tag on primer PCRlfwdFLAGhind was used so
that expression levels of the new chimera (CHX) could be compared with the
original H- and R-Ras chimeras, which all contain an N-terminal FLAG-tag.
However, using expression of CHI as a positive FLAG control, CHX showed no
expression in ojS-py cells (Figure 5.14A). Furthermore, CHX was not detected even
when using an anti-R-Ras antibody with a positive R-Ras G38V control (Figure
5.14B).
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PCR1 product PCR2 product
Figure 5.12 First stage PCR products for generation of new H-and R-Ras
chimera using splice-overlap extension by PCR.
Using high fidelity PCR, on R-Ras G38V (50ng), the two products for a new H-and
R-Ras chimera were amplified using 50pl reaction volumes. Gel A shows product 1
(lanes 1-4), resolved on a 1% agarose gel, using a lkb ladder. Gel B shows product 2
(lanes 1 -4), resolved on a 2% agarose gel, using a 25bp ladder. The negative control
PCRs, run in Lanes 5 and 6, of both gels, contain no primers and no template
respectively. The image contrast has been reversed to allow clear visualisation of
bands.
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Figure 5.13 Second stage product of slice-overlap extension by PCR
(A) Splice-overlap extension was performed using high fidelity PCR with the
products of the first stage PCRs as template DNA. The negative control (Lane 2)
contained no template DNA. PCR products were resolved on 1% agarose gel against
a lOObp ladder. (B) Restriction digest (Hindlll and EcoRI) of plasmid clones from
CHX ligations. Products were run on a 1% agarose gel against a lkb ladder. The
image contrast of gel B has been reversed to allow clear visualisation of bands.





Figure 5.14 Expression of new H-and R-Ras chimera, CHX.
Cell lysates were prepared from a(3-py cells transfected with lpg of CHX, R-Ras
G38V or CHI. Expression of CHI (A) and R-Ras (B) served as positive controls.
Cell lysates were probed for CHX expression using the anti-FLAG monoclonal
antibody (A) and the anti-R-Ras antibody (B).
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5.6 Correcting CHX N-terminus using unique restriction
enzyme sites.
Despite poor N-terminal sequencing of CHX, sequence analysis confirmed that the
exchange of R-Ras G38V C-terminal sequences acids Ser172 to Tyr194 for the
equivalent H-Ras G12V amino acid sequences Ser145 to His166 had been successful.
However, it was noticed that there was a one amino acid deletion within the overlap
sequence, H-Ras Asp1;>4 (base pairs 150-152, GAT) that had accidentally been
omitted from PCRlOvlp and PCR20vlp primer sequences.
5.6.1 Ligation of N-terminal sequences of R-Ras G38V into CHX.
Rather than repeat the complicated splice-overlap extension by PCR, it was decided
that the N-terminal sequence of CHX could be exchanged for the N-terminal
sequence ofR-Ras G38V, using a restriction site unique to R-Ras G38V. Figure 5.15
shows a schematic representation for the restriction digests and ligations involved in
the exchange of the N-terminus of CHX with that ofR-Ras G38V. SacII was selected
as the internal R-Ras G38V restriction enzyme for two reasons, it does not cleave the
pCDNA3.1 (+) vector and it cleaves R-Ras at position 293 thus removing the poor
N-terminal sequences of CHX (base pairs 1-120). Both R-Ras G38V and CHX
(cloned into pCDNA3.1 (+)) were digested with Hindlll and SacII, to remove the
respective N-terminal sequences. Figure 5.16 (lanes 2 and 4) shows that the resulting
products are about 6kb and <250bp.
The <250bp product from the R-Ras G38V restriction digest (Lane 2) and the 6kb
product from the CHX restriction digest (Lane 4) were gel excised and purified. The
6kb product from CHX (which should contain the base pair sequences 294 to 669 of
CHX in pCDNA3.1 (+)) was treated with shrimp alkaline phosphatase (SAP) for 30
minutes at 37°C then 62°C for 10 minutes, to inhibit self-ligation. The <250bp
product from the R-Ras G38V digest should contain the N-tenninal base pair
sequences 1 to 293 of R-Ras G38V. An overnight, 18°C ligation was set up between
the <250bp product from the R-Ras G38V restriction digest and the 6kb product
from the CHX restriction digest. The ligation product was subsequently transformed
into DH5a competent cells and resulting plasmid DNA prepared and tested by
restriction digest.
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Figure 5.15 Schematic representation of plan to generate full-length CHX
Schematic represents the restriction digests to be carried out on R-Ras G38V (red)
and CHX (blue), both cloned into pCDNA3.1(+). N-terminus of R-Ras G38V (red)
will be used to replace the N-terminus of CHX (blue), thus generating full-length
CHX. Points on pCDNA3.1(+) highlighted by dashed arrows indicate the positions
(228 and 3615) where the restriction enzyme Afllll cleaves the vector.
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Figure 5.16 Restriction digests of R-Ras G38V and CHX to exchange N-
termini.
R-Ras G38V, cloned into pCDNA3.1(+), was digested with EcoRI and SacII (lanel)
or Hindlll and SacII (lane 2).
CHX, cloned into pCDNA3.1(+), was digested with EcoRI and SacII (lane3) or
Hindlll and SacII (lane 4).
Products were resolved on a 1% agarose gel against a lkb ladder. Resulting products
from lanes 2 and 4, identified by white arrows, were gel excised.
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The restriction enzyme Afllll was selected to test the success of the R-Ras G38V N-
terminal ligation since it cleaves pCDNA3.1 (+) at positions 228 and 3615 (see
Figure 5.15) but does not cleave R-Ras G38V. An additional advantage of Afllll is
that it cleaves H-Ras at position 470, which is found in the area of amino acid
exchange between R-Ras and H-Ras for chimera CHX. This meant that restriction
analysis would also confirm the success of the SOE by PCR. Sequence analysis of
pCDNA3.1(+) and R-Ras G38V suggested that if the ligation of R-Ras G38V N-
terminal had been successful, bands were expected at sizes 1183bp, 2958bp and
2041bp.
Figure 5.17 shows the results of an Afllll restriction digest on ten CHX clones.
Lanes 4-13 correspond to clones CHX(l) to CHX(IO) respectively. Every clone
shows evidence of digest products at about 2 and 3 kb, which correspond to the
expected 2041 bp and 2958bp products. The band corresponding to the third digestion
product of clones 1, 3 and 4 (lanes 4, 6 and 7 respectively) ran at just over lkb. The
third digestion product for the other 7 clones ran closer to lkb.
5.6.2 Expression of CHX clones in CHO cells
A few of the CHX clones were selected for further analysis. The expression of the
clones was analysed in o^S-py cells using the N-terminal Myc-tag inherited from
ligation of the R-Ras G38V N-terminal.
Figure 5.18A shows that clones CHX(l) and CHX(3) showed positive for Myc-
tagged protein expression. The expressed proteins were of a similar size to R-Ras
G38V (about 23kDa). The presence of the Myc-tag at the N-terminus of the clones
also meant that immunofluorescence analysis could be carried out on transiently
transfected cells as a further indication of protein expression. Cells were stained
using anti-Myc (9E10) antibody, followed by Alexa 488-conjugated goat anti-mouse
IgG (green). Figure 5.18B shows positive staining for expression of a Myc-tagged
protein in CHX(l) and CHX(3). The clones CHX(5) and CHX(IO), did not show any
positive staining (results not shown). Expression of Myc-tagged R-Ras G38V was
used as a positive control for both western blot and immunofluorescence analyses.
CHX(l) and CHX(3) were sent for sequence verification. See Appendix (III).
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Figure 5.17 Restriction digest of N-terminal R-Ras G38V and C-terminal
CHX ligation into pCDNA3.1(+).
Mini-prepped DNA from N-terminal R-Ras G38V and C-terminal CHX ligations (4-
13) were digested with Afl III. Control digests carried out on pCDNA3.1(+) alone
(lane 1), H-Ras G12V cloned into pCDNA3.1 (+) (lane2) and R-Ras G38V cloned
into pCDNA3.1 (+) (lane 3).
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Figure 5.18 Expression of CHX clones
(A) Cell lysates were prepared from aP-py cells transfected with lpg of R-Ras G38V
or lpg of each CHX clone. Lysates were probed with anti-Myc antibody to check
expression levels.
(B) Expression was confirmed using immunofluorescence. Cells were stained using
anti-Myc antibody (green). Bars, 50pm.
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5.6.3 Effect ofCHX(l) and CHX(3) expression on integrin affinity
modulation.
Integrin affinity was determined in o^S-py cells transfected with control vector, R-Ras
G38V, CHX(l) and CHX(3) ± H-Ras G12V, see Figure 5.19. As a positive control,
full length R-Ras G38V was used to reverse H-Ras-mediated integrin suppression
from 50.3% to 10.85%. Preliminary data indicates that cells transfected with CHX(l)
alone mediate an activated integrin state similar to that observed with R-Ras G38V
however, CHX(l) was not as efficient as R-Ras G38V at reversing H-Ras-mediated
integrin suppression (from 50.3% to 29.8%). Cells transfected with CHX(3) show
about a 10% suppression of integrin activation which increases to 19.65% in the
presence ofH-Ras G12V.
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Figure 5.19 Reversal of H-Ras G12V-mediated integrin suppression by CHX
clones (n=l).
Integrin affinity was determined in a/3-py cells transfected with lpg of R-Ras G38V,
CHX(l) or CHX (3) ± H-Ras G12V (lgg). In each transfection, total DNA content
was standardised to 2pg using control vector. Percentage inhibition was calculated in
reference to control vector alone.
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5.7 Discussion
In Chapter 4, the C-terminal regions of H-Ras (149-174) and R-Ras (175-203) were
found to be required for integrin affinity modulation. In this chapter, these C-
terminal regions were further investigated using site-directed mutagenesis and by the
generation of a new H-and R-Ras chimera. The major findings in this chapter are:
that H-Ras amino acids sequences His166 to Glu170 are not sufficient to confer H-Ras
G12V-mediated integrin suppression properties to R-Ras G38V, however the
exchange of R-Ras G38V amino acids Tyr193 to Glu197 for these equivalent H-Ras
amino acids reduces the ability of R-Ras G38V to reverse H-Ras G12V-mediated
integrin suppression. Using splice-overlap extension by PCR to generate a new H-
172
and R-Ras chimera, CHX, succeeded in the exchange of R-Ras amino acids Ser to
Tyr193 for the equivalent H-Ras amino acids Ser145 to His166. CHX clones 1 and 3
were successfully expressed in Q}3-py cells.
The differing effects of H-and R-Ras chimeras on integrin-affinity modulation focus
attention on the possible influential effects of the hypervariable domains of H-Ras
and R-Ras, as well as sequences N-terminal to the HVR. The aims of this chapter
were to use a series of site-directed mutations within the C-terminal regions of R-Ras
G38V (175-203) and to generate a new H-and R-Ras chimera, where R-Ras G38V
domains were replaced with the appropriate H-Ras sequences, to elucidate whether
these specific regions are sufficient to confer integrin suppression by H-Ras or if they
are required for R-Ras reversal of H-Ras-mediated integrin suppression. The decision
to use R-Ras G38V as the template for further investigating the C-terminal domains
of H-Ras and R-Ras was based upon it being easier to observe a suppressive effect
(i.e. changing an R-Ras G38V effect into an H-Ras G12V effect) than to observe a
reversal of integrin suppression.
To further investigate the importance of the hypervariable domains with regard to
integrin affinity, site-directed mutagenesis was used to mutate R-Ras amino acids,
found within the hypervariable linker domain (Tyr193 to Glu198), into the equivalent
H-Ras amino acids. These particular amino acids were investigated first as they
overlapped with a 6 amino acid area within the HVR ofH-Ras shown to be important
for efficient interaction with effectors (Jaumot et al., 2002). Single amino-acid
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mutations, which required only a single base pair mutation, were attempted first.
Results showed that individually, H-Ras amino acids His166, Lys167 and Lys170 within
the linker domain do not confer an ability to suppress integrin affinity. Expanding the
region under test, it was decided that the entire five amino acid region of R-Ras
G38V should be mutated to the equivalent H-Ras sequence. The reasoning for this
action was that if no suppressive effect was conferred by the full five amino acid
exchange, then further single amino acid mutations within this region would be
unnecessary. While mutation of the entire 5 amino acid sequence did not confer the
ability to suppress integrin affinity, the capacity of R-Ras G38V to reverse H-Ras
G12V-mediated integrin suppression was diminished.
Although results from Chapter 4 suggested that the C-terminal regions of H-Ras
(149-174) and R-Ras (175-203) were found to be required for integrin affinity
modulation, the N-terminal sequences of the hypervariable linker domain were
investigated first. Several studies have recently identified the importance of the HVR
linker domain. Jaumot et al., (2002) showed using amino acid deletion and alanine
replacement that the N-terminal sequences of the HVR linker domain (H-Ras amino
acids His166- Asn172), in association with C-terminal spacer sequences (H-Ras amino
acids Prol73-Pro179) were necessary for the release of activated H-Ras from lipid
rafts. Confinement ofH-Ras G12V to the lipid rafts abrogated Raf-1, PI 3-kinase and
Akt activation (Jaumot et al., 2002). It has been hypothesised that the HVR
sequences of H-Ras might transmit conformational changes in the N-terminal
domains, coincident with GTP-loading, through to the membrane anchor (Prior et al.,
2001).
Results here show that mutation of the HVR N-terminal linker domain had no
significant effect on R-Ras-mediated integrin affinity, which suggests that these
sequences alone are not sufficient to influence integrin affinity. However, the
significant difference in the abilities of R-Ras G38V and the 5aaSDM product to
reverse H-Ras-mediated integrin suppression suggests that R-Ras amino acids
(Tyr193-Glu198) are required for reversal of H-Ras-mediated integrin affinity. As the
equivalent H-Ras amino acids have previously been shown to be required for GTP-
loaded release from lipid rafts and subsequent activation of effectors (Jaumot et al.,
2002) then perhaps H-Ras substitution of the R-Ras N-terminal linker domain
169
Analysis of H-Ras and R-Ras C-terminal domains
sequences affects R-Ras interaction with effectors by altering the targeting of the
activated protein.
193
Since site-directed mutagenesis of the five amino acids of R-Ras G38V (Tyr to
Glu198), to the equivalent H-Ras G12V amino acids did not confer integrin
suppression properties, it was decided that sequences N-terminal of these five amino
acids should be investigated. It is worth mentioning at this point that sequences C-
terminal to these five amino acids were not investigated further as current data at the
time indicated that the region acted as a spacer element (Jaumot et al., 2002) and
while the presence of the spacer element was required for proper H-Ras function,
amino acid substitution had no effect. Subsequently, this proline-rich region ofR-Ras
G38V has been found to be a binding site for the Nek adaptor protein, which has
been implicated in the recruitment of R-Ras effectors that are employed by R-Ras to
augment integrin affinity (Kinbara et al., 2003). If this is the case, then maintaining
this proline-rich region in the site-directed mutants may help R-Ras G38V promote
an activated integrin state. Whether H-Ras has similar binding sites in this region
remains to be investigated.
In order to investigate the importance of the N-terminal regions of H-Ras and R-Ras
upstream of the HVR, R-Ras sequences (Ser172 to Tyr193) were to be replaced by the
equivalent H-Ras sequences (Ser145 to His166), using the remaining R-Ras sequences
as the backbone of the new H-and R-Ras chimera. Figure 5.8 highlights the area of
R-Ras G38V to be exchanged for the equivalent H-Ras sequences. Instead of relying
on the presence of restriction sites at appropriate positions of both H-Ras and R-Ras,
which would allow the generation of the new chimera, PCR generation of hybrid
fragments and subsequent ligation was explored.
The original design of the four primers required for this technique was to rely on a
blunt-ended ligation between the two resulting PCR products to form the full-length
chimera. While the generation of the DNA fragments was successful (see Figures
5.9A and 5.9B), subsequent blunt-ended ligation of the DNA fragments and overall
ligation into the pCDNA3.1(+) vector was unsuccessful (Figure 5.10).
An alternative to the blunt-end ligation procedure, was to employ a technique of
splicing by overlap extension by PCR (SOE by PCR) as described by Horton et al.,
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(1989), where the PCR products contain a region of overlap. In this case, the
sequence of overlap was provided by the middle seven amino acids of the H-Ras
inserted sequence (Glu153 to Val160). The schematic representation of SOE by PCR
(Figure 5.11) shows that the first stage PCR generates two DNA fragments
containing the H-Ras overlap sequences. As the hybrid oligonucleotides are tipped
with a short sequence of homology, when the two first stage products are mixed they
can partially anneal and using the original flanking primers, be used as the template
for a second stage PCR to produce the final product. Although restriction enzyme
analysis of clones of the final product ligated into pCDNA3.1(+) indicated the
presence of a 500-750bp insert, sequence analysis could not verify the presence of
the N-terminal 120bp of R-Ras G38V. Sequence alignment of the selected clones
with R-Ras G38V indicated the poor N-terminal sequencing of each of the six clones
(sequences not shown). Although N-terminal sequencing was poor, the insertion of
H-Ras sequences Ser145 to His166 in place of the equivalent R-Ras G38V sequences
Ser172 to Tyr193 was successful. Detailed sequence analysis, however, revealed that a
single H-Ras amino acid (Asp154) was absent in all the clones. The omission was
tracked down to an error in the hybrid primers PCRlRevOvlp and PCR2FwdOvlp, in
which the H-Ras amino acid (Asp154) was absent. Rather than having to start at the
beginning again and redesign the hybrid primers for SOE by PCR, it was considered
easier to complete the generation of the H-and R-Ras chimera and then using site-
directed mutagenesis, re-insert the aspartic acid.
Transfection of a)3-py cells with the chimera DNA and subsequent western blot
analysis revealed that the chimeric protein was not expressed, this was most probably
due to the poor quality of the N-terminal sequences of R-Ras G38V. Despite
extensive repeated manipulation of the buffer conditions and PCR protocol, it was
impossible to generate the full-length H-and R-Ras chimera (CHX) with the correct
N-terminal sequence. R-Ras G38V is comprised of a very GC-rich section at its N-
terminal, with the first 75 base pairs almost 87% GC. As a direct result of this, the
PCRlfwdFLAGhind flanking primer at the N-terminus of the R-Ras G38V (which is
also GC-rich) may be mis-priming to an alternative section of the N-terminus.
Alternatively, the high GC-content may increase the melting temperature of this
section of R-Ras, and so it may not be sufficiently denatured in the PCR cycle thus
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preventing the annealing of the forward primer. To circumvent this problem, the poor
N-terminal sequence could be replaced by restriction digest with the appropriate
sequence from R-Ras G38V.
From sequence analyses of the CHX(l-6) clones, it was clear that the sequencing C-
terminal to Ras G38V Gly39 was satisfactory. As it was only the N-terminal
sequences of CHX that seemed to be causing the problem, it was hoped that by
replacing these sequences with the appropriate R-Ras G38V sequences that the
expression problem may be resolved. The restriction enzyme, SacII (ccgc/gg),
cleaves R-Ras G38V at position 254. As this restriction enzyme is unique to R-Ras
G38V (when cloned into pCDNA3.1(+)) and cuts sufficiently downstream of the
problem N-terminal sequence (base pairs 1-120), it was used to remove the N-
terminal sequence of R-Ras G38V from pCDNA3.1(+). This N-terminal R-Ras
G38V fragment was used to replace the equivalent section in the new H-and R-Ras
chimera (CHX), thus maintaining the hybrid C-terminal section of CHX (see Figure
5.15 for schematic representation of restriction digests and subsequent ligation).
Following ligation, clones were mini-prepped and restriction digest analysis was
used to confirm the presence of the N-terminal R-Ras G38V sequences. A diagnostic
enzyme, Afllll was selected as it cleaves pCDNA3.1 (+) at positions 228 and 3615
but does not cleave R-Ras G38V. Additionally, Afllll also cleaves H-Ras G12V, at
position 470 which is included in the H-Ras sequences of CHX. This meant that
further confirmation of the H-Ras insert into R-Ras G38V could be confirmed by
restriction digest of the clones with Afllll.
Despite all clones being positive for the H-Ras insert (confirmed by the presence of
three bands as opposed to just two) it was more difficult to try and distinguish
between clones which contained the N-terminal R-Ras G38V and those that may be
missing the N-terminal 254 base pairs, removed by SacII cleavage. Analysis of
restriction enzyme maps for Afllll cleavage of pCDNA3.1(+) and H-Ras, suggested
that if the chimera contained the N-terminal R-Ras G38V sequences, bands would be
expected at 2041bp, 2958bp and 1183bp (the latter being influenced by the presence
of the R-Ras N-terminal sequences). However, should the chimera not contain the N-
terminal sequences, the third product band would be about 950bp rather than 1183bp.
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Consequently, it was expected that clones CHX(l), CHX(3) and CHX(4) (see Figure
5.17) would contain the R-Ras G38V N-terminal sequences as the third digestion
product band of these clones ran slightly higher than that of the remaining seven
clones. To avoid missing the correct clone, in addition to CHX(l) and CFIX(3), the
CHX(5) and CHX(IO) clones, which contained a smaller sized third product, were
also tested. As a consequence of exchanging the N-terminal sequences of CHX with
that of R-Ras G38V, the resulting clones inherited the Myc-tag. Western blot
analysis showed that CHX(l) and CHX(3) were expressed in a(3-py cells but that
CHX(5) and CHX(IO) were not. This was further confirmed using
immunofluorescence. These results verify the presence of the N-terminal R-Ras
G38V sequence on CHX(l) and CHX(3) as the Myc-tagged protein would not
otherwise be expressed. As CHX(5) and CHX(IO) were not expressed in o^S-py cells
would suggest that, in accordance with the AflHI restriction digest results, ligation of
the R-Ras G38V N-terminal sequence into CHX was not successful in these clones.
Despite clear evidence that CHX(l) and CHX(3) were both successfully expressed in
afi-py cells and that restriction digest analysis revealed product sizes backing up the
presence of the full-length H-and R-Ras chimera, there were problems with the
sequencing of full-length CHX(l) and CHX(3). As with earlier sequence analysis of
the CHX products, sequencing of the N-terminal region of the chimera was
unsuccessful. Appendix III shows that the C-terminal H-Ras sequences equivalent to
172 193R-Ras Ser to Tyr have been maintained during restriction enzyme manipulation
but that sequences N-terminal of R-Ras Val40 have not been sufficiently sequenced.
The high GC content of the N-terminal is probably responsible for the poor DNA
sequencing. R-Ras was first identified by Lowe et al., (1987); this group also had
problems with the sequencing of the N-terminal region of R-Ras. They describe that
the N-terminal region of R-ras mRNA proved refractory to reverse transcription by
oligo (dT) priming and from priming from primers complementary to the codon 30
region (Lowe et al., 1987). As yet, PCR conditions to sequence this region have not
been identified either by in-house sequencing facilities or commercial facilities.
Taking that the proteins could be expressed; it can be assumed that the N-terminal
region, carrying the Myc-tag, is present. However, time limitations prevented further
attempts to re-sequence the CHX chimeras.
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A preliminary experiment was carried out to see how the CHX clones CHX(l) and
CHX(3) affected integrin affinity modulation. Results indicated that the exchange of
R-Ras amino acids Ser172 to Tyr193, for the equivalent H-Ras sequences affects the
ability of R-Ras G38V to modulate integrin affinity. CHX(l) and CHX(3) both
demonstrated a diminished ability to reverse H-Ras G12V-mediated integrin
suppression, compared with R-Ras G38V. The chimeras were not convincing in their
suppressive abilities. However as time only permitted a preliminary experiment to be
carried out on these new constructs, further investigations are required to fully
understand whether this region is sufficient to modulate integrin affinity. These
investigations should probably take into account the amino acids C-terminal to the
HVR linker domain, as this proline-rich region of R-Ras G38V has recently been
implicated in the recruitment of R-Ras effectors that are employed by R-Ras to
augment integrin affinity (Kinbara et al., 2003). If this is the case, then perhaps
i n') i Q"3 m
exchange of these amino acids as well as R-Ras amino acids Ser to Tyr might
confer the full suppressive effect of full-length H-Ras G12V to R-Ras.
5.7.1 Summary
Site-directed mutagenesis of R-Ras G38V to exchange amino acids Tyr193 to Glu198
for the equivalent H-Ras amino acids His166 to Glu170 did not confer an ability to R-
Ras G38V to suppress integrin affinity. From this it can be deduced that the H-Ras
G12V amino acids His166 to Glu170 alone are not sufficient to suppress integrin
affinity modulation. The generation of a new H-and R-Ras chimera to further
elucidate the importance of the C-terminal regions, using SOE by PCR, was
successful in exchanging the appropriate regions of R-Ras G38V for the equivalent
H-Ras sequences.
A preliminary study revealed that H-Ras G12V amino acids Ser145 to His166 are
sufficient to impede the ability of R-Ras G38V to reverse H-Ras-mediated
suppression, but not to confer the full suppressive effect of full-length H-Ras G12V.
However, time limitations preventing further analysis of integrin-affmity and the
reoccurring problems arising from the sequencing of the R-Ras G38V N-termina!
sequence mean that the results obtained using the new H-and R-Ras chimera (CHX)
are not fully substantiated.
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Appendix I
R-Ras SDMI
1 15 16 30 31 45 46 60 61 75 76 90
sdml NNGAANATTTAAAGC GTGAGGGGTGGNTTT GGNACAGNTCGGGNT GGTCCANGTGGGGGG AGGTTCAGGGTCCCG GGGAACCNTCCGCCC 90
r-ras ATGAGCA GC G GGGCGGCGTCC GGGACAGGGCGGGGG CGGCCCCG-GGGCGG GGGACCTGGG-CCCG GGGA-CCCCCCGCCC 78
91 105 106 120 121 135
sdml TAGGCGAAACACAAC NAGCCTTGTGGTTTG TGGGNTGGTGTCGGG
r-ras A—GCGAGACACA-C AAGC-TGGTGGTC-G TGGGC-GGCGGCGG-
136 150 151 165 166 180
CGNGGGNCAAGAGCG GGCTGACCATCCCAG TTCATCCAGTCCTAT 180
CGTGGGC-AAGAGCG CGCTGACCATCC-AG TTCATCCAGTCCTAC 159
181 195 196 210 211 225
sdml TTGG-GTCTGANTAC GACCCCACTATTGAG GACTCCTACACGAAG
r-ras TTCGTGTCTGACTAC GACCCCACTATTGAG GACTCCTACACGAAG
226 240 241 255 256 270
ATNTGCAGGTGTGGA TGGCATCCCAGCCCG GGCTGGACATCCTGG 269
ATCTGCAG-TGTGGA TGGCATCCCAGCCCG G-CTGGACATCCTGG 247
271 285 286 300 301 315
sdml ACACCGCGGGCCAGG AAGAGTTCGGGGCCA TGAGAGAGCAGTACA
r-ras ACACCGCGGGCCAGG AAGAGTTCGGGGCCA TGAGAGAGCAGTACA
316 330 331 345 346 360
TGCGTGCTGGCCACG GCTTCCTGCTGGTGT TCGCCATTAATGACC 359
TGCGTGCTGGCCACG GCTTCCTGCTGGTGT TCGCCATTAATGACC 337
361 375 376 390 391 405
sdml GGCAGAGTTTCAACG AGGTGGGCAAGCTCT TCACGCAGATTCTGC
r-ras GGCAGAGTTTCAACG AGGTGGGCAAGCTCT TCACGCAGATTCTGC
406 420 421 435 436 450
GGGTCAAGGACCGCG ACGACTTCCCCGTTG TGTTGGTCGGGAACA 449
GGGTCAAGGACCGCG ACGACTTCCCCGTTG TGTTGGTCGGGAACA 427
451 465 466 480 481 495
sdml AGGCAGATCTGGAGT CACAGCGCCAGGTCC CCCGATCAGAAGCCT
r-ras AGGCAGATCTGGAGT CACAGCGCCAGGTCC CCCGATCAGAAGCCT
496 510 511 525 526 540
CTGCCTTCGGCGCCT CCCACCACGTGGCCT ACTTTGAGGCCTCGG 539
CTGCCTTCGGCGCCT CCCACCACGTGGCCT ACTTTGAGGCCTCGG 517
541 555 556 570 571 585
sdml CCAAACTGCGTCTCA ACGTGGACGAGGCTT TTGAGCAGCTGGTGC
r-ras CCAAACTGCGTCTCA ACGTGGACGAGGCTT TTGAGCAGCTGGTGC
586 600 601 615 616 630
GGGCTGTCCGGAAAC ACCAGGAACAAGAGC TCCCACCGAGCCCTC 629
GGGCTGTCCGGAAAT ACCAGGAACAAGAGC TCCCACCGAGCCCTC 607
Page 8.1
631 645 646 660 661 675
sdml CCAGTGCCCCCAGGA AGAAGGGCGGGGGCT GCCCCTGCGTCCTCC TGTAG
r-ras CCAGTGCCCCCAGGA AGAAGGGCGGGGGCT GCCCCTGCGTCCTCC TGTAG
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R-RasSDM2
1 15 16 30 31 45 46 60 61 75 76 90
sdm2 ATGAGCTNNGGTGCT GCNTCTGGTACAGTT CGTGT-CGTCCACGT GGTGGAGGTCCAGGT CCCGGG-ACCCTCCG CCTAGCGAGACACAC
r-ras ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC
91 105 106 120 121 135 136 150 151 165 166 180
sdm2 AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC
r-ras AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC
181 195 196 210 211 225 226 240 241 255 256 270
sdm2 ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC
r-ras ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC
271 285 286 300 301 315 316 330 331 345 346 360
sdm2 GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC
r-ras GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC
361 375 376 390 391 405 406 420 421 435 436 450
Sdm2 AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC
r-ras AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC
451 465 466 480 481 495 496 510 511 525 526 540
sdm2 CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC
r-ras CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC
541 555 556 570 571 585 586 600 601 615 616 630
sdm2 GAGGCTTTTGAGCAG CTGGTGCGGGCTGTC CGGAAATAC GAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC
r-ras GAGGCTTTTGAGCAG CTGGTGCGGGCTGTC CGGAAATACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC
631 645 646 660 661
sdm2 GGGGGCTGCCCCTGC GTCCTCCTGTAG 655
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R-RasSDM5
1 15 16 30 31 45 46 60 61 75 76 90
Sdm5 ATGAGCTNNGGTGCT GCTTCTGGTACAGNT CGTGGTCGTCCAACG TGGTGGAGNTCCAGN TCCCCGGGACCCTCC CGCCTAGCGAGACAC
r-ras ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCC-CG GGGCGGGGGACCTGG GCCCGGGGACCC-CC CGCCCAGCGAGACAC
91 105 106 120 121 135 136 150 151 165 166 180
sdm5 ACNAGCTTGTGNTCG TGGGTGGTGTCGGCG TGGGCAAGAGCGCGC TGACCATCCAGTTCA TCCAGTCCTACTTCG TGTCTGACTACGACC
r-ras ACAAGCTGGTGGTCG TGGGCGGCGGCGGCG TGGGCAAGAGCGCGC TGACCATCCAGTTCA TCCAGTCCTACTTCG TGTCTGACTACGACC
181 195 196 210 211 225 226 240 241 255 256 270
sdm5 CCACTATTGAGGACT CCTACACGAAGATCT GCAGTGTGGATGGCA TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT
r-ras CCACTATTGAGGACT CCTACACGAAGATCT GCAGTGTGGATGGCA TCCCAGCCCGGCTGG ACATCCTGGACACCG CGGGCCAGGAAGAGT
271 285 286 300 301 315 316 330 331 345 346 360
Sdm5 TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG
r-ras TCGGGGCCATGAGAG AGCAGTACATGCGTG CTGGCCACGGCTTCC TGCTGGTGTTCGCCA TTAATGACCGGCAGA GTTTCAACGAGGTGG
361 375 376 390 391 405 406 420 421 435 436 450
sdm5 GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC
r-ras GCAAGCTCTTCACGC AGATTCTGCGGGTCA AGGACCGCGACGACT TCCCCGTTGTGTTGG TCGGGAACAAGGCAG ATCTGGAGTCACAGC
451 465 466 480 481 495 496 510 511 525 526 540
sdm5 GCCAGGTCCCCCGAT CAGAAGCCTCTGCCT TCGGCGCCTCCCACC ACGTGGCCTACTTTG AGGCCTCGGCCAAAC TGCGTCTCAACGTGG
r-ras GCCAGGTCCCCCGAT CAGAAGCCTCTGCCT TCGGCGCCTCCCACC ACGTGGCCTACTTTG AGGCCTCGGCCAAAC TGCGTCTCAACGTGG
541 555 556 570 571 585 586 600 601 615 616 630
Sdm5 ACGAGGCTTTTGAGC AGCTGGTGCGGGCTG TCCGGAAATACCAGG AACAAAAGCTCCCAC CGAGCCCTCCCAGTG CCCCCAGGAAGAAGG
r-ras ACGAGGCTTTTGAGC AGCTGGTGCGGGCTG TCCGGAAATACCAGG AACAAGAGCTCCCAC CGAGCCCTCCCAGTG CCCCCAGGAAGAAGG
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Appendix II
R-Ras 5aaSDM sequence alignment
1 15 16 30 31 45 46 60 61 75 76 90
R-Ras ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
5aa ATGAGTCT-GGTGCT GCTTCTGG-ACAGGT CGTGGTCGTCCACGT GGTGHAGG-CCAGGT CCCGGGGACCCTCCG CCTAGCGAGACACAC 87
91 105 106 120 121 135 136 150 151 165 166 180
R-Ras AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
5aa AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 177
181 195 196 210 211 225 226 240 241 255 256 270
R-Ras ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 270
5aa ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 267
271 285 286 300 301 315 316 330 331 345 346 360
R-Ras GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 360
5aa GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 357
361 375 376 390 391 405 406 420 421 435 436 450
R-Ras AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 450
5aa AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 447
451 465 466 480 481 495 496 510 511 525 526 540
R-Ras CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC 540
5aa CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC 537
541 555 556 570 571 585 586 600 601 615 616 630
R-Ras GAGGCTTTTGAGCAG CTGGTGCGGGCTGTC CGGAAATACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 630
5aa GAGGCTTTTGAGCAG CTGGTGCGGGCTGGT CGGAAACACAAGCTG CGGAAGCTGCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 627
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Appendix III
CHXl sequence alignment
1 15 16 30 31 45 46 60 61 75 76 90
R-Ras ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
chxl NTCCG CCTAGCGAGACACAC 20
91 105 106 120 121 135 136 150 151 165 166 180
R-Ras AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
Chxl AAGCTTGTG-TCGTG GGTGGTGTCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 109
181 195 196 210 211 225 226 240 241 255 256 270
R-Ras ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 270
Chxl ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 199
271 285 286 300 301 315 316 330 331 345 346 360
R-Ras GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 360
chxl GGGGCCATGAGAGAG CAGTACATGCGTGCT GGTCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 289
361 375 376 390 391 405 406 420 421 435 436 450
R-Ras AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 450
chxl AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACAACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 379
451 465 466 480 481 495 496 510 511 525 526 540
R-Ras CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC 540
Chxl CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAGACC CGGC AGGGAGTG 466
541 555 556 570 571 585 586 600 601 615 616 630
R-Ras GAGGCTTTTGAGCAG CTGGTGCGGGCTGTC CGGAAATACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 630
Chxl GAGGCCTTCTACACG TTGGTGCGTGAGATC CGGCAGCACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 556
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CHX(3) sequence alignment
1 15 16 30 31 45 46 60 61 75 76 SO
r-ras ATGAGCAGCGGGGCG GCGTCCGGGACAGGG CGGGGGCGGCCCCGG GGCGGGGGACCTGGG CCCGGGGACCCCCCG CCCAGCGAGACACAC 90
chx3 CCTTCCG CNTAGCGAGACACAC 22
91 105 106 120 121 135 136 150 151 165 166 180
r-ras AAGCTGGTGGTCGTG GGCGGCGGCGGCGTG GGCAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 180
chx3 AAGCTTGTGGTCGTG GGTGGTGTCGGCGTG G-CAAGAGCGCGCTG ACCATCCAGTTCATC CAGTCCTACTTCGTG TCTGACTACGACCCC 111
181 195 196 210 211 225 226 240 241 255 256 270
r-ras ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 270
chx3 ACTATTGAGGACTCC TACACGAAGATCTGC AGTGTGGATGGCATC CCAGCCCGGCTGGAC ATCCTGGACACCGCG GGCCAGGAAGAGTTC 201
271 285 286 300 301 315 316 330 331 345 346 360
r-ras GGGGCCATGAGAGAG CAGTACATGCGTGCT GGCCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 360
chx3 GGGGCCATGAGAGAG CAGTACATGCGTGCT GGTCACGGCTTCCTG CTGGTGTTCGCCATT AATGACCGGCAGAGT TTCAACGAGGTGGGC 291
361 375 376 390 391 405 406 420 421 435 436 450
r-ras AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACGACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 450
chx3 AAGCTCTTCACGCAG ATTCTGCGGGTCAAG GACCGCGACAACTTC CCCGTTGTGTTGGTC GGGAACAAGGCAGAT CTGGAGTCACAGCGC 381
451 465 466 480 481 495 496 510 511 525 526 540
r-ras CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAACTG CGTCTCAACGTGGAC 540
chx3 CAGGTCCCCCGATCA GAAGCCTCTGCCTTC GGCGCCTCCCACCAC GTGGCCTACTTTGAG GCCTCGGCCAAGACC CGGC AGGGAGTG 468
541 555 556 570 571 585 586 600 601 615 616 630
r-ras GAGGCTTTTGAGCAG CTGGTGCGGGCTGTC CGGAAATACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 630
chx3 GAGGCCTTCTACACG TTGGTGCGTGAGATC CGGCAGCACCAGGAA CAAGAGCTCCCACCG AGCCCTCCCAGTGCC CCCAGGAAGAAGGGC 558
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Chapter 6
Analysis of the effects of H-Ras and R-Ras on CHO
cell morphology
6.1 Introduction
The main sequence of divergence between the Ras isoforms is the final 24 residues,
the hypervariable region (Prior et al., 2001). The hypervariable region contains the
signalling sequences that cooperate in targeting Ras to the plasma membrane. An
important consequence of the hypervariable divergence is that the plasma membrane
anchors of H-Ras, N-Ras and K-Ras are all different. The membrane anchors consist
of a methylesterified prenylcysteine group, common to all three Ras proteins, plus
one or two palmitoylated cysteine residues in N- and H-Ras, or a polybasic domain
of six contiguous lysines in K-Ras (Hancock et al., 1989; Hancock et al., 1990).
Prior et al., (2001) showed using GFP-labelled proteins, that the membrane anchor of
H-Ras targets to the lipid rafts while the membrane anchor of K-Ras targets
predominantly to non-raft plasma membrane. The distinct microlocalisation of the H-
and K-Ras proteins has important potential consequences for downstream effector
interactions and activation of downstream pathways. Chemically depleting plasma
membrane cholesterol selectively abrogates H-Ras- but not K-Ras-mediated
activation of Raf-1 (Roy et al., 1999). Expression of a dominant-negative caveolin
mutant, caveolin-DGV, which reduces cell surface cholesterol by interfering with
intracellular cholesterol transport (Pol et al., 2001), also block H-Ras but not K-Ras
signalling pathways (Roy et al., 1999). Therefore, the functional integrity of the H-
Ras domain depends on cholesterol.
Like H-Ras, R-Ras contains a palmitoylation site on its membrane anchor, which
suggests a similar microlocalisation target to H-Ras which may also be dependent on
cholesterol. The targeted microlocalisation of R-Ras has not yet been identified,
however, when activated R-Ras is found localised with focal adhesions (Furuhjelm
and Peranen, 2003).
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Early studies suggested that integrins were not localised to lipid rafts (Fra et al.,
1994), but recently integrins such as ov/33, LFA-1 and a:4/31 have been found to be
raft associated (Green et al., 1999; Leitinger and Flogg, 2001). Thorne et al., (2000)
have also identified a6(3\ as being associated with lipid rafts, but a preferential
association with the active form of the integrin has not been noted.
The aims of this chapter are to use confocal microscopy to try and elucidate the
membrane microlocalisation of R-Ras and to determine the consequences of
overexpressing H-Ras G12V and R-Ras G38V on CHO cell cytoskeletal structure.
Since H-Ras and integrins have been found to be associated with lipid rafts, it was
hoped that by manipulating the cholesterol content of the plasma membrane, it could
be determined if the targeting of H-Ras and R-Ras to specific plasma membrane
microdomains (such as lipid rafts) is necessary for their effects on integrin affinity
modulation.
A further aim of this chapter is to produce CHO-K1 cell lines stably expressing H-
Ras G12V, R-Ras G38V and the H-and R-Ras chimeras. It is hoped that by using the
stable cell lines, further characterisation of H-Ras and R-Ras sequences may help to
determine what role, if any, sequence variations may play in conferring their
differing properties with respect to cellular structure and morphology.
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6.2 Confocal microscopy to define cellular localisation of
activated H-Ras and R-Ras
Immuno-fluorescence has provided an invaluable tool for investigating the specific
targeted domains of labelled endogenous proteins and proteins introduced to the cell
by means such as transfection. Confocal microscopy improves the quality of
immuno-fluorescent images by removing any background staining that may interfere
with the required image. It also allows the user to check for 'bleeding' from other
fluorescent channels, which may result in a false image being produced. One of the
main concerns with immuno-fluorescence is determining whether the staining
observed is specific or non-specific. To counteract this problem users provide a
negative control for staining, using only the secondary antibody. However, using a
transient system in immuno-fluorescence means that you have an in-built negative
control for staining. In the transient system, specific staining is very clear, as it is
only those cells that have been successfully transfected that express the protein of
interest. The in-house confocal facility was used, to study the cellular localisation of
transiently over expressed H-Ras G12V and R-Ras G38V in a(3-py cells.
6.2.1 H-Ras G12V and R-Ras G38V both localise to the plasma membrane
The presence of the Ha-tag on H-Ras G12V and the Myc-tag on R-Ras G38V meant
that immuno-fluorescence could be performed on transfected cells. Cells were seeded
onto coverslips and allowed to adhere overnight prior to transfection. Following
transfection, cells were incubated overnight in complete DMEM and then gently
washed with PBS prior to staining.
Cells were stained using; anti-HA (Y-ll) antibody, followed by Alexa 488-
conjugated goat anti-rabbit IgG (green) to determine H-Ras G12V localisation; and
anti-Myc (9E10) antibody, followed by Alexa 568-conjugated goat anti-mouse IgG
(red) to determine R-Ras G38V localisation. H-Ras G12V, shown in green in Figure
6.1A, localises to the plasma membrane of the cell. R-Ras G38V, shown in red in
Figure 6.IB, also localises to the plasma membrane. Cells expressing both proteins
allowed a merged image to be produced to compare the localisation of H-Ras G12V
and R-Ras G38V. Figure 6.1C shows the merged image of Figures 6.1A and 6. IB.
ToPro3 was used to clearly define the nucleus of the cell, allowing us to better judge
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the localisation of the proteins compared with the position of the nucleus. The yellow
colour observed in Figure 6.1C suggests that H-Ras G12V and R-Ras G38V are both
localised to similar areas of the plasma membrane of the transfected cell.
6.2.2 Actin cytoskeleton disrupted in H-Ras G12V transfected cells.
In order to determine the effects that H-Ras G12V and R-Ras G38V may have on the
cytoskeleton of cells we made use of phalloidin, a fungal toxin that binds specifically
to F-actin. Rhodamine-conjugated phalloidin provides a very convenient tool, in
immuno-fluorescence, to study the distribution of F-actin in permeabilised cells.
Figure 6.2A reveals the well-defined actin stress fibres (shown in red) of a
representative cell transiently transfected with control vector. Cells are well spread
(about 100pm diameter) and the stress fibres are distinctly organised across the
whole body of the cell.
The staining of H-Ras G12V and R-Ras G38V in the merged images of this
experiment is not very apparent. However, in order to clearly visualise stress fibres,
cell images need to be taken from the lowest point of the cell i.e. where it has
adhered to the coverslip. This can make visualising other proteins difficult as they
can be more disperse on this lower plane. Therefore, as well as a final merged image,
figures 6.2B and 6.2C provide a separate green and red channel to facilitate
visualisation of the tagged proteins and actin cytoskeleton respectively.
In contrast to control cells, H-Ras G12V transfected cells show a much more
rounded morphology (Figure 6.2B shows a representative cell). H-Ras G12V cells
have a diameter less than half that of the control cell (approximately 40pm in
diameter). Figure 6.2B shows positive staining for H-Ras G12V using the anti-HA
(Y-11) antibody (shown in green). H-Ras G12V localises to the plasma membrane.
Cells have punctate F-actin staining (shown in red) but no stress fibres are visible.
Figure 6.2C shows a representative R-Ras G38V transfected cell. R-Ras G38V
transfected cells maintain a well spread morphology (approximately 80pm in
diameter) and have a much less disrupted cytoskeletal structure (shown in red)
compared with H-Ras G12V transfected cells. Figure 6.2C shows positive staining
for R-Ras G38V using the anti-Myc (9E10) antibody (shown in green). R-Ras G38V
appears to localise to the plasma membrane.
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Figure 6.1 Cellular localisation ofH-Ras G12V and R-Ras G38V.
Cells co-transfected with lpg each of H-Ras G12V and R-Ras G38V. Cells were
stained with antibodies against; (A) H-Ras G12V expression shown in green; (B) R-
Ras G38V expression shown in red; (C) merged image of red and green channels,
areas of yellow represent co-incident staining of H-Ras G12V and R-Ras G38V
expression. ToPro3 used for nuclear definition (shown in blue). Greyscale images
used for the individual green and red channel images to allow optimal visualisation
of staining. Bars, 10pm.







Myc (Green) Phallodin (Red) Merged
R-Ras
Figure 6.2 Actin cytoskeleton staining in H-Ras G12V and R-Ras G38V
transfected cells.
Cells transfected with (A) control vector (lpg), (B) HA-tagged H-Ras G12V (lpg)
and (C) Myc-tagged R-Ras G38V (lpg). Expression of H-Ras G12V and R-Ras
G38V visualised using Alexa 488-conjugated antibodies, shown in green.
Rhodamine-conjugated phallodin used to reveal the actin cytoskeleton, shown in red.
In the merged images of red and green channels, areas of yellow represent co¬
incident staining of H-Ras G12V and R-Ras G38V expression with actin
cytoskeleton. ToPro3 (shown in blue) used for nuclear definition. Greyscale images
used for the individual green and red channel images to allow optimal visualisation
of staining. Bars, 20pm.
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6.2.3 H-Ras G12V transfection results in disorganisation of focal adhesions.
To determine whether the disruption of the actin cytoskeleton observed in H-Ras
transfected cells reflected a reorganisation of the cellular adhesion sites, we analysed
cells transiently transfected with H-Ras G12V and R-Ras G38V using a monoclonal
anti-vinculin antibody. Vinculin is a 117kDa protein localised to focal adhesions.
Figure 6.3A shows the typical pattern of vinculin staining of a control cell. The
control cell has a diameter of about 50pm and vinculin staining can be observed
around the periphery of the cell. In order to clearly visualise the transfected tagged
proteins and vinculin staining, figures 6.3B and 6.3C provide a separate green and
red channel image as well as a final merged image
The rounded morphology of the H-Ras G12V transfected cell (Figure 6.3B) was
consistent with a disruption of focal adhesions, with reduced peripheral staining and
a cell diameter of about 30pm. H-Ras G12V is shown to be localised to the plasma
membrane of the cell, shown by the red staining. Figure 6.3C shows a cell that has
been transfected with R-Ras G38V. In this experiment it was necessary to use the
anti-Myc (A-14) rabbit polyclonal antibody for staining R-Ras G38V to prevent
cross-reaction between the previously used anti-Myc (9E10) antibody and the anti-
human vinculin antibody, which are both mouse monoclonals. The vinculin staining
in this cell is very pronounced. There are an increased number of focal adhesions
around the periphery, compared with the control cell, resulting in a well spread
morphology (about 60pm diameter).
Interestingly, Figure 6.3C shows that areas of vinculin expression overlap with areas
of R-Ras G38V expression, in particular around the plasma membrane. Although R-
Ras G38V is shown to be predominately localised to the plasma membrane of the
cell, shown by red staining, some internal staining can be seen in Figure 6.3C.
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Figure 6.3 Vinculin staining of H-Ras G12V and R-Ras G38V transfected cells.
Cells transfected with (A) control vector (lpg), (B) HA-tagged H-Ras G12V (lpg)
and (C) Myc-tagged R-Ras G38V (lpg). Expression of H-Ras G12V and R-Ras
G38V visualised using Alexa 568-conjugated antibodies, shown in red. Cells were
stained with an anti-vinculin antibody (green). In the merged images of red and green
channels, areas of yellow represent co-incident staining of H-Ras G12V and R-Ras
G38V expression with vinculin. Greyscale images used for the individual green and
red channel images to allow optimal visualisation of staining. Bars, 1 Opm.
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6.3 The effect of cellular localisation of H-Ras G12V and R-
Ras G38V on integrin affinity modulation.
Earlier results revealed that both H-Ras G12V and R-Ras G38V localise to the
plasma membrane. H-Ras G12V has previously been shown to target to lipid rafts
within the plasma membrane (Prior et al., 2001). Methyl-/3-cyclodextrin (M/3CD) can
be used to deplete the cholesterol content and therefore disrupt lipid rafts within the
plasma membrane (Hooper, 1999; Ostermeyer et al., 1999). M/3CD treatment of cells
was used to check for its effects on integrin affinity modulation and to decide
whether localisation to specific membrane domains is required for H-Ras G12V
suppression of integrin affinity and R-Ras G38V reversal of H-Ras G12V integrin
suppression.
6.3.1 Treatment of CHO-K1 cells with MjSCD affects lipid raft distribution.
It is possible to detect lipid rafts within the plasma membrane by cross-linking the
raft enriched glycosphinolipid GM1 through binding to a rhodamine-conjugated
cholera toxin (Ctx) B subunit and patching with rabbit anti-Ctx antibody (Janes et al.,
1999). The rhodamine-conjugated Ctx-B allows visualisation of the rafts in immuno¬
fluorescence studies (Janes et al., 1999).
Preliminary experiments carried out on CHO-K1 cells revealed a problem in
detecting the lipid rafts using Ctx-B. Upon investigation it was discovered that unlike
wild-type CHO cells, CHO-K1 cells do not synthesise the complex ganglioside,
GM1 (Rusnati et al., 1999). It was possible to overcome this by incorporation of
exogenous GM1 into the cell membranes (Rusnati et al., 1999). A considerable
incorporation of GM1 (approximately 3-fold the amount of endogenous GM3) has
been observed when CHO cells were incubated with the exogenous GM1 lipid
(Crespo et al., 2002). The exogenous addition of GM1 has been shown to displace
GPI-anchored proteins from lipid rafts in living cells (Simons et al., 1999).
Exogenously added gangliosides can affect biological systems, leading to increased
cell adhesiveness, inhibited cell growth and they can promote cell differentiation
(Hakomori and Igarashi, 1995). However, since we are only using GM1 to help
identify lipid rafts, the exogenous application of GM1 to CHO-K1 cells was
considered a reasonable alternative to obtaining wild-type CHO cells.
189
Analysis of the effects of H-Ras and R-Ras on CHO cell morphology
Cells were incubated for 96 hours in fresh DMEM containing 0.4% FCS with
100pM GM1 before being used for further investigation (Rusnati et cil., 2002). The
cell fixation method for immuno-fluorescence utilised elsewhere in this thesis uses
3% paraformaldyhyde. As this may result in the permeabilisation of the cell
membrane, which may in turn affect the positioning of GM1, it was decided to
observe the lipid raft distribution in live cells.
Employing the method used by Janes et al., (1999), lipid rafts were visualised using
fluorescence microscopy. Figure 6.4A shows the homologous distribution of GM1
gangliosides in untreated cells, revealed with rhodamine-conjugated Ctx-B. Cells
have a diameter of approximately 50pm. Following treatment with a rabbit anti-Ctx
antibody to induce Ctx-B cross-linking, staining became concentrated to distinct
patches within the membrane (Figure 6.4B). These distinct patches are caused by the
clustering of the GM1 raft marker, caused by the cross-linking of the anti-Ctx
antibody. Treatment of cells with the anti-Ctx antibody had no effect on the cell
morphology, diameter between 50 and 60pm, compared with the untreated cell.
To assess the effect of M/3CD on lipid rafts, cells were incubated with 1% (lOmM)
M/3CD (found to be the optimal concentration) for 1 hour at 37°C prior to staining
with rhodamine-conjugated Ctx-B. Figure 6.4C shows cells which are much less
spread than either the untreated (6.4A) or cross-linked (6.4B) cells. The cells in 6.4C
have diameters of at least half of those cells shown in 6.4A and 6.4B. The Ctx-B
staining is less evenly distributed than seen with untreated cells, forming patches
within the membrane similar to that observed following antibody cross-linking of the
anti-Ctx antibody.
Therefore, these preliminary experiments demonstrated that M/3CD disrupts the
normal lipid raft distribution of CFIO-Kl cells.
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Figure 6.4 Treatment of cells with MpCD affects lipid raft distribution.
CHO-K1 cells were incubated with exogenous GM-1 for 96 hours at 37°C. Immuno¬
fluorescence performed on live cells. (A) Untreated cells stained with Rhodamine-
conjugated Ctx-B. (B) Untreated cells stained with Rhodamine -conjugated Ctx-B,
then cross-linked with rabbit anti-Ctx antibody. (C) Cells treated with 1% MpCD for
1 hour at 37°C followed by staining with Rhodamine-conjugated Ctx-B. Greyscale
images provided to allow optimal visualisation of staining. Bars, 20pm.
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6.3.2 M/3CD treatment has no significant effect on integrin affinity modulation
by either H-Ras G12V or R-Ras G38V.
It has been demonstrated earlier that treatment of cells with M/3CD results in the
disruption of lipid rafts distribution in CHO-K1 cells. To test whether integrin
affinity modulation by H-Ras G12V or R-Ras G38V requires intact lipid rafts, oj3-py
cells were treated with M/3CD. To control for non-specific effects of M/3CD
treatment on cells, cells were treated with 5mM MjSCD-cholesterol conjugates
(inclusion complexes) for 1 hour at 37°C, following treatment with 1% M/3CD. The
addition of inclusion complexes provides the cell with cholesterol in the form of
M/3CD-cholesterol conjugates, which facilitate the incorporation of exogenous
cholesterol into membranes (Klein et al., 1995), which reverse the effects of M/3CD
on lipid rafts. For these experiments, cells were transfected with control vector, H-
Ras G12V and R-Ras G38V ± H-Ras G12V and PAC1 binding was assessed.
M/3CD treatment of cells had no effect on H-Ras G12V- or R-Ras G38V- mediated
changes in integrin affinity. Figure 6.5 shows that levels of integrin affinity of
control vector or H-Ras G12V transfected cells did not undergo any significant
change during any of the treatments.
However, addition of inclusion complexes significantly attenuated R-Ras G38V
activation, and blocked R-Ras G38V reversal of H-Ras G12V-mediated integrin
suppression. The levels of integrin affinity in cells transfected with R-Ras G38V
alone were significantly reduced to the baseline activity observed with control vector
transfection, when compared with untreated and M/3CD treated cells. Also, addition
of inclusion complexes significantly diminished the ability ofR-Ras G38V to reverse
H-Ras G12V suppression (P<0.001) when compared with untreated and M/3CD
treated cells. The inclusion complexes did not mediate a toxic effect on R-Ras G38V
transfected cells since they did not affect H-Ras G12V or control transfected cells.
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Figure 6.5 Effects of M/3CD treatment on integrin affinity modulation by H-Ras
G12V and R-Ras G38V.
Flow cytometry was performed on cq3-py cells transfected with control vector (1 pg),
H-Ras G12V (lpg) or R-Ras G38V ± H-Ras G12V (lpg). In each transfection, total
DNA content was standardised to 2pg using control vector. Integrin affinity
modulation was determined under three conditions: untreated cells; cells treated with
1% M/3CD for 1 hour at 37°C; and cells incubated with inclusion complexes for 1
hour at 37°C, following treatment with 1% M/3CD for 1 hour at 37°C. The results
shown are the mean ± SEM of 4 independent experiments. Statistical analysis was
performed by one-way ANOVA test, within each test DNA sample asterisks
represent P<0.01 (**) and P<0.001 (***) compared with untreated cells, while
hashes represent P<0.01 (##) and P<0.001 (###) compared with M/3CD treated cells.
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6.3.3 M/3CD treatment affects the localisation ofwild-type H-Ras but not H-
Ras G12V
Using fluorescence confocal microscopy, the effect on cellular localisation of H-Ras
by M/3CD treatment was examined in CHO-K1 cells transiently expressing pEGFP
control vector, GFP-H-Ras (G12V) and GFP-H-Ras (WT). Since the
permeabilisation of the cell membrane may affect the positioning of lipid rafts, the
localisations of the GFP-tagged proteins were observed in live cells. For each of the
above constructs, Figure 6.6 shows images with and without a phase contrast overlay
of an untreated control cells and M/3CD treated cells. Protein localisation was easily
determined by GFP expression (green).
Transfection with pEFGP control vector results in an even distribution of protein
throughout the cell and these cells maintain a well spread morphology (about 40pm
diameter). M/3CD treatment of pEGFP transfected cells has little effect on the
distribution of the protein or on the morphology of the cell compared with the
untreated control.
GFP-H-Ras (WT) was found to be localised to the plasma membrane, with some
perinuclear localisation possibly within the golgi apparatus. GFP-H-Ras (WT)
expressing cells maintain morphology similar to that observed with the pEGFP
positive cells, with a diameter of about 40pm. M/3CD treatment ofGFP-H-Ras (WT)
transfected cells resulted in a striking change in the compartmentalisation of GFP-H-
Ras (WT), which localised mainly to intracellular compartments rather than the
intact plasma membrane. M/3CD treated cells maintain a spread morphology similar
to the pEGFP transfected cells.
GFP-H-Ras (G12V) was found to be localised to the plasma membrane, with some
perinuclear localisation possibly within the golgi apparatus. GFP-H-Ras (G12V)
expressing cells adopt a rounded morphology, with diameters of around 20pm.
M/3CD treatment of GFP-H-Ras (G12V) transfected cells has little effect on the
distribution of the protein or on the morphology of the cell compared with the
untreated control.
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Untreated 1 % MpCD
Figure 6.6 Using GFP-Iabelled proteins to determine if MpCD treatment affects
the localisation of H-Ras WT and H-Ras G12V
Confocal microscopy was performed on live cells transfected with pEGFP control
vector (lpg), pEGFP-H-Ras WT (lpg) or pEGFP-H-Ras G12V (lpg). Protein
localisation, demonstrated by GFP expression, was examined in untreated cells and
in cells treated with 1% M(3CD for 1 hour at 37°C. Images shown with a phase-
contrast overlay for cellular definition and without a phase-contrast overlay to
provide a better contrast for observing GFP expression and localisation. Bars, 20pm.
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6.4 Production of stable lines expressing chimeric DNA.
Stable lines expressing the H-and R-Ras chimeras, full-length H-Ras G12V and R-
Ras G38V were generated to facilitate further structural and functional
characterisation. All constructs were cloned into pCDNA3.1(+) encoding the
neomycin resistance gene, allowing for G418 selection in CHO-K1 cells. Stable lines
were screened by either intracellular FACS analysis or western blotting.
6.4.1 H-Ras G12V fails to express in stable lines.
The N-terminal HA-tag on H-Ras G12V enabled protein expression to be measured
by FACS analysis. Intracellular staining was carried out on cells using the anti-Ha
(Y-ll) antibody followed by a secondary FITC-conjugated anti-rabbit IgG. The
histogram shown in Figure 6.7A shows a negative control ofHa-binding, using only
the secondary antibody, in the FL-1 channel. Figure 6.7B shows a representative
histogram of the negligible levels of positive Ha-antibody staining observed with all
the H-Ras G12V clones. FACS analysis on all the remaining H-Ras G12V clones
resulted in less than 3% of the population being gated positive for HA-antibody
staining. To test the possibility that the poor levels ofHA antibody staining was due
to a problem with the intracellular FACS analysis, expression was tested by western
analysis. Figure 6.7C shows a representative blot indicating that no clone showed
positive for H-Ras G12V expression.
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Stable Fl-Ras G12V Clones
Figure 6.7 Analysis of H-Ras G12V stable lines.
Intracellular FACS staining of H-Ras G12V stable clones was performed using anti-
HA (Y-ll) antibody. Flow cytometry was performed to determine H-Ras expression
levels. (A) Negative control for H-Ras expression using secondary anti-rabbit IgG-
FITC staining only. (B) Representative histogram showing HA-staining of an H-Ras
G12V stable clone. (C) Cell lysates from stable lines were tested by western analysis
with the anti-HA antibody.
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6.4.2 Analysis of stable lines expressing R-Ras G38V or H-and R-Ras
chimeras.
The N-terminal Myc-tag on R-Ras G38V enabled protein expression in the stable
lines to be tested by FACS analysis. Intracellular staining was carried out on cells
using the anti-Myc (9E10) antibody followed by a secondary FITC-conjugated anti-
mouse IgG. FACS analysis was carried out on a negative control for Myc-binding
using only the secondary antibody (see Figure 6.8A). Figure 6.8B shows a
representative histogram of the levels of positive Myc antibody staining observed
with an R-Ras G38V clone. FACS analysis on all the potential R-Ras G38V clones
enabled positive clones to be identified, with the percentage of the populations
showing positive for Myc-antibody binding ranging from 10%-98% (data not
shown).
Using the N-terminal FLAG-tag on the H-and R-Ras chimeras, stable protein
expression was measured by FACS analysis. Intracellular staining was carried out on
cells using the anti-FLAG monoclonal antibody followed by a secondary FITC-
conjugated anti-mouse IgG. Figures 6.9A and B show histograms representing
negative and positive staining for FLAG-binding respectively. As with R-Ras G38V
clones, levels of stable protein expression of the H-and R-Ras chimeras varied
greatly (data not shown).
For subsequent analyses of the stable lines, clones with comparable levels of chimera
expression were selected. Figure 6.10 shows the levels of stable protein expression of
the clones selected, ranging between 35-55%.
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FL1-Myc antibody Binding
FL1-Myc antibody Binding
Figure 6.8 Analysis ofR-Ras G38V expressing stable lines.
Intracellular staining ofR-Ras G38V stable clones was performed using the anti-Myc
antibody and the secondary anti-mouse IgG-FITC. Flow cytometry was performed to
determine R-Ras expression levels. (A) Negative control for R-Ras expression,
determined using secondary anti-rabbit IgG-FITC staining only. (B) Histogram
showing R-Ras G38V expression in a stable clone.
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FL1-FLAG antibody Binding
Figure 6.9 Intracellular staining of FLAG-tagged proteins.
Intracellular staining of FLAG-tagged proteins was performed using anti-FLAG
monoclonal antibody and the secondary anti-mouse IgG-FITC. Flow cytometry was
performed on potential clones. (A) Negative control for FLAG expression,
determined by secondary anti-mouse IgG-FITC staining only. (B) Histogram
showing FLAG-tagged chimera expression in stable lines.
Analysis of the effects of H-Ras and R-Ras on CHO cell morphology
75 -i
Figure 6.10 Level of protein expression in stable clones.
Intracellular FACS analysis was used to determine protein expression levels of H-
and R-Ras chimeras. Data represent the range of protein expression levels for the
chimeras.
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6.5 Comparing structure and morphology of stable lines
Previous results have shown that transient expression of H-Ras G12V or R-Ras
G38V bestow very different structural properties on to cells. The stable H-and R-Ras
chimera lines were used to determine the role, if any, the sequence variations of H-
Ras G12V and R-Ras G38V may play on their differing properties with respect to
cellular structure. Structural and morphological variability will be assessed using
immuno-fluorescence and electron microscopy techniques. For each of the stable
lines, chimeric protein expression was checked for using immuno-fluorescent
staining of the FLAG-tagged proteins. However, in order to clearly visualise stress
fibres, cell images need to be taken from the lowest point of the cell i.e. where it has
adhered to the coverslip. This can make visualising other proteins difficult as they
can be more dispersed on this lower plane.
6.5.1 Cytoskeletal structural variations between H-Ras G12V N-terminal
chimeric stable lines
The chimeras CH3, CH6, HI97 and H201 all possess, to varying degrees, the N-
terminal sequences of H-Ras G12V. Using immuno-fluorescence the structural
variance between the stable lines was investigated. Figure 6.11 shows the distribution
of F-actin, using rhodamine-conjugated phalloidin (shown in red), of these stable
lines. Stable protein expression was confirmed using an anti-FLAG monoclonal
antibody followed by a secondary FITC-conjugated anti-mouse IgG antibody (shown
in green).
The cell lines stably expressing CH3 and CH6 are well spread (more than 50% of the
cells were about 100pm diameter) and have stress fibres organised across the whole
body of the cell see Figures 6.11 A and B respectively. Protein expression is mainly
localised to points around the membrane area of the cells. The HI 97 and H201 stable
lines have markedly different cell morphologies compared with the CH3 and CH6
stable lines. Cells stably expressing H197 and H201, shown by Figures 6.11C and D
respectively, are much rounder and have less than half the diameter of CH3 and CH6
stable lines. HI97 and H201 cells contain stress fibres and stable protein expression
is localised to the membrane.
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6.5.2 Cytoskeletal structural variations between R-Ras G38V N-terminal
chimeric stable lines
The chimeras CHI, CH5, R197 and R201 all possess, to varying degrees, the N-
terminal sequences of R-Ras G38V. As with H-Ras G12V N-terminal chimeric
stable lines, the structural variance between these stable lines was investigated.
Figure 6.12 shows the distribution of F-actin, using rhodamine-conjugated phalloidin
(shown in red). Protein expression was confirmed using an anti-FLAG monoclonal
antibody followed by a secondary FITC-conjugated anti-mouse IgG antibody (shown
in green).
The CHI stable cells were well spread (more than 50% of the cells were about 80pm
diameter) and had stress fibres organised across the whole body of the cell. Protein
expression is localised to the membrane (Figure 6.12A). Figure 6.12B reveals that
CH5 stable cells adopt a well spread morphology, like the CHI stable cells. The cell
edges are not clearly defined by F-actin staining in the CH5 stable cells, with the
only visible stress fibres arranged internally. Protein expression is localised to the
outermost regions of the cells. R197 stable cells are not as well spread as CHI and
CH5 stable lines (less than 60pm in diameter), with stress fibres seen across the
length of the cells (Figure 6.12C). Protein expression is localised to the membrane
areas of the cells. R201 stable cells (Figure 6.12D), have very well defined stress
fibre structures within the cells, stable protein expression can be seen in some
internal structures as well as at the membrane.
In brief, the CH3, CH6 and R201 stable lines have a well spread morphology with
clearly defined stress fibres organised across the body of the cell. These
morphologies are similar to those observed with R-Ras G38V transiently transfected
cells (Figure 6.2). The CHI, H197 and H201 stable lines have a less spread, more
rounded morphology with a more peripheral pattern of actin staining. These
morphologies are similar to those observed with H-Ras G12V transiently transfected
cells (Figure 6.2). Results suggest that R-Ras G38V sequences 175 to 203 (residues
between CH6 and R201) are required for a well defined actin skeleton, while H-Ras
G12V sequences 60 to 199 (residues between CHI and HI97) are required for an H-
Ras-like effect on the actin skeleton. See section 6.2.2 for H-Ras and R-Ras effects
on the actin cytoskeleton.
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Figure 6.11 Actin cytoskeleton staining of H-Ras G12V N-terminal stable lines.
H-Ras G12V N-Terminal stable lines were stained using anti-FLAG monoclonal
antibody followed by the secondary anti-mouse IgG-FITC. F-actin cytoskeleton was
stained with rhodamine-conjugated phalloidin for 20mins at room temperature. The
panels show the following stable lines: (A) chimera CH3; (B) chimera CH6; (C)
chimera HI 97 and (D) chimera H201. Bars, 20pm.
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Figure 6.12 Actin cytoskeleton staining of R-Ras G38V N-terminal stable lines.
R-Ras G38V N-Terminal stable lines cells were stained using anti-FLAG
monoclonal antibody followed by the secondary anti-mouse IgG-FITC. F-actin
cytoskeleton was stained with rhodamine-conjugated phalloidin for 20mins at room
temperature. The panels show the following stable lines: (A) chimera CHI; (B)
chimera CH5; (C) chimera R197 and (D) chimera R201. Bars, 20pm.
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6.5.3 Morphological analysis of R-Ras G38V stable lines.
Scanned electron microscope images of control (pCDNA3.1(+)) and R-Ras G38V
stable lines (Figure 6.13) were taken for high resolution cell morphology. Control
stable cells (Figures 6.13A and B) are well spread (diameters between 20 and 30pm),
with well defined, smooth cell edges and there are the occasional blebs visible on the
cell surface (circled areas). R-Ras G38V stable cells (Figures 6.13C and D) are much
flatter compared with control cells. They have diameters reaching 40pm, with well
defined, smooth cell edges and fewer, smaller surface blebs (circled area) than
observed with control stable cells.
6.5.4 Morphological variations between H-Ras G12V N-terminal stable lines.
The chimeric stable lines expressing CH3, CFI6, HI97 and H201 all possess N-
terminal sequences of H-Ras G12V. Images in Figure 6.14 show representative
micrographs from each of the individual stable cell lines. CH3 stable cells (Figures
6.14A and B) and CH6 stable cells (Figures 6.14C and D) have very similar
morphologies to control cells. In each case the cells are well spread (diameters are
about 30pm); they have well-defined, smooth edges and exhibit some membrane
blebs over the cell surfaces (circled areas). The HI97 (Figures 6.14E and F) and
H201 (Figures 6.14G and H) stable cells have strikingly different morphologies
compared to control cells. Cells are very rounded up, with diameters barely
exceeding 10pm. The cell edges are very ruffled, with a number of protrusions
(highlighted with arrows). Cells have larger blebs over their surfaces (circled areas).
The ruffled cell edges and the increased number and size of surface blebs are
indicative of a transformed phenotype.
6.5.5 Morphological variations between R-Ras G38V N-terminal stable lines.
The chimeric stable lines expressing CHI, CH5, R197 and R201 all possess N-
terminal sequences of R-Ras G38V. Images in Figure 6.15 show representative
micrographs from each of the individual stable cell lines. CHI stable cells (Figures
6.15A and B) have diameters of about 20pm. Compared with control cells, CHI
expressing cells have fairly ruffled edges (arrows) and a few large membrane blebs
(circled areas). The CH5 stable cells (Figures 6.15C and D) have diameters of about
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30pm. They have a very well spread morphology with fairly smooth cell edges and
membrane blebs are concentrated around the nuclear area (circled areas). R197 stable
cells (Figures 6.15E and F) diameters of about 15pm. These cells are much more
rounded than the control cells as well as CHI and CH5 expressing cells. The surfaces
of the R197 stable cells are covered in fairly large membrane blebs (circled areas).
Cells have ruffled edges (arrows). The R201 stable cells (Figures 6.15G and H) are
very well spread, with diameters reaching 40pm (similar to R-Ras G38V stable
lines). Cells have very smooth edges and minimal membrane blebbing.
In brief, the CH3, CH6 and R201 stable lines have flattened cell morphologies
similar to control cells and cells stably expressing R-Ras G38V. Cells expressing
R201 have the most R-Ras G38V-like cell shape. All these cell lines have smooth,
well defined cell edges and minor cell surface blebbing. Results suggest that R-Ras
G38V sequences 175 to 203 (residues between CH6 and R201) influence the R-Ras
G38V cell morphology.
The CHI, HI97 and H201 stable lines have a less spread, more rounded morphology.
These stable cell lines have ruffled cell edges and quite large cell surface blebs,
indicative of a transformed phenotype. H-Ras G12V sequences 60 to 199 (residues
between CHI and HI97) are required for a transformed cell morphology.
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Figure 6.13 Scanning electron micrographs of control and R-Ras G38V stable
lines.
Scanning electron micrographs were taken of control vector (panels A and B) and R-
Ras G38V (panels C and D) expressing stable lines. Magnifications of each
micrograph shown in the lower right hand corner of each panel. Circled areas in
higher magnification panels highlight areas ofmembrane blebbing.
Bars represent 10pm.





Figure 6.14 Scanning electron micrographs of H-Ras G12V N-Terminal stable
lines.
Scanning electron micrographs were taken of CH3 (panels A and B), CH6 (panels C
and D), HI97 (panels E and F) and H201 (panels G and H) expressing stable lines.
Magnifications of each micrograph shown in the lower right hand corner of each
panel. Circled areas in higher magnification panels highlight areas of membrane
blebbing. Arrows in higher magnification panels indicated areas of membrane
ruffling. Bars represent 10pm.
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Figure 6.15 Scanning electron micrographs of R-Ras G38V N-Terminal stable
lines.
Scanning electron micrographs were taken ofCHI (panels A and B), CH5 (panels C
and D), R197 (panels E and F) and R201 (panels G and H) expressing stable lines.
Magnifications of each micrograph shown in the lower right hand corner of each
panel. Circled areas in higher magnification panels highlight areas of membrane
blebbing. Arrows in higher magnification panels indicated areas of membrane
ruffling. Bars represent 10pm.
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6.6 Discussion
In this chapter, the microlocalisations of H-Ras and R-Ras have been investigated
with relation to integrin affinity modulation and using H-and R-Ras chimera stable
lines, the regions of H-Ras and R-Ras responsible for conferring their differential
effects on cellular structure and morphology have been explored. The major findings
of this chapter are as follows: H-Ras G12V and R-Ras G38V localise to similar
microdomains within the plasma membrane. Membrane disruption using M/3CD has
no affect on integrin affinity modulation by H-Ras G12V or R-Ras G38V. Stable
expression of H-Ras G12V in CHO-K1 cells is non-viable. The H-Ras sequences
Gly60 to Leu171 are important in conferring H-Ras G12V cytoskeletal structure and
cellular morphology, since the CHI, HI97 and H201 stable lines are all H-Ras-like.
The R-Ras sequences Leu175 to Pro203 are important in conferring R-Ras G38V
cytoskeletal structure and cellular morphology, since the CH6 and R201 stable lines
are both R-Ras-like.
The cellular localisation of R-Ras has not been formally identified by any previous
studies. Using confocal microscopy, the cellular localisations of transiently expressed
H-Ras G12V and R-RasG38V were examined. Results reveal both H-Ras G12V and
R-Ras G38V are targeted to similar microdomains within the plasma membrane
(Figure 6.1). The earliest insight into Ras microlocalisation came with the
observations that disrupting lipid raft structure, by chemically depleting plasma
membrane cholesterol, selectively abrogates H-Ras- but not K-Ras-mediated
activation of Raf-1 (Roy et al., 1999). More recently, Prior et al., (2001) have shown
using the C-terminal 9 amino-acids of H-Ras cloned onto the C-terminus of GFP,
that the C-terminal anchor of H-Ras targets to caveolae and lipid rafts. The efficient
targeting of H-Ras to lipid rafts and caveolae is dependent on palmitoylation,
because non-palmitoylated H-Ras mutants accumulate in the ER (Choy et al., 1999;
Apolloni et al., 2000). As a general rule, palmitoylated peripheral membrane proteins
can associate with lipid rafts because the saturated palmitate packs well into the
liquid-ordered raft structures, whereas unsaturated, branched chain prenyl groups do
not (Melkonian et al., 1999). As R-Ras also contains a palmitoylation sequence, it is
not unreasonable to assume that it may be targeted to similar lipid raft microdomains
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as H-Ras. Also, RhoB and TC10 proteins, which have a geranylgeranylated motif
and are palmitoylated, like R-Ras, have been shown to localise at the plasma
membrane and golgi (Michaelson et al., 2001), which suggests a similar trafficking
pathway to H-Ras. A recent study by Furuhjelm and Peranen, (2003) showed, using
EGFP-tagged R-Ras (WT, G38V and 43N) proteins, that each of the proteins
localised to the perinuclear region, to the golgi and to the plasma membrane,
suggesting that R-Ras does use an analogous endomembrane trafficking route to H-
Ras and N-Ras (Choy et al., 1999).
Although inactive H-Ras has been located to lipid rafts and caveolae, it has been
demonstrated that GTP loading ofH-Ras is sufficient to drive H-Ras out of lipid rafts
(Prior et al., 2001). Insolubility in 1% Triton X-100 is widely used as an assay for
lipid raft association. The increased detergent solubility of GTP-bound H-Ras G12V,
as compared with GDP-bound H-Ras, is consistent with activated H-Ras being
driven into disordered plasma membrane (Prior et al., 2001). The results presented in
Figure 6.1 show that activated H-Ras G12V and activated R-Ras G38V localise to
similar domains within the plasma membrane and so it is probable that upon GTP-
loading, R-Ras also migrates to the disordered plasma domain.
The actin cytoskeleton mediates a variety of essential biological functions in all
eukaryotic cells. It provides a structural framework around which cell shape and
polarity are defined (Hall, 1998). Ras is involved in regulating the organisation of the
actin cytoskeleton, with Rho and Rac being downstream effectors (Hall, 1994).
Confocal microscopy, following immunostaining with rhodamine-conjugated
phalloidin and vinculin, demonstrates the cellular morphological changes correlating
with the distribution of cell-substratum contacts, following transient expression ofH-
Ras G12V and R-Ras G38V in CHO cells. Wild-type CHO cells have the typical
well spread, polyglonal shape (Figure 6.2A). Expression of H-Ras G12V results in
the loss of stress fibres and a reduction in cell size (Figure 6.2B). The rounded
morphology and thickened cortical actin around the periphery of the H-Ras G12V
transfected cells are consistent with Ras-transformed epithelial cells (Zhong et al.,
1997). The significant effects on cell morphology, inducing loss of adhesions and
changes in cell shape, are also typical of the transformed morphology of Swiss 3T3
fibroblasts (Nobes and Hall, 1999). Activated H-Ras has a suppressive function on
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integrins, inducing a reduction and enhanced turnover of adhesions (Nobes and Hall,
1999; Hughes et al., 1997), which might help to explain the reduced size of the H-
Ras G12V transfected cell. Although the R-Ras G38V transfected cells had fewer
stress fibres than the control cell, they maintained a well spread morphology and
there was no obvious thickening of cortical actin. This would suggest that unlike H-
Ras G12V, R-Ras G38V does not have the ability to transform CHO cells.
Upon adhesion, CHO cell adhesion receptors cluster into highly organised cellular
structures named focal contacts that link the extracellular matrix to actin
microfilaments and a number of cytoskeleton proteins such as talin, vinculin and a-
actinin (reviewed by Turner and Burridge, 1991). Complete spreading is achieved by
dynamic peripheral adhesion plaques (focal adhesions) in equilibrium with a pool of
free adhesion receptors (such as the c6(31 integrin) subjected to the endocytic cycle
(Tranquil et al., 1993). Since H-Ras G12V transfected cells remain adhered to the
coverslips, but have a loss of the polygonal shape of the control cells, suggests that
focal contacts are formed, however, disorganisation and subsequent disruption of the
focal adhesions leading to enhanced turnover of adhesions at the cell periphery,
results in a rounded morphology.
Focal adhesions are specialised signalling platforms on the cell surface that mediate
cell-matrix interactions via integrins, which are in turn associated with different
cytoskeletal proteins (Sastry and Burridge, 2000). Using vinculin as a marker,
confocal microscopy showed that R-Ras G38V localised with vinculin and increased
the number and size of peripheral focal adhesions (Figure 6.3C). A very recent
publication by Furuhjelm and Peranen, (2003) demonstrated, using EGFP-labelled R-
Raswt and EGFP-labelled R-RasG38V, that R-Ras is targeted to focal adhesions and
that this is dependent on R-Ras being in a GTP-bound state.
Transfection with H-Ras GUV results in an overall reduction in the number and size
of focal adhesions, resulting in the rounding up of the cell (Figure 6.3B). When H-
Ras GUV is expressed at relatively low levels and at early time points (2 hours),
Nobes and Hall, (1999) have clearly observed H-Ras concentrated at focal adhesion
sites using the anti-Ras antibody, Y13-238.
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The cytoskeletal protein, Talin-1, binds directly to integrins (Liu et al., 2000) and to
the actin cytoskeleton (Hemmings et al., 1996). Furuhjelm and Peranen, (2003)
showed that the /31-integrin, talin and paxillin localise at focal adhesions. Given that
activated R-Ras and H-Ras have been shown to localise to focal adhesions; and that
focal adhesions are regions where integrins (such as /31-integrin) can associate with
the cytoskeleton of cells (through such proteins as talin-1), it is possible that at, least
in adherent cells, focal adhesions provide the opportunity for H-Ras and R-Ras to be
in the vicinity of integrins where they may be involved with inside-out signalling.
As previously mentioned, disrupting lipid raft structures, by chemically depleting
plasma membrane cholesterol, selectively abrogates H-Ras- but not K-Ras-mediated
activation of Raf-1 in baby hamster kidney (BHK) cells (Roy et al., 1999).
Furuhjelm and Peranen (2003) have also demonstrated that depleting cholesterol
from serum-starved Hela cells expressing EGFP-R-Ras-38V resulted in the loss of
EGFP-R-Ras-38V from focal adhesions and a smooth redistribution to the plasma
membrane. Lipid rafts consist of dynamic assemblies of cholesterol and sphinolipids
(Simons and Toomre, 2000). Cholesterol associates with sphingolipids in the golgi
complex and serves to stabilise the lipid raft microdomains, therefore proteins with
raft affinity can become associated by way of lipid-lipid interactions (Ilangumaran
and Hoessli, 1998). Proteins with lipid raft affinity include
glycosylphosphatidylinositol (GPI)-anchored proteins, Src-family kinases, a-subunits
of heterotrimeric G proteins, cholesterol and palmitoylated proteins (Simons and
Toomre, 2000).
/3-cyclodextrins have been found to selectively extract cholesterol from the plasma
membrane, in preference to other membrane lipids (Ohtani et al., 1989), by
complexing with the cholesterol (Klein et al., 1995). Results shown in Figure 6.5
revealed that M/3CD treatment of o^3-py cells transfected with H-Ras G12V and R-
Ras G38V had no significant effect on their abilities to modulate integrin affinity
modulation.
Since M/3CD treatment of a/3-py cells transfected with R-Ras G38V did not affect the
ability of R-Ras to mediate integrin affinity modulation, but that similar M/3CD
treatment of Hela cells by Furuhjelm and Peranen, (2003) resulted in a loss of EGFP-
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R-Ras G38V from focal adhesions, suggests that R-Ras G38V does not mediate its
effect on integrin affinity from focal adhesions. It was interesting to note the
significant difference in the effects of R-Ras G38V-mediated, but not H-Ras G12V-
mediated, integrin affinity modulation following the addition of the inclusion
complexes. Since the incorporation of inclusion complexes had no effect on H-Ras
G12V, a toxic effect by the inclusion complexes can be ruled out. It may be possible
that the inclusion complexes are simply preventing integrin activation by R-Ras
G38V by some non-specific mechanism, such as steric hindrance.
Several hypothesises can be put forward to explain the lack of effect of M/3CD
treatment, of cq3-py cells transfected with H-Ras G12V and R-Ras G38V, on integrin
affinity modulation: First, Figure 6.4 clearly shows the disruption of membrane rafts,
following cholesterol depletion by M/3CD, in CHO-K1 cells plated onto coverslips
resulting in a loss of adhesion and a rounding up of the cells compared with control.
Ilangumaran and Hoessli (1998), also describe a rounding up of human umbilical
vein-derived endothelial cells (ECV304) following M/3CD treatment. A publication
by Ilangumaran and Hoessli, (1998) described the successful treatment of suspended
murine T-lymphocyte cells with M/3CD to remove plasma membrane cholesterol. It
was therefore assumed that M^CD treatment of suspended aj3-py cells would have
the same cholesterol-depleting effect as that observed with the attached CHO-K1
cells. However, if this is not the case, then this would explain the negligible effect
that M/3CD treatment has on integrin affinity modulation by H-Ras G12V and R-Ras
G38V.
Second, Leitinger and Hogg, (2002) have demonstrated using immunostaining and
adhesion studies that disruption of raft integrity through depletion of membrane
cholesterol with M/3CD completely disrupted a.4(3l cluster formation. As membrane
disruption, using a similar M/3CD treatment as described by Leitinger and Hogg
(2002), had little effect on the ability of H-Ras G12V and R-Ras G38V to modulate
integrin affinity; this may indicate that lipid rafts play an important role in
controlling integrin avidity and not integrin affinity.
Third, it has been demonstrated that GTP loading of H-Ras is sufficient to drive H-
Ras out of caveolae (Prior et al., 2001). Consistent with this, the cytoplasmic
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localisation of pEGFP-H-Ras WT and not pEGFP-H-Ras G12V, following M/3CD
treatment (see Figure 6.6) confirms that cholesterol depletion only affects the
localisation of the inactivated form of H-Ras and not the H-Ras G12V activated
mutant. Prior et al., (2003) further confirmed this using immunogold electron
microscopy, showing that activated H-Ras clusters in microdomains and that the
cluster patterns are not disrupted by cholesterol depletion. If R-Ras is located to
similar cholesterol-sensitive domains as H-Ras, but that a similar displacement is
observed with GTP-loaded R-Ras G38V, then treatment to disrupt the cholesterol
rich domains of the membrane should not have an effect on GTP-bound H-Ras
G12V- and R-Ras G38V-mediated integrin affinity modulation.
Several other methods could also be employed to investigate the
compartmentalisation of Ras proteins. Electron microscopy following immunogold
labelling of GFP-tagged proteins or fractionating the membranes over sucrose
gradients and analysing by immunoblotting (Prior and Hancock, 2001; Prior et al.,
(2001). Also, filipin could be used in place ofM/3CD for disrupting the lipid rafts.
It was hoped that by using PCR techniques R-Ras WT and G38V could be cloned
into a dsRed-expressing construct allowing us to visualise their distributions in live
cells and compare them to the GFP-tagged H-Ras constructs (Figure 6.6). However,
due to the high GC content of the N-terminus of R-Ras, it was very difficult to
sequence the resulting PCR products. After several failed attempts to sequence PCR
products, time constraints prevented further investigations using this method.
Stable lines expressing R-Ras G38V and the H-and R-Ras chimeras (schematic
representation shown in Chapter 4, Figure 4.1) were produced in CHO-K1 cells in
order to elucidate which areas ofH-Ras and R-Ras were important in conferring their
different effects on cellular morphology.
Although H-Ras G12V was successfully expressed in a transient system, repeated
attempts to produce an H-Ras G12V stable line in CHO-K1 cells proved futile.
Despite G418 selection, none of the prospective clones expressed H-Ras G12V. We
suspect that perhaps the CHO-K1 cells became spontaneously G418 resistant,
explaining why they were capable of growing in the selection media without plasmid
expression.
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Previous studies have shown H-Ras stables lines to be successfully produced in NIH
3T3 cells (Hansen et al., 2002; Kawano et al., 2000). However, Kawano et al.,
(2000) used an H-Ras G12V gene that was under the control of an IPTG-inducible
promoter and therefore the transient expression of the H-Ras G12V gene could be
regulated. Hansen et al., (2002) used an H-Ras with mutations G12R and A59T,
which may have contributed to its ability to be expressed in a stable system. H-Ras
has been shown to have a lethal effect on cells. Expression of H-Ras (wt) or H-Ras
G12V in a neuroblastoma cell line caused the cells to round up and fragment
(Kitanaka et al., 2002). This H-Ras-mediated cell death is a process distinct from
apoptosis, since it was not prevented by the overexpression of the anti-apoptotic
protein Bcl2 or by the addition of caspase inhibitors (Kitanaka et al., 2002). Other
results from this group showed that the H-Ras G12V/D38N mutant failed to induce
cell death (Kitanaka et al., 2002). The H-Ras D38N mutation abolishes Raf-1
binding, which suggests that the H-Ras-mediated cell death requires Raf-1 activation.
This may help to explain why it was possible to produce a stable line expressing
H201 (which comprises 88% H-Ras, residues 1-174). This chimera was not as
effective as H-Ras G12V at activating Raf and so, unlike the overexpression of H-
Ras G12V, H201 overexpression may not induce cell death.
Although it would have been ideal to have both H-Ras G12V and R-Ras G38V stable
lines to use as controls for comparing differences in phenotypes, it was decided that
the cells transiently transfected with H-Ras G12V and R-Ras G38V (see Figures
6.2B and 6.2C) would serve as comparisons for actin cytoskeleton structure. The
H201 stable line was used in place of an H-Ras G12V stable in comparing the
electron microscopy images as it had a similar transforming effect on CHO-K1
cellular morphology to transiently transfected H-Ras G12V (see Figures 6.1 ID and
6.2B respectively).
Comparing the actin cytoskeleton structures and electron-microscopy images of the
chimeric stables has indicated the importance of the hypervariable N-terminal linker
region of H-Ras for conferring activated H-Ras transforming effect on cells. This
conclusion was drawn from two observations; first, that the CHI stables, comprising
H-Ras sequences C-terminal of Gly60, (R-Ras 85; H-Ras 60-198), was sufficient to
convey a transformed phenotype (Figures 6.12A, 6.14A and 6.14B). Second, that the
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H197 stable, that contains H-Ras residues N-terminal of Leu171 (H-Ras 171; R-Ras
199-219) was able to confer a transformed phenotype (Figures 6.11C, 6.13E and
6.13F). Results also suggest that H-Ras sequences N-terminal of the H-Ras HVR
linker domain are necessary to confer a transformed phenotype. This conclusion was
drawn from the observation that while expression of CHI (comprising H-Ras
sequences C-terminal of Gly60), was sufficient to confer a transformed phenotype,
expression of CH5 (comprising H-Ras sequences C-terminal of Lys149) was not
sufficient to confer a transformed phenotype (Figures 6.12B, 6.14C and 6.14D). The
sequence divergence between CHI and CH5 overlaps with the Switch II region (H-
Ras residues 60 to 149). Upon activation, the exchange of GDP for GTP drives an
allosteric change in the Switch I and Switch II regions (Boriack-Sjodin et al., 1998).
This conformational change allows the Switch I region to bind effectors (Ehrhardt et
al., 2002). It may be that the presence of the R-Ras Switch II region in chimera CH5,
in place of the H-Ras Switch II region, may alter the GTP-bound conformation and
impair the ability of this protein to interact efficiently with the H-Ras effectors
required for a fully-transformed phenotype.
The 28-amino-acid stretch of R-Ras, which includes the R-Ras hypervariable region,
comprising residues 175-203, is sufficient to confer an R-Ras G38V-like phenotype
to CHO-K1 cells. This conclusion was drawn from the following observations; first,
the CH6 stables, comprising R-Ras sequences C-terminal of Leu175, (H-Ras 146; R-
Ras 175-219), was sufficient to confer an R-Ras G38V-like phenotype to CHO-K1
cells (Figures 6.1 IB, 6.13C and 6.13D). Second, that R201 stables, that contain R-
Ras residues N-terminal of Pro203 (R-Ras 203; H-Ras 175-189) convey an R-Ras-like
phenotype (Figures 6.12D, 6.14E and 6.14H).
Of particular interest are the differences in morphology seen with chimera stables
R197 and R201. While expression of R201 confers an R-Ras like phenotype, cells
expressing R197 exhibit some properties indicative of a transformed phenotype
(Figures 6.12 and 6.14) i.e. a slight rounded morphology. These chimeras comprise
N-terminal R-Ras sequences, differing in only five R-Ras amino acids at the C-
terminal end of the R-Ras hypervariable region. These five amino acids comprise the
proline-rich domain of R-Ras, which has previously been shown to have influence
over the ability of R-Ras G38V to modulate integrin affinity (see Chapter 4). Here,
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the presence of the proline-rich domain ofR-Ras seems necessary to fully bestow the
well spread, 'fried egg', phenotype of R-Ras G38V. However, the transformed
phenotype of H197 (H-Ras 171; R-Ras 199-219) (Figures 6.11C, 6.13E and 6.13F)
implies that the presence of R-Ras C-terminal sequences alone, including the
proline-rich domain, are not wholly sufficient to confer an R-Ras G38V phenotype
and that R-Ras C-terminal sequences 175-199, the residues of divergence between
CH6 stable (which have an R-Ras like phenotype) and HI97 stables (which have a
transformed phenotype), are also important in determining phenotype.
In Chapter 4, the hypervariable regions of H-Ras and R-Ras have already been
shown to be of importance in modulating integrin affinity. In this chapter, it has been
shown that the hypervariable domains are also important in the transforming abilities
of H-Ras and R-Ras. The importance of the hypervariable domains has also been
confirmed by Prior et al. (2001), who showed that the removal of the hypervariable
domain of H-Ras (HAhvrG12V) abrogates the GTP-dependent redistribution of H-
Ras from rafts to the bulk plasma membrane thus preventing Raf activation. Also, the
recent publication by Furuhjelm and Peranen, (2003) demonstrated that when the
hypervariable region of R-Ras (amino acids 175-218) was replaced with the
corresponding region (amino acids 147-189) of H-Ras, the targeting of R-Ras to
focal adhesions was inhibited. Furthermore, when the hypervariable region of H-Ras
(amino acids 147-189) was replaced by the corresponding region (amino acids 175-
218) of R-Ras, the H-Ras molecule was targeted to focal adhesions (Furuhjelm and
Peranen, 2003). Hancock (2003) postulates that the hypervariable region might
interact with other plasma-membrane proteins to regulate the later segregation ofH-
Ras and that galectin-1 was a possible candidate. Galectin-1 interacts with H-Ras
GTP (Paz et al., 2001). Down-regulation of galectin-1 expression abolishes H-Ras
G12V clustering at the plasma membrane, resulting in partial mislocalisation of H-
Ras G12V to the cytosol (Paz et al., 2001; Prior et al., 2003).
6.6.1 Summary
Both H-Ras G12V and R-Ras G38V are targeted to similar domains within the
plasma membrane. Integrin affinity modulation by these proteins is not affected by
the depletion of plasma membrane cholesterol, which suggests that they do not
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influence integrin affinity from cholesterol-sensitive microdomains such as the lipid
rafts and focal adhesions.
Confocal microscopy has shown that transient transfection of CHO-K1 cells with H-
Ras G12V results in a transformed phenotype. In contrast, R-Ras G38V expression
does not transform CHO-K1 cells.
Results in Chapter 4 revealed that a 25-amino acid stretch ofH-Ras (Arg140 to Pro174)
is required for integrin suppression. Results from this chapter suggest that a 111-
amino stretch of H-Ras (Gly60 to Leu171) is required for conferring a transformed
phenotype. This area overlaps with the 25-amino acid stretch required for integrin
affinity modulation, but includes the Switch II region of H-Ras (Gly60 to Gly75),
which may be important for efficient effector binding.
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Results from Chapter 4 revealed that a 28-amino acid stretch of R-Ras (Leu to
Pro203) is sufficient to reverse H-Ras mediated integrin suppression. Results from this
chapter show that the same 28-amino acid stretch is sufficient to confer an R-Ras-
like phenotype. Interestingly, the presence of the proline-rich domain of R-Ras
(residues 198 to 203) seems to be required for conferring the full R-Ras phenotype,
since expression of R201 confers a full R-Ras-like phenotype while expression of
R197 does not. This region has also been shown to be important for modulating
integrin affinity (chapter 4).
Since the presence of H-Ras amino acids Leu171 to Pro174 are not required for a
transformed phenotype but that the equivalent proline-rich amino acids of R-Ras
198 203
(Pro to Pro ) are required for a full R-Ras phenotype, suggests an important role
for these amino acids in R-Ras signalling.
Stable or prolonged transient expression ofH-Ras G12V in CHO-K1 cells may result
in H-Ras-mediated cell death. This process may be dependent on full activation of
Raf-1, since stable lines expressing the H201 chimera (which activated Raf-1 to a
lesser extent than H-Ras G12V) are viable.
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Chapter 7
Functional characterisation of H-Ras and R-Ras
7.1 Introduction
In Chapter 6, results showed that transfection of CHO cells with R-Ras G38V
increased cell spreading and focal adhesion formation. In contrast, H-Ras G12V
expression resulted in a rounding up of CHO cells, which correlated with a decrease
in focal adhesion formation and disruption of the actin cytoskeleton. The regulation
of cell migration and adhesion are central to many normal and pathological processes
including wound healing, inflammation and tumor metastasis. Regulation is
dependent upon rapid, controlled alterations in integrin affinity for their extracellular
ligands (Huttenlocher et al., 1996).
In vitro and in vivo growth properties that distinguish transformed cells from normal
counterparts include alterations in cellular morphology, decreased dependence on
serum growth factors, loss of cell-cell contact growth inhibition, the ability to
proliferate in suspension or semi-solid growth medium and the ability to form
tumours when introduced into the appropriate host (Freedman and Shin, 1974;
Stanbridge and Wilkinson, 1978).
The ease of transfection and sensitivity to transformation of rodent fibroblastic cell
lines make them the system of choice for analysing the alterations in cell phenotype
induced by oncogenic expression (Clark et al., 1995). In vitro, fibroblastic-like CHO
cells grow as an adherent monolayer. Following transformation by cytoplasmic
oncogenes such as Ras or Src, cell detachment induced apoptosis does not occur and
is accompanied by the ability to grown in suspension (Frisch and Francis, 1994).
The aims of this chapter are as follows: First, to compare the effects of integrin
affinity modulation by H-Ras G12V and R-Ras G38V expression on the adhesion
and migration properties ofCHO cells using the a/3-py cells to relate integrin-affinity
state to cell adhesion and migration. Second, using CHO cells stably expressing H-
and R-Ras chimeras, determine if specific regions of H-Ras and R-Ras are required
for their effects on cell adhesion and migration. Thirdly, using the H-and R-Ras
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chimera stable lines, determine which specific sequences of H-Ras G12V are
required to convey transformation of CHO cells, as characterised by enhanced
proliferation and anchorage-independent growth and to determine if integrin-affmity
modulation by H-Ras and R-Ras bears any relation to their transforming abilities.
7.2 Effects of integrin affinity modulation on cell adhesion
and migration.
It has previously been reported that H-Ras G12V suppresses integrin affinity while
R-Ras G38V promotes an activated state of integrin. As integrins mediate cell
adhesion (Hynes, 1987; Hynes, 1992), it was decided to investigate if expression of
H-Ras G12V or R-Ras G38V affects cellular adhesion and migration in CHO cells.
Furthermore, examination of adhesion and migration of CHO cells stably expressing
H-and R-Ras chimeras may help to determine if the specific domains of H-Ras and
R-Ras required for integrin affinity modulation (see Chapter 4) also affect cellular
adhesion and migration. In each of the following experiments, cells transfected with
pCDNA3.1(+) serve as control cells.
7.2.1 Transient expression of H-Ras G12V reduces cell adhesion.
The presence of the stably expressed aUbOt(,Ap3p\ chimeric integrin on a(3-py cells
allows for these cells to be used in an adhesion assay to assess the abilities of H-Ras
G12V and R-RasG38V, to regulate cell adhesion to the natural anbfo ligand,
fibrinogen. As this was an assay based on transient expression ofDNA and not stable
expression, it was deemed necessary to co-transfect test DNA with a GFP-expressing
vector to serve as a co-reporter for transfection, allowing only those cells expressing
GFP to be assessed. Also, expression of GFP permitted the use of a fluorescent plate
reader to evaluate cell adhesion, which proved to be a much more efficient method
than traditional staining methods.
Adhesion was compared between cells plated onto untreated wells and cells plated
onto wells that had been pre-coated with lOpg/ml fibrinogen, following incubation at
37°C for 15 minutes. Figure 7.1 shows that there is only minor adhesion observed in
cells plated on untreated (plastic) wells compared with samples plated onto the
fibrinogen-coated wells. There were no significant changes in adhesion observed
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between cells plated onto plastic. When plated onto fibrinogen, H-Ras G12V
transfected cells showed a significant decrease (PO.Ol) in the levels of adhesion
when compared with control cells. R-Ras G38V transfection had no significant effect
on levels of adhesion when compared with control however, levels of adhesion were
significantly increased (PO.OOl) when compared with H-Ras G12V transfected
cells.
7.2.2 Stable expression of H- and R-Ras chimeras does not affect cell adhesion
Cell adhesion was assessed in CHO-K1 cells stably expressing control vector, R-Ras
G38V and the H-and R-Ras chimeras. Stable protein expression eliminated the need
to transfect cells with GFP-expressing construct to act as a reporter of transfection.
Fibronectin was used to coat the wells, as CHO-K1 cells do not naturally express the
aiib/33 integrin. Cells were plated onto untreated wells (plastic) and onto wells pre-
coated with 20pg/ml fibronectin and adhesion compared following incubation at
37°C for 15 minutes. Figure 7.2 shows no significant difference between levels of
adhesion between stable lines plated onto fibronectin, compared with control.
The average percentage adhesion of control cells for each experiment, i.e. percentage
of total cell count, was about 60% (data not shown). Therefore, the lack of significant
difference between the stable cell lines and the control cells was not as a result of
maximum adhesion of control cells (i.e. 100% of total cell count) following
incubation at 37°C for 15 minutes on 20pg/ml fibronectin.
There were no significant changes in adhesion observed between stables plated onto
plastic (data not shown).
223







Figure 7.1 H-Ras G12V reduces cell adhesion.
Cell adhesion was determined in afi-py cells co-transfected with control vector
(3pg), H-Ras G12V (3pg) or R-Ras G38V (3pg) and a GFP reporter construct
(1.5pg). Cell adhesion was carried out for 15 minutes at 37°C on wells left uncoated
(plastic) or coated with lOpg/ml fibrinogen. Fold increase was calculated where
control cells on fibrinogen = 1. Values represent mean ± SEM of 3 experiments.
Statistical analysis was performed by one-way ANOVA test within each individual
condition. ** = significant difference, PO.Ol, compared with pCDNA3.1(+).
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Figure 7.2 H- and R-Ras chimera stable lines have no significant effect on cell
adhesion.
Cell adhesion was determined in CHO-K1 cells stably expressing H-and R-Ras
chimeras. Cell adhesion was carried out for 15 minutes at 37°C on wells coated with
20pg/ml fibronectin. Cell adhesion was assessed by colorimetric detection. Fold
increase was calculated where control cells on fibronectin = 1. Values represent
mean ± SEM of 3-5 experiments
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7.2.3 Transient expression of R-Ras G38V reduces cell migration
The abilities of transiently expressed H-Ras G12V and R-Ras G38V to regulate cell
migration in c^S-py cells, to the natural platelet ligand fibrinogen, was determined
using a Boyden chamber haptotactic assay (Keely et al., 1995; Keely et al., 1999) in
which transwells were coated on the underside with lOpg/ml fibrinogen and
migration compared in the absence of serum. Cell migration was also determined
chemo-tactically, where transwells were left uncoated and migration compared in the
presence of 10% serum. Cells were transiently transfected with control vector, H-Ras
G12V and R-Ras G38V, together with GFP to serve as a reporter of transfected cells.
A fluorescent plate reader was used to evaluate cell migration of GFP-expressing
cells. Figure 7.3 shows that R-Ras G38V significantly inhibited cell migration in the
haptotactic assay (P<0.05) compared with control. The migration of cells expressing
R-Ras G38V was significantly reduced (P<0.01) in response to serum, compared
with H-Ras G12V expressing cells.
7.2.4 Stable expression of H- and R-Ras chimeras does not affect cell
migration
The ability of stably expressed chimeras to regulate the migration of CHO-K1 cells
on fibronectin was determined using a Boyden chamber haptotatic assay, in which
transwells were coated on the underside with 20pg/ml fibronectin. As with the stable
adhesion assays, stable protein expression eliminated the need to transfect cells with
a GFP-expressing reporter construct. Cells were plated onto chambers pre-coated
with 20pg/ml fibronectin and migration compared following incubation at 37°C for 4
hours. Figure 7.4 shows no significant difference between levels of adhesion between
stable lines plated onto fibronectin, in the absence of serum, compared with control.
Moreover, there were no significant changes in migration observed between stable
cell lines plated onto uncoated transwells migrating towards 10% serum conditions
(data not shown). The average percentage migration of control cells for each
experiment, i.e. percentage of total cell count, was about 55% (data not shown).
Therefore, the lack of significant difference between the stable cell lines and the
control cells was not as a result ofmaximum migration of control cells (i.e. 100% of
total cell count) following incubation at 37°C for 4 hours on 20pg/ml fibronectin.
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Control H-Ras R-Ras
Figure 7.3 Transient expression of R-Ras G38V reduces cell migration.
Cell migration was determined in cq3-py cells transfected with control vector (3pg),
H-Ras G12V (3pg) or R-Ras G38V (3pg) a GFP reporter construct (1.5pg). Cell
migration was carried out for 4 hours at 37°C on chambers left uncoated or coated
from the underside with lOpg/ml fibrinogen. Readings were taken using a
fluorescent plate reader. Fold increase was calculated where control cells on
fibrinogen = 1. Values represent mean ± SEM of 3 experiments. Statistical analysis
was performed by one-way ANOVA test, within each individual condition. * =
significant difference, P<0.05, compared with control.
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Figure 7.4 H- and R-Ras chimera stable lines have no significant effect on cell
migration.
Cell migration was determined in CHO-K1 cells stably expressing H-and R-Ras
chimeras. Cell migration was carried out on chambers coated from the underside
with 20pg/ml fibronectin and left to migrate towards DMEM (without serum) for 4
hours at 37°C. Cell migration was assessed by colorimetric detection Fold increase
was calculated where control cells on fibronectin = 1. Values represent mean ± SEM
of 3-5 experiments.
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7.2.5 Wound assay analysis of cell migration.
To investigate the role of H-Ras and R-Ras in CHO-K1 cell motility, cell motility
was assessed by the wound assay method. Following wounding, cells were
maintained in a serum-free growth media to reduce levels of cell proliferation. Thus,
any movement into the wound space should be a consequence of cellular migration
and not cell growth. Identical wound areas were assessed at 0, 24 and 48 hour time
points (see Figures 7.5, 7.6 and 7.7), to help determine the extent of cell movement
into the wound. The original wound width, at 0 hours, has been marked onto the each
of the subsequent time point images to allow for easier interpretation. Figure 7.5
shows the migration of control vector and R-Ras G38V stable lines. By 24 hours,
control cells at the wound edge have become less rounded and have started to
respread and extend into the open space. By 48 hours, cells have developed an
elongated morphology and there are areas where the wound has almost closed. In
contrast, R-Ras G38V stables show negligible movement into the wound. The wound
edges are well defined throughout the assay and cells remain tightly packed and
maintain a polygonal morphology.
Figure 7.6 shows the cell migration of H-Ras G12V N-terminal stable line chimeras.
Compared with the control cells (Figure 7.5), CH3 and H201 stables show negligible
movement into the wound space throughout the 48 hour assay, maintaining well
defined wound edges similar to that observed with the R-Ras G38V stables (Figure
7.5). In contrast, the CH6 and HI97 stables show cells extending into the open space
of the wound at 48 hours. The CH6 stable cells have taken on a more noticeably
elongated, spindle-shaped morphology than observed with control cells. While the
HI97 cells have migrated into the wound space, have a less spindle shape and more
polarised morphology than the control cells. Interestingly, both the CH6 and HI97
stables have developed areas of cell aggregation surrounding the wound area. The
areas immediately surrounding the cell aggregates are clear of cells, suggesting
migration/aggregation of cells from the original monolayer rather than cell
proliferation. CH6 stables have formed very large cell aggregates, which seemed to
merge into each other. In contrast, the HI97 stable line had much smaller, clearly
defined aggregates.
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Figure 7.7 shows the migration of R-Ras G38V N-terminal stable lines. Compared
with control cells (Figure 7.5), R197 and R201 stables show negligible movement
into the wound space throughout the 48-hour assay. As with the R-Ras G38V stables,
(Figure 7.5) the wound edges remain clearly defined and the cells maintain a normal
morphology. As with the control cells, CHI and CH5 stables show movement into
the wound space at both 24 and 48-hour time points. CHI stable cells have a spindle-
shaped morphology similar to that observed with the control cells and by 24 hours
they have developed areas of cell aggregation within the cellular monolayer, similar
to CH6 and HI97. In contrast, CH5 stable cells maintained a very flat, polarised
morphology with extensions localised only at the leading edges of the cells.
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Figure 7.5 Wound assays of control and R-Ras G38V stable lines
Plates were seeded with stable cell lines expressing control vector and R-Ras G38V.
Cell monolayers were wounded and images were taken at 0, 24 and 48 hour time
points. Original wound width, at 0 hours, has been marked on all subsequent images.
Images are representative of 4 individual experiments.
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Figure 7.6 Wound assays of H-Ras G12V N-terminal chimeric stable lines
Plates were seeded with stable cell lines expressing H-and R-Ras chimeras CH3,
CH6, H197 and H201. Cell monolayers were wounded and cell images were taken at
0, 24 and 48 hour time points. Original wound width, at 0 hours, has been marked on
all subsequent images. Images are representative of 4 individual experiments.
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Figure 7.7 Wound assays of R-Ras G38V N-terminal chimeric stable lines
Plates were seeded with stable cell lines expressing H-and R-Ras chimeras CHI,
CH5, R197 and R201.Cell monolayers were wounded and cell images were taken at
0, 24 and 48 hour time points. Original wound width, at 0 hours, has been marked on
all subsequent images. Images are representative of 4 individual experiments.
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7.3 Analysis of anchorage-independent growth potential
An excellent in vitro indicator of the ability of a gene to provoke malignant
turmorigenicity is an ability to promote growth in an anchorage-independent
environment (Der et al., 1988; Clark et al., 1995). Untransformed CHO-K1 cells
need to adhere to a solid substratum in order to grow whereas Ras-transformed cells
lose this requirement and readily proliferate in suspension in liquid culture or when
suspended in semisolid medium (Stanbridge and Wilkinson, 1978). Growth in soft
agar is the most commonly used assay for Ras-transformed cells, this assay currently
represents the best in vitro correlate to in vivo growth potential (Clark et al., 1995).
7.3.1 Transient expression of H-Ras G12V confers anchorage independent
growth in CHO-K1 cells.
The abilities of H-Ras G12V and R-Ras G38V to induce colony formation were
compared. As attempts to produce an H-Ras G12V stable line were unsuccessful (see
Chapter 6), it was necessary to use transient colony assays. As expression of H-Ras
G12V and R-Ras G38V was only transient, colony counts were taken on Days 1 and
2 post-seeding. Assays were set up using untransfected CHO-K1 cells and cells
transiently transfected with control vector, H-Ras G12V and R-Ras G38V. Colonies
of three or more cells were counted and represented as cloning efficiency.
Figure 7.8A compares Day 2 colony formation in 1% serum. The data shows that
there was no significant difference in the cloning efficiency of untransfected cells
(2.52 ± 0.73%), cells transfected with control vector (3.38 ± 0.18%) and R-Ras
G38V (1.96 ± 0.47%). The cloning efficiency of H-Ras G12V transfected cells (6.18
± 0.35%) was significantly increased (P<0.01), compared with control vector cells.
There was a highly significant difference in the cloning efficiencies of cells
transfected with H-Ras G12V and R-Ras G38V (PO.OOl). A similar trend in cloning
efficiencies was observed when colony assays were performed in the presence of 5%
serum. Figure 7.8B shows that H-Ras G12V transfected cells (6.76 ± 0.47%)
significantly increased cloning efficiency compared with control cells (P<0.001). The
data also showed that there was a significant difference in the cloning efficiencies of
cells transfected with H-Ras G12V and R-Ras G38V (P<0.01).
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7.3.2 Stable expression of H201 confers anchorage-independent growth in
CHO-K1 cells.
Percentage cloning efficiencies were compared between CHO-K1 cells stably
expressing control vector and H-and R-Ras chimeras. Colonies were counted where
they consisted of three or more cells and represented as cloning efficiency. In order
to extend the colony assays to Day 6, cells were maintained in 5% serum conditions.
Figure 7.9 shows the cloning efficiencies of stable lines on Day 4, which was shown
to be the optimal day for comparing cloning efficiencies.
R-Ras G38V stables have a reduced cloning efficiency (2.86 ± 0.8%) compared with
control stables (8.21 ± 2.8%). CH3 (2.76 ± 0.74%), CH6 (2.56 ± .78%), H197 (3.73
± 0.88%) and R201 (2.31 ± 0.8%) stable lines also demonstrate a reduced cloning
efficiency compared with control cells.
CHI (7.81 ± 3.4%) and CH5 (6.67 ± 1.25%) stable lines show levels of cloning
efficiency similar to control stables while stable expression ofH201 (20.54 ± 6.31%)
significantly increased the cloning efficiency of cells (P<0.01). The data also shows
that there was a significant difference in the cloning efficiencies of cells stably
expressing H201 andR201 (P<0.01).
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Figure 7.8 Transient expression of H-Ras G12V confers anchorage-independent
growth.
Colony formation was determined in CHO-K1 cells transfected with pCDNA3.1(+)
(3pg), H-Ras G12V (3pg), R-Ras G38V(3pg) or left untransfected (control). Cells
were plated out in triplicate in either 1% serum conditions (A) or 5% serum
conditions (B), and incubated at 37°C. Colonies were counted on day 2 and
percentage cloning efficiency was calculated for each of the samples.
Values represent mean ± SEM of 3 experiments. Statistical analysis was performed,
** and *** denoting PO.Ol and PO.OOl respectively, compared with pCDNA3.1.
The significant difference between H-Ras and R-Ras are shown by ## and ###
denoting P<0.01 and PO.OOl respectively.
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Figure 7.9 Stable expression of H201 confers anchorage-independent growth.
Colony formation was determined in CHO-K1 cells stably expressing H-and R-Ras
chimeras. Cells were plated out in triplicate in 5% serum conditions, and incubated at
37°C. Colonies were counted on day 4 and percentage cloning efficiency was
calculated for each of the samples.
Values represent mean ± SEM of 5 experiments. Statistical analysis was performed,
**
- P<0.01 compared with pCDNA3.1. The significant difference between H201
and R201 is shown by ## denoting PO.Ol.
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7.3.3 Activation and inhibition of /3-1 integrin has a significant effect on
anchorage-independent growth
The H201 and R201 stable lines show H-Ras and R-Ras-like effects on cloning
efficiency respectively (Figure 7.9). Previous results have shown that H201 and
R201 transient expression in o^S-py cells modulated integrin affinity similarly to H-
Ras G12V and R-Ras G38V respectively. In an effort to determine whether
anchorage-independent growth was influenced by integrin activation state, it was
decided to investigate the abilities of H201 and R201 stables to form colonies
following treatment with /3-1 integrin activating (TS2-16) and blocking (4B4)
antibodies. As controls, stables were left untreated or treated with IgGi isotype
antibody.
Figure 7.10 shows the percentage cloning efficiencies for H201 (black bars) and
R201 (grey bars) from day 6, which was shown to be the optimal day for comparing
cloning efficiencies following antibody treatment. H201 stables treated with the j8-l
integrin activating integrin, TS2-16, significantly decreased cloning efficiency
compared with untreated control (from 22.71 ± 5.21% to 4.9 ± 2.18%) (P<0.05). In
contrast, H201 stables showed no significant difference in percentage cloning
efficiency between untreated (22.71 ± 5.21%), isotype control (25.83 ± 8.4%) and
4B4 treated (30.61 ± 7.59%) cells.
With the R201 stables, treatment with the /3-1 integrin blocking antibody, 4B4,
significantly increased cloning efficiency compared with untreated control (from
5.26 ± 1.46% to 26.03 ± 6.13%) (P<0.05). There was no significant difference in
percentage cloning efficiency between untreated (5.26 ± 1.46%), isotype control (4.8
± 2.03%) and TS2-16 treated (5.74 ± 1.78%) cells.
We were concerned by the possibility of the sodium azide (NaNs) concent in the
IgGl isotype and 4B4-inhibiting antibody solutions affecting the results. To test this
hypothesis, a control colony assay was performed in the presence of NaN3. Figure
7.11 shows that addition of 15pM NaN3 to H201 and R201 stables did not affect the
colony forming abilities ofH201 and R201 stable lines.
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Figure 7.10 Anti /31-integrin antibodies affect colony formation by H201 and
R201 stable lines.
Colony formation was determined in CHO-K1 cells stably expressing H201and R201
chimeras. Cells were plated out in triplicate in DMEM containing 5% serum and
were left untreated (control) or treated with the addition of IgGi isotype, 4B4 or TS2-
16 antibodies at lOpg/ml, and incubated at 37°C. Antibodies were added to the 0.3%
agarose layer. Colonies were counted on day 6 and percentage cloning efficiency was
calculated for each of the samples. Values represent mean ± SEM of 4 experiments.
Statistical analysis was performed, * = P<0.05, compared with control sample within
each individual stable line.
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Figure 7.11 The NaN3 content of antibody solutions does not affect colony
formation by H201 and R201 stable lines.
Colony formation was determined in CHO-K1 cells stably expressing H201and R201
chimeras in DMEMB containing 5% serum ± 15pM NaN3, and incubated at 37°C.
Colonies were counted on days 2, 4 and 6. Percentage cloning efficiency was
calculated for each of the samples.
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7.4 Comparison of stable proliferation rates
Previous studies have demonstrated that transformed adherent cell types have the
ability to proliferate in suspension. It was decided to compare the proliferation rates
of control, R-Ras G38V and H-and R-Ras chimeric stable lines. Proliferation rates
were assessed in conditions where cells were allowed to adhere.
7.4.1 Growth curves for stable lines
To assess the normal growth curves of the control, R-Ras G38V and H-and R-Ras
stable lines, cells were seeded at 2xl04 cells per 10cm plate and ten plates were
seeded for each stable line for each experiment.
Figure 7.12 shows the growth curves for control, R-Ras G38V and H-Ras N-terminal
stables. Like the R-Ras G38V stable, CH3 and CH6 stables grow at a consistent, but
slightly slower rate to control stables. The HI97 stables reach a peak at Day 8
(4.16xl06 ± 2.26x105 cells) and then cell number begins to decrease. From Day 6,
the H201 stables proliferate at a higher rate than the control cells, reaching a density
of 5.3xl06 ± 5.21x10s cells by day 10 compared with 4.78xl06 ± 1.06xl05 for
control cells.
Figure 7.13 shows the growth curves for control, R-Ras G38V and R-Ras N-terminal
stables. Like the R-Ras G38V stables, CH5 and R201 stables grow at a consistent,
but slightly slower rate to control cells. The R197 stables reach a peak at day 8
(3.19xl06 ± 2.84xl05) and then cell number begins to decrease. From day 8, the CHI
stables begin to proliferate at a higher rate than control cells, reaching a density of
5.5xl06 ± 1.4xl05 cells by day 10 compared with 4.78xl06 ± 1.06xl05 for control
cells.
Statistical analysis showed that only the saturation densities (day 10 data) of the
HI97 and R197 stable lines were significantly lower than control, P<0.01 and
P<0.05 respectively.
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Figure 7.12 Growth curves of H-Ras G12V N-terminal stable lines
Proliferation was determined in CHO-K1 cells stably expressing H-and R-Ras
chimeras. Cell number for each stable line was determined using a coulter counter on
ten consecutive days. Values represent mean ± SEM of 3-6 experiments. Statistical
analysis was performed on day 10 saturation densities , ** = P<0.01, compared with
control sample.







Figure 7.13 Growth curves of R-Ras G38V N-terminal stable lines
Proliferation was determined in CHO-K1 cells stably expressing H-and R-Ras
chimeras. Cell number for each stable line was determined using a coulter counter on
ten consecutive days. Values represent mean ± SEM of 3-6 experiments. Statistical
analysis was performed on day 10 saturation densities, * = P<0.05, compared with
control sample.
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7.5 Discussion
In this chapter, the effects of H-Ras and R-Ras on cell motility and transformation
have been investigated. Studies have been carried out using CHO-K1 cells stably
expressing H- and R-Ras chimeras, with the aim of mapping the regions of H-Ras
and R-Ras responsible for their effects on cell function. The major findings of this
chapter are as follows: Expression of full-length H-Ras G12V reduces cell adhesion.
Expression of full-length R-Ras G38V reduces chemotactic and haptotactic cell
migration, while expression of H-Ras G12V only reduces haptotactic migration. H-
Ras G12V sequences 60-174 are sufficient to increase proliferation rates of CHO
cells however H-Ras sequences 1-174 are required to promote a fully-transformed
phenotype, confirmed by anchorage-independent growth.
7.5.1 Cell motility
The initial attachment of many cell types to extracellular matrix proteins is a
prerequisite for many adhesion-dependent processes including cell migration,
survival and proliferation. A mathematical relationship between the extent of cell
adhesion and migration has been described by Palecek et al., (1997). These authors
determined that the rate of cell migration could be plotted as an approximate bell-
shaped curve against adhesion, whereby the extent of cell adhesion increases with
increasing substrate concentration, cell surface integrin expression or increased
integrin affinity. The adhesive state of the cell can potentially cause either an
increase or decrease in cell migration, depending on where one starts on the bell-
shaped curve (Holly et al., 2000).
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Integrins form a structural link between the extracellular matrix and the cell's
cytoskeletal and signal transduction apparatus (Berrier et al., 2000). Integrin affinity
modulation is thought to be the major mechanism for activating the adhesion ability
of the major platelet integrin Oiibft (Ginsberg., et al 1992). Integrin affinity
modulation and integrin avidity also stimulate adhesion mediated by leukocyte (32
subunit-containing integrins (Schwartz et al., 1995). Studies carried out using Q}S-py
cells represent a useful system for the interactions between integrins and substrate, as
CHO-K1 cells do not express an endogenous receptor for fibrinogen. This was
highlighted by Huttenlocher et al., (1996) who showed that the migration of aubft-
expressing CHO-K1 cells on a fibrinogen substrate was inhibited by a specific
fibrinogen receptor peptide, RO43-5054, and a function-blocking antibody specific
to the aiibfo receptor, 2G12. Using afi-py cells, transiently transfected with H-Ras
G12V and R-Ras G38V, revealed that H-Ras G12V resulted in a significant (P<0.01)
reduction in oj3-py cell adhesion to the otubfe ligand fibrinogen (Figure 7.1). The
levels of adhesion with control and R-Ras G38V transfected cells were about two
fold greater than observed with H-Ras G12V expressing cells (Figure 7.1). Zhang et
al., (1996) demonstrated that constitutively active R-Ras G38V could enhance the
adhesion of CH02b3a cells which express the full length 0^183 integrin, in a low
affinity state, (O'Toole et al., 1991; O'Toole et al., 1994) by enhancing the ligand
binding affinity of the anbft. That R-Ras G38V enhances adhesion in the CH02b3a
cells but confers levels of adhesion similar to control in the oj3-py cells can be
explained by the basal Oubft affinity state of the model cell systems, which is
constitutively low in the CH02b3a cells and constitutively high in the a/3-py cells. A
number of recent studies carried out to investigate the effects of integrin signalling
on the initial attachment and subsequent spreading of cells on substratum may help to
elucidate the reasons for the differences between H-Ras G12V and R-Ras G38V
mediated cell adhesion.
The reduced cell adhesion observed with the H-Ras G12V transfected c$-py cells to
fibrinogen may simply be explained by the suppression of the anbft integrin (shown
in Chapters 3 and 4). In its inactive conformation, this integrin has a reduced
capacity to bind to its ligand, fibrinogen. Conversely, R-Ras has no overall effect on
cell adhesion, compared to control cells. R-Ras promotes an activated integrin state
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and therefore expression of R-Ras in Q}3-py cells, expressing the constitutively active
anbOfeAftiSi chimera should not affect cell adhesion. For the cell adhesion assays, an
incubation time of 15 minutes was used as this was found to be the optimal time
point for observing differences between the transiently transfected cells. H-Ras
G12V transfected cells, left to adhere for longer time points showed levels of
adhesion comparable to control vector or R-Ras G38V transfected cells.
R-Ras has previously been implicated in the control of integrin-mediated adhesion,
converting the suspension-cell lines, mouse 32D and human myeloid cells, into
highly adherent cells (Zhang et al., 1996). Expression of R-Ras G38V also induces
the adhesion of bone-marrow-derived mast cells through activation of an3\ (Kinashi
et al., 2000). The Ras-like small GTPase, Rapl, has also been shown to be involved
in integrin-mediated cell adhesion (Bos et al., 2003; Caron, 2003). Katagiri et al.,
(2000) showed that, in Jurkat cells, the introduction of Rapl induces integrin aL/32
(LFAl)-mediated adhesion to ICAMS. Furthermore, in Jurkat cells, ligation of the
adhesion molecule CD31 induces activation of aL/32, which was inhibited by
blocking Rapl signalling (Reedquist et al., 2000). The studies mentioned show, by
using the binding of a soluble ligand (Katagiri et al., 2000) or a conformation-
specific antibody (Reedquist et al., 2000; Katagiri et al., 2000) rather than mere
adhesion to substratum (which results from both inside-out and outside-in
signalling), that Rapl controls inside-out rather than outside-in signalling to integrins
in Jurkat cells. Although it remains to be established whether active R-Ras induces
cell adhesion through activation of Rapl, it has been shown that RapGAP expression
blocks R-Ras-induced effects in several cell types, which suggests that Rapl acts
downstream ofR-Ras (Self et al., 2001).
The fibronectin receptor (FnR) of CHO cells is the counterpart of the human VLA5
or a5/31 (Hemler, 1990). The a5f3\ expressed by adherent cells (such as CHO cells)
is intrinsically activated, and the maintenance of this activated state is dependent on
intracellular signalling (Faull et al., 1994). As previously mentioned, R-Ras can
induce the adhesion of bone-marrow-derived mast cells to fibronectin through
activation of c^/Si (Kinashi et al., 2000). In contrast, H-Ras G12V expression has
been shown to markedly reduce the levels of a (3\-dependent osteoblast adhesion to
fibronectin (FN) via signals mediated by the Raf-l/ERK pathway, as demonstrated
246
Functional characterisation of H-Ras and R-Ras
by the H-Ras G12V Y40C mutant (Tanaka et al., 2002). Despite the contrasting
effects of activated H-Ras and R-Ras on cellular adhesion mediated though a5(3\, no
significant changes in cell adhesion were observed with the H-and R-Ras CHO-K1
stable lines plated onto fibronectin (Figure 7.2). If H-Ras G12V expression reduces
the levels of adhesion in CHO cells via signals mediated by the Raf-l/ERK pathway,
like that observed with osteoblasts, then the insignificant levels of Raf-l/ERK
activation seen with expression of the chimeras in Chapter 4 (Figures 4.4, 4.5 and
4.6) may explain the negligible effects on CHO cell adhesion.
Integrins play an important role during cell migration by linking the extracellular
matrix and the actin cytoskeleton and by transmitting the forces required for
migration (Laufenburger and Horwitz, 1996). Cell migration plays a central role in
diverse processes including embryonic development, wound healing, inflammation
and tumour metastasis (Huttenlocher et al., 1998). Migration can be divided up into
four distinct phases: initial attachment, spreading, contraction and tail retraction
(Holly et al., 2000). Each phase of cell migration requires the regulation of integrin-
mediated ligand binding.
Since integrins play an important role in cell migration, the effects of H-Ras G12V-
and R-Ras G38V-mediated integrin affinity on cell motility were investigated. Using
cq3-py cells, transiently transfected with H-Ras G12V and R-Ras G38V, migration
assays revealed that expression of R-Ras G38V significantly inhibited both
chemotactic and haptotactic migration (P<0.05) (Figure 7.4). Huttenlocher et al.,
(1996) found that an inverse relationship between focal adhesion organisation and
cell migration rates existed, using CHO cells expressing an anbA9966P3 mutant
(which produced increased organisation of focal adhesions and actin microfilament
bundles). Dunlevy and Couchman, (1993) also showed that fibroblast migration rate
decreases as focal adhesion increases. In Chapter 6, (Figure 6.3) expression of R-Ras
G38V in CHO cells was shown to increase the size and number of focal adhesions.
Therefore, the reduced migration of R-Ras G38V transfected cells could be as a
result of increased focal adhesion assembly. The increase in focal adhesion assembly
may impede cell detachment from matrix, resulting in reduced migration rate. As H-
Ras G12V transfected cells showed reduced adhesion (Figure7.1) and a reduced
number of focal adhesions (Figure 6.3), it was hypothesised that they might show an
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increase in cell migration. Results revealed that levels of chemotactic migration
(towards serum) in H-Ras G12V transfected cells are slightly higher than those
observed with control cells, while levels of haptotactic migration are lower than with
control cells (Figure 7.3). That H-Ras G12V expression reduced haptotactic and not
chemotactic migration may be interpreted as follows: chemotactic migration may be
limited by the ability of the cell to release adhesions at the cell rear (tail retraction),
thus in H-Ras G12V expressing cells the increased rate of adhesive release at the rear
of the cell, caused by suppression of integrins, may promote the increase in
migration. However, haptotactic migration may be inhibited by an inability to form
adhesions at the cell front that are strong enough to mediate the migration through
the transwell membrane.
Haptotactic migration assays with R-Ras G38V and H-and R-Ras stable lines
demonstrated no significant difference between the stable lines compared with
control cells on a fibronectin matrix (Figure 7.4). In CHO cells, as(3\-mediated
activation of Racl and Cdc42 is maximal at intermediate fibronectin levels whereas
Rho activity continues to increase with increasing fibronectin levels (Cox et al.,
2001). Since Racl and Cdc42 promote, but RhoA inhibits membrane protrusions,
increased integrin-mediated activation of Rho halts migration in these cells (Cox et
al., 2001). Expression of chimeras CH3, CH6 and R201, which promote an activated
state of integrin, therefore increasing integrin-ligand binding, may inhibit migration
through increased activation of Rho. Studies with H-Ras G12V transiently
transfected cqS-py cells show an inhibition of haptotactic migration, which may be
due to an inability to efficiently form adhesions at the cell front to mediate migration.
By reducing ligand-integrin binding (suppressed integrins) in chimeras CHI, CH5
and H201, the decreased RhoA activity may result in the reduced degree of
haptotactic migration. Studies to investigate the levels of RhoA activity in the cells
expressing H-Ras G12V or R-Ras G38V would determine if RhoA activity is
affected by the expression of these proteins. Rho activity in these cells could be
investigated using the method described by Nobes and Hall, (1999) who determined
Rho activity in Swiss 3T3 fibroblasts by visualising the formation of stress fibres,
since Rho activity is required for both the formation and maintenance of actin stress
fibres and focal adhesions (Ridley and Hall, 1992; Hotchin and Hall, 1995).
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Other cell signalling pathways have also been implicated in control of cell migration.
Cellular transformation by H-Ras is associated with increased MAP kinase activity
and enhanced cell proliferation and migration in human breast epithelial cells
(Ochieng et al., 1991). A study by Klemke et al., (1997) provided evidence that
MAP kinase (ERK1 and ERK2) signalling can regulate cell migration by directly
impacting the migratory machinery. MAP kinase enhances the activity of myosin
light chain kinase (MLCK) leading to the phosphorylation and increased function of
myosin light chain (MLC) (Klemke et al., 1997). MLC promotes myosin ATPase
activity and polymerisation of actin, resulting in a fully functional actin-myosin
motor unit used to generate the contractile force required for cell motility (Klemke et
al., 1997).
Wound assays examine the cell's ability to migrate once contact-inhibition has been
removed. Where cells are in contact with each other, cadherins as well as integrin
receptors co-ordinately regulate cell migration (Huttenlocher et al., 1998). Cadherins
promote strong intercellular adhesions, and their expression is associated with
decreased tumor cell invasiveness and metastasis in vivo (Takeichi, 1993). Two
probable mechanisms for this inhibition are increased cell-cell adhesion and effects
on cell motility (Chen and Obrink, 1997; Chen et al., 1997). Wound assay studies by
Huttenlocher et al., (1998) which examined the effects of integrin-mediated
signalling on myoblast migration, revealed that enhanced integrin-mediated
signalling promotes contact-mediated inhibition of migration by N-cadherin and as a
result wound closure was inhibited. Huttenlocher et al., (1998) demonstrated that
enhanced adhesive signalling through ectopic 015 or /3] expression on myoblasts, led
to an upregulation ofN-cadherin expression and inhibition of cell migration through
enhanced cell-cell aggregation and cessation of motile activity. Integrin-mediated
signalling is required for the cessation of motile activity, as ectopic N-cadherin
expression alone does not result in contact-mediated suppression of motile activity
that is seen in ectopic a5-expressing myoblasts (Huttenlocher et al., 1998).
The characteristics of contact-mediated suppression of motile activity can be seen
with the CH3, CH6 and HI97 stables (Figure 7.6) where cells demonstrate
aggregation and delayed wound closure (compared with control cells, Figure 7.5).
Stable expression of R-Ras G38V and R201 (Figures 7.5 and 7.7 respectively) both
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show signs of inhibited wound closure however this was not accompanied by any
cell aggregation. An increase in the number of focal adhesions (promoting cell
spreading) and RhoA activation (which inhibits cell migration) by increased integrin-
mediated signalling may explain the complete cessation of migration by these cell
lines.
Transient expression of CHI, CH5 and H201 has previously been shown to mediate
integrin suppression (Chapter 4, Figure 4.2). The resulting decrease in integrin-
mediated signalling may therefore release the contact-mediated inhibition. In support
of this, CH5 and to a lesser extent CHI stable lines both initiate wound closure
(Figure 7.7). The CHI and CH5 cells do not display aggregated growth to the same
extent as CH6 and H197; this could be explained by a reduction of N-cadherin
regulation. Although H201 expression also suppresses integrins, there was a
complete cessation of cell motility observed in the forty-eight hour wound assay
(Figure 7.6). This could be explained by a reduced ability of integrins to form
adhesive contacts at the leading edge of the cells that are strong enough to mediate
the migration, thus disrupting the balance between cell adhesion and detachment
required for cell migration. The formation of focal adhesions and actin stress fibres
could be compared for each stable line during the wound assays by fixing the
wounds at specified time points, and then staining the cells with anti-vinculin
antibody (vinculin is a protein which is localised to focal adhesions) or rhodamine-
conjugated phallodin (which binds to F-actin).
It is important to note that the effects of H-Ras G12V and R-Ras G38V expression
on cell motility are cell-type and integrin specific. We have found that expression of
activated R-Ras significantly inhibits cell migration of oj8-py cells on fibrinogen and
has no significant effect on CHO cell migration on fibronectin. However, R-Ras has
been shown to enhance migration in breast epithelial cells on collagen through the (X2
integrin cytoplasmic domain (Keely et al., 1999). Here, expression of H-Ras G12V
has been shown to reduce adhesion of a(3-py cells on fibrinogen, conversely H-Ras
has been shown to activate asj3\ in mast cells to stimulate adhesion on fibronectin
(Kinashi et al., 2000).
250
Functional characterisation of H-Ras and R-Ras
7.5.2 Cellular transformation
Many mammalian cell types are dependent on adhesion to the extracellular matrix
for their continued survival. Primary cells of epithelial (MDCK) and endothelial
(HUVEC) origin undergo rapid apoptosis when denied proper substrate adhesion in a
process called anoikis (Frisch and France, 1994). Transformed cells are frequently
characterised by their ability to grow in the absence of contacts with a solid
extracellular matrix (Stoker et al., 1968). As well as the ability to proliferate in
suspension, other properties commonly associated with the transformed phenotype
induced by most oncogenes include a loss of density-dependent growth, enhanced
growth rates and a reduction in the requirement for serum growth factors (Cox and
Der , 1994). Flere, the effects of H-Ras G12V, R-Ras G38V and H-and R-Ras
chimera expression on CHO cell transformation have been investigated using
anchorage-independent growth assays (colony assays) and proliferation assays.
Results from colony assays carried out with CHO cells show a significant increase in
percentage cloning efficiency with H-Ras G12V transfected cells in 1% serum and
5% serum conditions (P<0.01 and P<0.001 respectively) (Figure 7.8A and B).
Results suggested that transient transfection of H-Ras G12V in CHO-K1 cells
confers a transformed phenotype that is capable of anchorage-independent growth in
serum-deprived conditions. Transient transfection of CHO-K1 cells with R-Ras
G38V did not confer a transformed phenotype, percentage cloning efficiency was
significantly lower that that observed with H-Ras G12V transfected cells in both 1%
and 5% serum conditions (P<0.001 and P<0.01 respectively).
Anchorage-independent growth assays were carried out with the H-and R-Ras
chimera stable lines to try and elucidate if any specific regions of H-Ras G12V have
the ability to confer a transformed phenotype. The only stable line to display a
significant increase in percentage cloning efficiency was the H201 stable line (Figure
7.9). This suggests that H-Ras sequences 1-174, which include the effector binding
domains and C-terminal integrin-affinity modulating sequences, are required to
confer significant anchorage-independent growth. It was of interest to note that stable
lines that have an R-Ras like effect on the integrin affinity state i.e. CH3, CH6,
HI97, R197 and R201 (Chapter 4, Figure 4.2) demonstrated cloning efficiencies
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consistently less than control cells. The results suggest a relative trend between
integrin affinity state and cloning efficiency.
Alterations in integrins have been shown to play a role in the phenotype of
transformed cells. Studies on rodent cell lines have shown that the level of
expression of the a5j3i integrin (fibronectin receptor), is reduced in Ras-transformed
cells compared to normal cells (Plantefaber and Hynes, 1989), resulting in
anchorage-independent growth in agar and tumor formation in nude mice (Giancotti
and Ruoslahti, 1990) and that elevated levels of c^/Si can suppress the transformed
phenotype of CHO cells. Results here confirm the transforming abilities of H-Ras
G12V in CHO-K1 cells (Figure 7.8). Confirming that H-Ras G12V is not only
capable of suppressing the chimeric integrin expressed on a/3-py cells, but that it is
also capable of suppressing the endogenous integrins such as as(3\.
Further investigations of the role of the a5/3i integrin in anchorage-independent
growth, were carried out using the most H-Ras-like and R-Ras-like stable lines
(H201 and R201 respectively) along with /3i-integrin mAbs. The (3\ integrin
activating (TS2-16) and blocking (4B4) monoclonal antibodies bind to residues 207
to 218 of the /3i subunit (Takada and Puzon, 1993). Studies have suggested that
activating mAbs may change the conformation of the /Si subunit upon binding, and
that this is a direct antibody-induced change that does not require intracellular
signalling (Faull et al., 1993). It has been suggested that activating mAbs might fix
the conformation in an activated state, while inhibiting mAbs may fix the integrin
conformation in an inactive conformation (Takada and Puzon, 1993). The finding
that anchorage-independent growth could be abrogated by a function-activating (3\
antibody (TS2-16) and enhanced by a function-blocking jSj antibody (4B4), confirms
a j(3i integrin-mediated role in CHO cell transformation (Figure 7.11).
The loss of fibronectin matrix assembly has been associated with acquisition of a
transformed phenotype. Hughes et al., (1997) showed that expression of H-Ras
G12V in fibroblasts resulted in decreased fibronectin matrix assembly. Transformed
cells frequently show decreased synthesis and increased degradation of fibronectin
(Olden and Yamada, 1977). A study by Brenner et al., (2000) showed that matrix
formation by HT1080, human fibrosarcoma, cells was triggered by decreasing the
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amount of Ras signalling with a MEK1 inhibitor or by increasing integrin activity
with an anti-/3i integrin stimulatory antibody. If fibronectin matrix assembly is linked
to cellular transformation then observations made in this study, see Figure 7.10,
suggest that the integrin-suppressing ability of the H201 chimera or the function
blocking anti-/3i antibody, 4B4, promote anchorage-independent growth by reducing
the ability of the cells to form a fibronectin matrix and that these effects can be
negated by addition of the function activating anti-/3j antibody, TS2-16. The integrin-
activating ability of R201 may enhance levels of a5/3\ activation, which has been
shown to suppress the transformed phenotype of CHO cells (Giancotti and Ruoslahti,
1990). Expression of R201 may increase fibronectin matrix assembly by activating
the 015/31 integrin and this activity can be blocked using the anti-/3i antibody 4B4. It
would be of interest to determine if the magnitude of matrix assembly by chimera
stable-lines is inversely related to the ability to promote anchorage-independent
growth.
Enhanced growth rates and saturation densities were observed with the CHI and
H201 stable lines (Figures 7.12 and 7.13), suggesting that H-Ras sequences 60-174
are sufficient to promote the characteristic increase in proliferation rates observed
with transformed cells. However, as only the H201 stable line (H-Ras sequences 1-
174) showed any significant ability to promote anchorage-independent growth would
suggest that for a fully transformed phenotype, the N-terminal effector binding
sequences of H-Ras are also required. The downstream effectors of H-Ras have been
associated with cellular transformation. PI 3-Kinase activation has been implicated in
anchorage-independent growth, metastasis and cell invasion (Shaw et al., 1997;
Keely et al., 1997) and with integrin-dependent proliferation through the
downregulation of p27kip resulting in cyclin D1 induction (Feng et al., 2000).
Integrin-mediated proliferation also depends on the activation of the ERK1/2
pathway, which controls expression of cyclin D1 and p21cip (Brakebuch et al.,
2002). Integrins and growth factor receptors regulate some of the same signalling
pathways; in many instances both are required for activation of downstream
signalling events. It has been hypothesised that constitutive activation of the
downstream signalling events by oncogenes overrides the requirement for integrin
activation, resulting in increased proliferation and anchorage-independence. Studies
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have shown that the loss of integrin-mediated adhesion inhibits the activation of
MAP kinase by serum or active forms of Ras and Raf (Lin et al., 1997; Renshaw et
al., 1996). However, cytoplasmic oncogenes may provide a constitutively activated
signal, usually initiated by ligand-bound integrins, and in doing so overcome
anchorage dependence (Sethi et al., 1999). Expression of oncogenic Ras and Raf can
induce ERK1/2 activation in suspension cells to levels which revoke the need for
adhesion, resulting in anchorage-independent survival (Schwartz, 1997). However,
as the H-and R-Ras chimeras were incapable of activating Raf and ERK1/2 to levels
observed with full-length H-Ras G12V (Chapter 4, Figures 4.4, 4.5 and 4.6), then it
is unlikely that the increased proliferation rates observed with CHI and H201 and the
anchorage-independent growth of H201 stables are simply due to activation of the
ERK1/2 pathway.
Upon engagement of integrins to ECM proteins, PI 3-kinase becomes constitutively
activated to a significant level in MDCK cells (Khwaja et al., 1997). The PI 3-kinase
lipid products provide a protective signal acting through PKB/Akt, which has
previously been reported to be required for cell survival (Yao and Cooper, 1996).
Upon cell detachment from matrix, PI 3-kinase and PKB/Akt become inactive, even
in the presence of serum factors and an apoptosis pathway is engaged. The ability of
oncogenic Ras to activate PI 3-kinase, by binding directly to pi 10 (Rodriguez-
Viciana et al., 1994, Rodriguez-Viciana et al., 1996), and hence PKB/Akt, in the
absence of adhesion to the ECM, promotes anchorage-independent survival. As PI 3-
kinase has also been implicated in cell proliferation, it would be interesting to assess
the abilities of the chimeras to activate PI 3-kinase using either PI 3-kinase assays or
by western blot analysis with phospho-AKT antibodies. It would also be interesting
to determine whether PI-3-kinase inhibitors affect cell growth and to find out if
proliferation rates are a consequence of cell survival or cell death eg. by measuring
levels of apoptosis.
The results here show that H-Ras G12V can transform CHO cells. However, while
R-Ras is incapable of transforming CHO cells, it has demonstrated transforming
abilities in NIH3T3 cells, inducing anchorage-independent growth (Cox et al., 1994)
and foci-formation (Hansen et al., 2002). Investigations show that the effects of H-
Ras and R-Ras are cell type specific. Studies of the transforming effects of Ras or
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Ras effectors make use of rodent cell lines due to their ease of transfection and
because they are easily transformed by oncoproteins (Gupta et al., 2000). However,
it is possible that rodent models may not accurately reflect the functional
consequences of the expression of oncogenic Ras proteins in human cells. Further
investigations to compare transforming abilities of H-Ras and R-Ras in a human cell
line to their transforming abilities in CHO cells would be appealing.
7.5.3 Summary
The extent of cell adhesion and cell migration rate can both be affected by integrin
affinity state. Cell adhesion assays revealed that expression of full-length H-Ras
G12V (which suppresses integrin affinity) reduced CHO cell adhesion to fibrinogen.
Cell migration assays revealed that H-Ras increased chemotactic migration of CHO
cells however, haptotactic migration was reduced. The reduced degree of haptotactic
migration ofH-Ras G12V transfected cells is probably due to the suppressive effects
upon the integrins, which prevent the formation of adhesive contacts at the front of
the cell required for directional migration. Integrin activation in R-Ras G38V
transfected cells results in increased cell spreading and focal adhesion formation,
which in turn inhibits CHO cell migration in chemotactic and haptotactic migration
assays. Stable lines expressing the H-and R-Ras chimeras had little overall effect on
CHO cell adhesion and rate ofmigration.
Transient expression of full-length H-Ras G12V and stable expression of H201 both
resulted in anchorage-independent growth of CHO cells, indicative of a transformed
phenotype. As H201 stable cells were the only chimeric stables to induce a
transformed phenotype, suggests that the entire 174 N-terminal stretch of H-Ras (1-
174) is required to confer a transformed phenotype in CHO cells. Anchorage-
independent growth appears to be influenced by the activation state of the CHO cell
integrin since suppression of the integrin by expression of H-Ras G12V or H201,
or by the use of a the /^-blocking antibody, 4B4, leads to anchorage-independent
growth. In contrast, activation of the integrin by expression ofR-Ras G38V or R201,
or the use of the /Si-activating antibody prevents anchorage independent growth.
These results may be a consequence of the changes in fibronectin-matrix assembly,
which has been shown to be mediated via the a5(3\ integrin and reduced in
transformed cells.
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Chapter 8
Concluding remarks and future directions
In order to achieve correct cellular function, the interactions between integrins and
their ligands must be strictly regulated. The rapid activation of integrins is essential
for the ability of a cell to respond to environmental changes. Integrins in the ft, ft, ft
and ft subfamilies have been shown to modulate their integrin-binding affinity
through conformational changes, in response to inside-out signalling (Hughes and
Pfaff, 1998). A number of intracellular signalling pathways have been implicated in
modulating integrin affinity; however they have yet to be fully defined. Recent
studies have indicated that the Ras family of small GTP-binding proteins, and their
effectors, play a crucial role in integrin affinity modulation (Keely et al., 1998;
Hughes et al., 1997).
Despite their sequence homology and overlapping use of effectors and GEFs, H-Ras
and R-Ras have different functional effects on integrins. In CHO cells, expression of
R-Ras promotes the active integrin state while expression of H-Ras suppresses
integrin activation. Furthermore, co-expression of active R-Ras G38V with active H-
Ras G12V, in CHO cells, reversed H-Ras-mediated integrin suppression (Sethi et al.,
1999). The central aim of this thesis was to use a series of H-and R-Ras chimeras to
elucidate the role, if any, the sequence variations in H-Ras and R-Ras may play in
their differing properties with respect to integrin affinity modulation. Table 8.1
shows the effects of the chimeras on integrin affinity, compared to H-Ras and R-Ras,
and their effects on ERK1/2 phosphorylation.
The H/R-Ras chimeras imply that the C-terminal sequences of H-Ras and R-Ras are
critical to determining their different effects on integrin affinity. More specifically, a
25-amino acid stretch ofH-Ras (Arg149 to Pro174) is required for integrin suppression,
and a 28-amino acid stretch ofR-Ras (Leu175 to Pro203) is sufficient to reverse H-Ras
mediated integrin suppression. Like PI-Ras G12V, chimeras CHI, CH5 and H201, all
suppressed integrin affinity. However, only H201 induced integrin suppression
correlated with ERK1/2 activation, which suggests that Ras-induced integrin
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suppression may be independent of the bulk activation of ERK1/2. Recently, PLCe
has been identified as a new H-Ras effector (Wing et al., 2003). Work carried out by
our group has implicated PLCe in a Raf-independent integrin suppression pathway.
PLCe has been shown to be activated by the H-Ras E37G mutant (which does not
bind Rat) and that kinase-dead PLCe blocks H-Ras-mediated integrin suppression
(personal communication, Dr. Yatish Lad). Results presented in this thesis also imply
the presence of a Raf-independent integrin suppression pathway; the CHI, CH5 and
H201 chimeras all demonstrate the ability to confer integrin suppression despite
being less competent at activating Raf-1 than H-Ras G12V.
Characterisation of the H-and R-Ras chimeras suggested an important role for the R-
Ras G38V proline-rich domain Ras (residues Pro199 to Pro206), particularly for the
reversal of H-Ras-mediated integrin suppression. This domain has been shown to
bind the adaptor protein Nek (Wang et al., 2000) and so it was hypothesised that the
relationship between R-Ras and the Nek adaptor protein may be important for
conferring R-Ras's properties. However, a publication released during the course of
the write-up of this thesis, showed that alanine substitution of the proline-rich
domain had no effect on the R-Ras modulation of integrin function (Hansen et al.,
2003). Investigations using H-and R-Ras chimeras demonstrated that R-Ras amino
1 Q9 ?f)T
acids Tyr to Pro , which include the proline-rich domain, are necessary but not
sufficient, for increased integrin activation (Hansen et al., 2003). This area overlaps
with the HVR linker domain of R-Ras. Results from this thesis would suggest that
sequences N-terminal to the residues Tyr193 to Pro203 of R-Ras are involved (the 28-
amino acid stretch from Leu175 to Pro203).
It has been hypothesised that one way in which H-Ras and R-Ras could confer their
contrasting properties is by targeting to different membrane microdomains. H-Ras
has been demonstrated to redistribute from lipid rafts into the bulk plasma membrane
upon GTP-loading (Niv et al., 2002; Prior et al., 2001; Prior et al., 2003).
Experiments were carried out to disrupt the membrane cholesterol content of CHO
cells, in order to help determine the importance of membrane localisation with
regards to integrin affinity modulation and to help reveal the subcellular localisation
of R-Ras. Results demonstrated that cholesterol depletion, and subsequent disruption
of lipid rafts, had no effect on the abilities of H-Ras and R-Ras to modulate integrin
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affinity. However, the ability of R-Ras to mediate its effect on integrin affinity was
diminished by the repletion of membrane cholesterol in the form of inclusion
complexes.
We had hypothesised that the reason that lipid raft disruption had no effect on the
ability of R-Ras to modulate integrin affinity might be due to a similar redistribution
of the GTP-bound protein as that observed with activated H-Ras i.e. migration out of
the cholesterol sensitive lipid rafts and into the bulk plasma membrane. Attempts to
produce GFP-tagged R-Ras constructs to confirm this were unsuccessful due to poor
sequencing of the N-terminal R-Ras residues. Investigations by Hansen et al., (2003)
showed that the activated mutant GFP-R-Ras 87L seemed to be more enriched in
lipid rafts/caveolae fractions than wildtype GFP-R-Ras. This suggests that unlike H-
Ras, which upon activation migrates out of the lipid rafts/caveolae, R-Ras does not
and is in fact more enriched in these fractions when activated. Further investigations
by these authors, using GFP-tagged H-and R-Ras chimeras demonstrated that the
microlocalisation of these proteins specifies their capacity to activate downstream
effectors, such as Raf-1, but does not correlate with their effects on integrins (Hansen
et al., 2003). This would explain why M/3CD treatment of CHO cells had no effect
on H-Ras-and R-Ras-mediated integrin affinity.
The diminished R-Ras effects on integrin affinity following the addition of inclusion
complexes may be explained by the targeting of activated R-Ras to cholesterol
sensitive lipid rafts (Hansen et al., 2003). It had been hypothesised that perhaps the
addition of cholesterol inclusion complexes resulted in some form of steric
hindrance. This seems to be a very likely situation since we now know that activated
R-Ras is targeted to microdomains sensitive to cholesterol content. The addition of
inclusion complexes may increase the basal levels of cholesterol found in lipid rafts
and as a result may prevent normal R-Ras signalling. Using GFP-tagged R-Ras (wt)
and (G38V) constructs, confocal microscopy could be used to visualise the effects of
M/3CD treatment on R-Ras membrane microlocalisation.
The cellular consequences of H-Ras-and R-Ras-mediated integrin affinity have also
been investigated in this thesis. The adhesion of H-Ras GUV transfected ojS-py cells
on fibrinogen is significantly reduced, suggesting that H-Ras G12V-mediated
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integrin suppression (of the chimeric integrin) does affect cell adhesion. Confocal
microscopy has revealed that these cells have a rounded shape with reduced numbers
of focal adhesions. In contrast, R-Ras G38V transfected cells have an increased
number of focal adhesions and a well-spread polygonal shape and cells adhere as
well as to fibrinogen as the control o^S-py cells.
Cell migration requires the transient adhesion and detachment of the cell at the
leading and trailing edge respectively (Lauffenburger and Horwitz, 1996). These
effects can be mediated by the cycling of focal adhesions during cell ligation (Petit
and Thiery, 2000). The integrin-activating effect of R-Ras G38V reduces both
chemotactic and haptotactic migration of a/3-py cells, this is probably due to the
increased number of focal adhesions. H-Ras G12V reduced haptotactic migration,
this may be due to the suppressed state of the integrin and may inhibit the formation
of adhesions at the cell front that are strong enough to mediate the migration through
across the matrix
The H-and R-Ras chimeras had no overall effect on CHO cell adhesion to fibronectin
or cell migration. This suggests that cell adhesion and migration, although partially
correlating with integrin affinity state, also rely on downstream effectors involved
with cytoskeletal machinery. A study by Klemke et al., (1997) provided evidence
that MAP kinase (ERK1 and ERK2) signalling can regulate cell migration by
directly impacting the migratory machinery. ERK1/2 enhances the activity ofmyosin
light chain kinase (MLCK) leading to the phosphorylation and increased function of
myosin light chain (MLC) (Klemke et al., 1997). The low levels of ERK1/2
activation seen by the H-and R-Ras chimeras may explain their insignificant effect
on CHO cell migration, despite mediating effects on integrin affinity.
CHO cells are readily transformed by H-Ras, resulting in anchorage-independent
growth. Of all the chimeras only H201 showed any transforming abilities, which
suggests that H-Ras amino acids 1-174 are required to confer a transformed
phenotype. Investigations into how integrin affinity state influences cellular
transformation has suggested that suppression of the j3\-integrin, by H201 expression
or by use of a /3j-integrin blocking antibody (4B4), can increase anchorage-
independent growth. In contrast, activation of this integrin either by expression of the
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R201 chimera or by use of a /3i-integrin activating antibody (TS2-16) inhibits
anchorage-independent growth. It would be of interest to investigate the effects that
the /3i-integrin antibodies alone have on control cells.
It is important to note that the investigations described in this thesis have relied on
the over-expression of proteins, which may affect normal cellular events. It would be
interesting to use methods such as siRNA and dominant negative protein expression,
and compare results to control cells, to further substantiate the findings made here.
Also, further analysis of the 3D-protein structures of the chimeric proteins may help
to elucidate whether the folding of the proteins impairs the normal interactions with
effectors, compared with full length H-Ras and R-Ras.
Overall, this thesis has highlighted the importance of the HVR domain and N-
terminal sequences to the HVR, in conferring the contrasting abilities of H-Ras
G12V and R-Ras G38V to mediate integrin affinity. All chimeras containing H-Ras
residues Arg149 to Pro174 suppressed integrin affinity (CHI, CH5 and H201).,
conversely all chimeras containing R-Ras residues Leu175 to Pro203) reversed H-Ras
G12V-and Raf-BxB CAAX- mediated integrin suppression (CH3, CH6 and R201).
The microlocalisation of H-Ras and R-Ras does not correlate with their effects on
integrins. The extreme C-terminal residues of H-Ras and R-Ras, while important for
targeting the plasma membrane, are not necessary for mediating integrin affinity
modulation. The N-terminal and HVR sequences ofH-Ras are required for CHO cell
transformation, which suggests that integrin state alone is not sufficient to confer a
transformed phenotype but the signalling to downstream effectors is also required.
Table 8.1 provides a summary of all the findings made in this thesis with regards to
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